0001005201-20-000035.txt : 20200511 0001005201-20-000035.hdr.sgml : 20200511 20200511101009 ACCESSION NUMBER: 0001005201-20-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Therapeutics, Inc CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 20863050 BUSINESS ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 FORMER COMPANY: FORMER CONFORMED NAME: DEPOMED INC DATE OF NAME CHANGE: 19970408 10-Q 1 asrt-331202010q.htm 10-Q Document
P1MP2MP5DP5DP1MP2MP1Mfalse--12-31Q12020000100520114301000412300000.05198520.3235198P3Y0 0001005201 2020-01-01 2020-03-31 0001005201 2020-05-06 0001005201 2020-03-31 0001005201 2019-12-31 0001005201 us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 us-gaap:SeniorNotesMember 2020-03-31 0001005201 us-gaap:SeniorNotesMember 2019-12-31 0001005201 us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 2019-01-01 2019-03-31 0001005201 asrt:RoyaltiesAndMilestonesMember 2019-01-01 2019-03-31 0001005201 us-gaap:ProductMember 2019-01-01 2019-03-31 0001005201 asrt:NUCYNTAMember 2020-01-01 2020-03-31 0001005201 asrt:GraliseMember 2019-01-01 2019-03-31 0001005201 asrt:NUCYNTAMember 2019-01-01 2019-03-31 0001005201 us-gaap:ProductMember 2020-01-01 2020-03-31 0001005201 asrt:CommercializationAgreementMember 2020-01-01 2020-03-31 0001005201 asrt:CommercializationAgreementMember 2019-01-01 2019-03-31 0001005201 asrt:GraliseMember 2020-01-01 2020-03-31 0001005201 asrt:RoyaltiesAndMilestonesMember 2020-01-01 2020-03-31 0001005201 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001005201 us-gaap:RetainedEarningsMember 2019-03-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001005201 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001005201 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001005201 us-gaap:CommonStockMember 2019-03-31 0001005201 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001005201 us-gaap:CommonStockMember 2020-03-31 0001005201 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001005201 2018-12-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001005201 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001005201 2019-03-31 0001005201 us-gaap:CommonStockMember 2018-12-31 0001005201 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001005201 us-gaap:ConvertibleDebtMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001005201 us-gaap:ConvertibleDebtMember 2020-01-01 2020-03-31 0001005201 us-gaap:CommonStockMember 2019-12-31 0001005201 us-gaap:RetainedEarningsMember 2019-12-31 0001005201 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001005201 us-gaap:RetainedEarningsMember 2018-12-31 0001005201 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001005201 us-gaap:RetainedEarningsMember 2020-03-31 0001005201 us-gaap:ConvertibleDebtMember 2019-01-01 2019-03-31 0001005201 us-gaap:SeniorNotesMember 2019-01-01 2019-03-31 0001005201 us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0001005201 asrt:GraliseMember srt:MinimumMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:AmendedCommercializationAgreementMember 2018-11-08 0001005201 asrt:LazandaMember srt:MinimumMember 2020-01-01 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-02-19 0001005201 asrt:LazandaMember srt:MaximumMember 2020-01-01 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2020-01-01 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-03-11 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember 2020-02-13 2020-02-13 0001005201 srt:ScenarioForecastMember asrt:ZylaLifeSciencesMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-04-01 2020-06-30 0001005201 asrt:ZipsorMember 2020-01-01 2020-03-31 0001005201 asrt:GraliseMember srt:MaximumMember 2020-01-01 2020-03-31 0001005201 srt:MinimumMember asrt:PerformanceBasedRestrictedStockUnitsMember asrt:EquityIncentivePlan2014Member 2020-01-01 2020-03-31 0001005201 srt:MaximumMember 2020-01-01 2020-03-31 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:GraliseMember 2020-01-10 0001005201 asrt:CAMBIAMember srt:MaximumMember 2020-01-01 2020-03-31 0001005201 asrt:ZylaLifeSciencesMember srt:ScenarioForecastMember asrt:ZylaLifeSciencesMember us-gaap:SubsequentEventMember 2020-06-30 0001005201 asrt:AssertioParentMember srt:ScenarioForecastMember asrt:ZylaLifeSciencesMember us-gaap:SubsequentEventMember 2020-06-30 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:GraliseMember 2020-01-10 2020-01-10 0001005201 srt:MaximumMember asrt:PerformanceBasedRestrictedStockUnitsMember asrt:EquityIncentivePlan2014Member 2020-01-01 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2020-04-08 0001005201 asrt:NucyntaErAndNucyntaMember srt:MinimumMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:AmendedCommercializationAgreementMember 2018-11-08 2018-11-08 0001005201 asrt:CAMBIAMember srt:MinimumMember 2020-01-01 2020-03-31 0001005201 2020-01-01 0001005201 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001005201 asrt:NucyntaErAndNucyntaMember srt:MaximumMember 2020-01-01 2020-03-31 0001005201 srt:MinimumMember 2020-01-01 2020-03-31 0001005201 asrt:PerformanceBasedRestrictedStockUnitsMember asrt:EquityIncentivePlan2014Member 2020-01-01 2020-03-31 0001005201 asrt:JanssenNucyntaMember 2019-01-01 2019-03-31 0001005201 asrt:CommercializationRightsAndFacilitationServicesMember 2019-01-01 2019-03-31 0001005201 asrt:CommercializationRightsAndFacilitationServicesMember 2020-01-01 2020-03-31 0001005201 asrt:NeurologyProductMember 2019-01-01 2019-03-31 0001005201 asrt:CAMBIAMember 2019-01-01 2019-03-31 0001005201 asrt:NeurologyProductMember 2020-01-01 2020-03-31 0001005201 asrt:JanssenNucyntaMember 2020-01-01 2020-03-31 0001005201 asrt:ZipsorMember 2019-01-01 2019-03-31 0001005201 asrt:CAMBIAMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember 2019-12-31 0001005201 asrt:CollegiumPharmaceuticalIncMember 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:RoyaltiesAndMilestonesMember asrt:CommercializationAgreementAndAmendedCommercializationAgreementMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember 2018-01-31 0001005201 asrt:CambiaCanadaMember asrt:NuvoPharmaceuticalsAgreementMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:CommercializationAgreementAndAmendedCommercializationAgreementMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember 2018-01-01 2018-01-31 0001005201 asrt:CambiaCanadaMember asrt:NuvoPharmaceuticalsAgreementMember 2019-01-01 2019-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:RoyaltiesAndMilestonesMember asrt:CommercializationAgreementAndAmendedCommercializationAgreementMember 2019-01-01 2019-03-31 0001005201 asrt:CollaborativePartnersReceivableMember 2020-03-31 0001005201 asrt:CommercializationAgreementMember 2019-12-31 0001005201 asrt:ProductSalesReceivableMember 2019-12-31 0001005201 asrt:ProductSalesReceivableMember 2020-03-31 0001005201 asrt:CollaborativePartnersReceivableMember 2019-12-31 0001005201 asrt:CommercializationAgreementMember 2020-03-31 0001005201 2019-01-01 2019-12-31 0001005201 asrt:ZipsorMember asrt:ProductRightsMember 2019-12-31 0001005201 asrt:NUCYNTAMember asrt:ProductRightsMember 2019-12-31 0001005201 asrt:ZipsorMember asrt:ProductRightsMember 2020-03-31 0001005201 asrt:ZipsorMember asrt:ProductRightsMember 2020-01-01 2020-03-31 0001005201 asrt:NUCYNTAMember asrt:ProductRightsMember 2020-03-31 0001005201 asrt:CAMBIAMember asrt:ProductRightsMember 2019-12-31 0001005201 asrt:CAMBIAMember asrt:ProductRightsMember 2020-03-31 0001005201 asrt:NUCYNTAMember asrt:ProductRightsMember 2019-01-01 2019-12-31 0001005201 asrt:CAMBIAMember asrt:ProductRightsMember 2020-01-01 2020-03-31 0001005201 asrt:NUCYNTAMember asrt:ProductRightsMember 2020-01-01 2020-03-31 0001005201 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001005201 asrt:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2020-03-31 0001005201 us-gaap:EmployeeStockOptionMember 2020-03-31 0001005201 asrt:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001005201 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001005201 asrt:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001005201 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0001005201 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001005201 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001005201 us-gaap:RestructuringChargesMember 2020-01-01 2020-03-31 0001005201 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0001005201 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001005201 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001005201 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-01-01 2020-03-31 0001005201 asrt:JanssenNucyntaMember us-gaap:SeniorNotesMember 2015-04-02 2015-04-02 0001005201 us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-04-02 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2020-02-19 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2019-09-30 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-02-19 0001005201 us-gaap:SeniorNotesMember 2015-04-02 2015-04-02 0001005201 us-gaap:SeniorNotesMember 2015-04-02 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2019-08-13 2019-08-13 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2014-09-09 0001005201 us-gaap:SeniorNotesMember 2019-03-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2019-08-13 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2020-02-19 2020-02-19 0001005201 srt:MinimumMember us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-04-02 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2020-02-19 2020-02-19 0001005201 us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-04-02 2015-04-02 0001005201 us-gaap:CommonStockMember 2019-08-13 2019-08-13 0001005201 us-gaap:SeniorNotesMember 2020-02-13 2020-02-13 0001005201 us-gaap:SeniorNotesMember 2020-02-13 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-03-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:ConvertibleDebtMember 2019-08-13 2019-08-13 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001005201 asrt:OtherExpenseIncomeNetMember 2020-01-01 2020-03-31 0001005201 asrt:OtherExpenseIncomeNetMember 2019-01-01 2019-03-31 0001005201 asrt:MultidistrictOpioidLitigationMember srt:MinimumMember 2020-03-31 0001005201 asrt:ManufacturingMember 2020-03-31 0001005201 asrt:ConsultingServicesMember 2019-12-31 0001005201 asrt:ManufacturingMember 2019-12-31 0001005201 asrt:ConsultingServicesMember 2020-03-31 0001005201 asrt:SecuritiesClassActionLawsuitMember 2017-08-23 2017-08-23 0001005201 us-gaap:EmployeeSeveranceMember asrt:A2019CostSavingsInitiativeMember 2019-01-01 2019-12-31 0001005201 us-gaap:EmployeeSeveranceMember 2020-03-31 0001005201 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-03-31 0001005201 us-gaap:EmployeeSeveranceMember 2019-12-31 0001005201 us-gaap:ConvertibleDebtMember asrt:ConvertibleSeniorNotes5.0Member 2020-01-01 2020-03-31 0001005201 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001005201 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001005201 us-gaap:ConvertibleDebtMember asrt:ConvertibleSeniorNotes2.5Member 2020-01-01 2020-03-31 0001005201 us-gaap:ConvertibleDebtMember asrt:ConvertibleSeniorNotes5.0Member 2019-01-01 2019-03-31 0001005201 us-gaap:ConvertibleDebtMember asrt:ConvertibleSeniorNotes2.5Member 2019-01-01 2019-03-31 0001005201 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001005201 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:CommercializationAgreementMember 2018-01-01 2018-12-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2020-03-31 0001005201 us-gaap:WarrantMember asrt:OtherExpenseIncomeNetMember 2020-01-01 2020-03-31 0001005201 asrt:CollegiumPharmaceuticalIncMember asrt:CommercializationAgreementMember 2018-12-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 asrt:ConvertibleSeniorNotes5.0Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:ConvertibleDebtMember 2019-12-31 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember 2020-02-13 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:GraliseMember 2020-01-01 2020-03-31 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember 2020-01-01 2020-03-31 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember 2020-01-01 2020-02-11 0001005201 asrt:SlanMember asrt:LicenseAgreementMember 2020-02-06 2020-02-06 0001005201 asrt:SlanMember asrt:LicenseAgreementMember 2019-12-31 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember 2020-03-31 0001005201 asrt:SlanMember asrt:LicenseAgreementMember 2017-11-07 2017-11-07 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:NUCYNTAMember asrt:ThirdPartyConsentAgreementMember 2020-02-13 0001005201 asrt:SlanMember asrt:LicenseAgreementMember 2020-02-06 0001005201 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember asrt:GraliseMember 2020-03-31 0001005201 asrt:ConvertibleSeniorNotes2.5Member us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2020-04-08 asrt:renewal_option xbrli:shares iso4217:USD xbrli:shares asrt:action xbrli:pure asrt:payment asrt:segment asrt:case iso4217:USD asrt:sublease
 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 FORM 10-Q
 ☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020
 OR
 ☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROM TO      
 COMMISSION FILE NUMBER 001-13111
 ASSERTIO THERAPEUTICS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware
94-3229046
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
(I.R.S. EMPLOYER IDENTIFICATION NUMBER)
 100 South Saunders Road, Suite 300
Lake Forest, Illinois 60045
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES; ZIP CODE)
 (224) 419-7106
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
    
Trading Symbol(s):
 
Name of each exchange on which registered:
Common Stock, $0.0001 par value
 
ASRT
 
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
 
Large accelerated filer
☐
 
Accelerated filer
☒
 
 
 Non-accelerated filer
☐
 
Smaller reporting company
☐
 
 
Emerging growth company
☐
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
 
The number of issued and outstanding shares of the registrant’s Common Stock, $0.0001 par value, as of May 6, 2020 was 81,375,075.
 
 
 
 
 


ASSERTIO THERAPEUTICS, INC.
FORM 10-Q FOR THE PERIOD ENDING MARCH 31, 2020
TABLE OF CONTENTS
 
 
 
 
 
 
 
Item 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2. 
 
 
 
 
Item 3. 
 
 
 
 
Item 4. 
 
 
 
 
 
 
Item 1. 
 
 
 
 
Item 1A. 
 
 
 
 
Item 2.
 
 
 
 
Item 6. 
 
 
 
 
 

2


PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ASSERTIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
 
 
March 31, 2020
 
December 31, 2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
105,973

 
$
42,107

Accounts receivable, net
12,952

 
42,744

Inventories, net
518

 
3,412

Consideration receivable from sale of Gralise
50,019

 
—

Prepaid and other current assets
10,651

 
15,688

Total current assets
180,113

 
103,951

Property and equipment, net
3,233

 
3,497

Intangible assets, net
23,671

 
400,535

Investments, net
8,132

 
13,064

Other long-term assets
4,125

 
6,123

Total assets
$
219,274

 
$
527,170

LIABILITIES AND SHAREHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
4,982

 
$
16,193

Accrued rebates, returns and discounts
32,359

 
58,943

Accrued liabilities
24,716

 
18,948

Senior Notes, current portion
—

 
80,000

Convertible Notes, current portion
57,866

 
—

Interest payable
304

 
8,375

Other current liabilities
2,066

 
2,094

Total current liabilities
122,293

 
184,553

Senior Notes
—

 
76,443

Convertible Notes
—

 
194,815

Other long-term liabilities
12,944

 
13,401

Total liabilities
135,237

 
469,212

Commitments and contingencies

 

Shareholders’ equity:
 
 
 
Common stock
8

 
8

Additional paid-in capital
442,600

 
457,751

Accumulated deficit
(358,571
)
 
(399,801
)
Total shareholders’ equity
84,037

 
57,958

Total liabilities and shareholders' equity
$
219,274

 
$
527,170


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

ASSERTIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands, except per share data)
(Unaudited)
 
 
Three Months Ended March 31,
 
2020
 
2019
Revenues:
 
 
 
Product sales, net
$
9,252

 
$
26,450

Commercialization agreement, net
11,258

 
30,856

Royalties and milestones
407

 
623

Total revenues
20,917

 
57,929

Costs and expenses:
 
 
 
Cost of sales (excluding amortization of intangible assets)
1,399

 
2,575

Research and development expenses
1,041

 
1,793

Selling, general and administrative expenses
27,314

 
25,045

Amortization of intangible assets
7,795

 
25,444

Total costs and expenses
37,549

 
54,857

(Loss) income from operations
(16,632
)
 
3,072

Other income (expense):
 
 
 
Gain on sale of Gralise
127,505

 
—

Loss on extinguishment of convertible notes
(31,608
)
 
—

Loss on sale of NUCYNTA
(15,755
)
 
—

Interest expense
(8,674
)
 
(16,554
)
Loss on prepayment of Senior Notes
(8,233
)
 
—

Other
(3,325
)
 
(609
)
Total other income (expense)
59,910

 
(17,163
)
Net income (loss) before income taxes
43,278

 
(14,091
)
Income tax expense
(2,048
)
 
(210
)
Net income (loss) and Comprehensive income (loss)
$
41,230

 
$
(14,301
)
 
 
 
 
Basic net income (loss) per share
$
0.58

 
$
(0.22
)
Diluted net income (loss) per share
$
0.58

 
$
(0.22
)
Shares used in computing basic net income (loss) per share
70,940

 
64,239

Shares used in computing diluted net income (loss) per share
71,051

 
64,239

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

ASSERTIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands)
(Unaudited)

 
Common Stock
 
Additional
Paid-In
Capital
 
Accumulated
Earnings
(Deficit)
 
Accumulated
Other
Comprehensive
Loss
 
Shareholders’
Equity
 
Shares
 
Amount
 
 
 
 
Balances at December 31, 2018
64,185

 
$
6

 
$
402,934

 
$
(182,600
)
 
$
(5
)
 
$
220,335

Issuance of common stock upon exercise of options
14

 
—

 
25

 
—

 
—

 
25

Issuance of common stock in conjunction with vesting of restricted stock units
132

 
—

 
—

 
—

 
—

 
—

Stock-based compensation
—

 
—

 
2,702

 
—

 
—

 
2,702

Shares withheld for payment of employee's withholding tax liability
—

 
—

 
(216
)
 
—

 
—

 
(216
)
Net loss
—

 
—

 
—

 
(14,301
)
 
—

 
(14,301
)
Balances at March 31, 2019
64,331

 
$
6

 
$
405,445

 
$
(196,901
)
 
$
(5
)
 
$
208,545

 
 
 
 
 
 
 
 
 
 
 
 
Balances at December 31, 2019
80,888

 
$
8

 
$
457,751

 
$
(399,801
)
 
$
—

 
$
57,958

Issuance of common stock in conjunction with vesting of restricted stock units
434

 
—

 
—

 
—

 
—

 
—

Reacquisition of equity component of 2021 Notes and 2024 Notes
—

 
—

 
(16,814
)
 
—

 
—

 
(16,814
)
Stock-based compensation
—

 
—

 
1,934

 
—

 
—

 
1,934

Shares withheld for payment of employee's withholding tax liability
—

 
—

 
(271
)
 
—

 
—

 
(271
)
Net income
—

 
—

 
—

 
41,230

 
—

 
41,230

Balances at March 31, 2020
81,322

 
$
8

 
$
442,600

 
$
(358,571
)
 
$
—

 
$
84,037


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

ASSERTIO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 
Three Months Ended March 31,
 
2020
 
2019
Operating Activities
 
 
 
Net income (loss)
$
41,230

 
$
(14,301
)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
 
 
 
Gain on sale of Gralise
(127,500
)
 
—

Loss on extinguishment of convertible notes
31,608

 
—

Loss on prepayment of Senior Notes
8,233

 
—

Depreciation and amortization
8,068

 
25,990

Loss on sale of NUCYNTA
15,755

 
—

Accretion of debt discount and debt issuance costs
5,387

 
6,164

Recurring fair value measurement of assets and liabilities
3,147

 
28

Stock-based compensation
1,934

 
2,702

Provision for inventory and other assets
1,554

 
359

Other
(14
)
 
1,297

Changes in assets and liabilities:
 
 
 
Accounts receivable
29,792

 
(6,278
)
Inventories
(2,381
)
 
(40
)
Prepaid and other assets
3,289

 
30,592

Accounts payable and other accrued liabilities
(10,510
)
 
(12,361
)
Accrued rebates, returns and discounts
(26,584
)
 
(4,105
)
Interest payable
(8,071
)
 
(2,852
)
Net cash (used in) provided by operating activities
(25,063
)
 
27,195

Investing Activities
 
 
 
Purchases of property and equipment
(9
)
 
(13
)
Proceeds from sale of NUCYNTA
367,958

 
—

Proceeds from sale of Gralise
81,087

 
—

Net cash provided by (used in) investing activities
449,036

 
(13
)
Financing Activities
 
 
 
Payments in connection with Senior Note prepayment
(171,775
)
 
(28,249
)
Payments in connection with convertible note extinguishment
(188,060
)
 
—

Proceeds from issuance of common stock
—

 
25

Shares withheld for payment of employee's withholding tax liability
(272
)
 
(216
)
Net cash used in financing activities
(360,107
)
 
(28,440
)
Net increase (decrease) in cash and cash equivalents
63,866

 
(1,258
)
Cash and cash equivalents at beginning of year
42,107

 
110,949

Cash and cash equivalents at end of period
$
105,973

 
$
109,691

 
 
 
 
Supplemental Disclosure of Cash Flow Information
 
 
 
Net cash paid for income taxes
$
100

 
$
—

Cash paid for interest
$
10,842

 
$
13,213

Capital expenditures incurred but not yet paid
$
—

 
$
130


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

ASSERTIO THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited) 
NOTE 1.  ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization
 
Assertio Therapeutics, Inc. (Assertio or the Company) is a leading diversified, specialty pharmaceutical company focused on distinctive products that offer enhanced therapeutic options for patients in need, while maintaining the highest ethical standards in all our business practices.

As of March 31, 2020, the Company’s specialty pharmaceutical business consisted primarily of CAMBIA®(diclofenac potassium for oral solution), a nonsteroidal anti-inflammatory drug for the acute treatment of migraine attacks, acquired by the Company in December 2013; and Zipsor® (diclofenac potassium liquid filled capsules), a nonsteroidal anti-inflammatory drug for the treatment of mild to moderate acute pain, acquired by the Company in June 2012, both marketed in the U.S.

In 2017, the Company announced that it was in the process of transforming into a leading diversified, specialty pharmaceutical company with a goal of rapidly deleveraging its balance sheet, growing its core business, and opportunistically building for the future via business development. The Company continues to position itself to actively pursue business development, strategic partnerships, and investment opportunities to build and grow for the future. As part of this transformational initiative, the Company executed on several strategic transactions:

On December 4, 2017, the Company announced a commercialization agreement with Collegium Pharmaceutical, Inc. (Collegium), pursuant to which the Company granted Collegium the right to commercialize the NUCYNTA® franchise of products in the U.S. (the Commercialization Agreement). Pursuant to the Commercialization Agreement, Collegium assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing, and the Company received royalties on all NUCYNTA revenues based on certain net sales thresholds.

On January 10, 2020, the Company completed the sale of Gralise® (gabapentin) to Golf Acquiror LLC, an affiliate to Alvogen, Inc. (Alvogen), for total value of $127.5 million. This included $75.0 million in cash at closing, and the balance payable as 75% of Alvogen’s first $70.0 million of Gralise net sales after the closing. Alvogen also paid the Company for certain inventories relating to Gralise.

On February 13, 2020, the Company entered into a definitive agreement to divest its remaining rights, title and interest in and to the NUCYNTA franchise to Collegium for $375.0 million in cash, less royalties, paid to the Company in 2020. Pursuant to the agreement, Collegium assumed certain contracts, liabilities and obligations of the Company relating to the NUCYNTA products, including those related to manufacturing and supply, post-market commitments and clinical development costs. Collegium also paid the Company for certain inventories relating to the products.

On February 13, 2020, the Company had repaid in full its outstanding aggregate principal amount of senior secured notes (Senior Notes) pursuant to a Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement) and all subsequent amendments to the Note Purchase Agreement.

On February 19, 2020, the Company entered into separate, privately negotiated agreements with a limited number of holders of the Company’s 2021 Notes and 2024 Notes to repurchase $188.0 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, the Company announced the completion and final results for its cash tender offers which the Company settled approximately $76.7 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

Merger Agreement

On March 16, 2020, the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Zyla Life Sciences (Zyla), Assertio Holdings, Inc., a newly created wholly-owned subsidiary of Assertio (Parent), Assertio Merger Sub, Inc., a newly created wholly-owned subsidiary of Parent (Assertio Merger Sub), and Zebra Merger Sub, Inc., a newly

7

created wholly-owned subsidiary of Parent (Merger Sub). The Merger Agreement provides that, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Zyla (the Merger), with Zyla surviving the Merger and becoming a wholly-owned subsidiary of Parent. Prior to the consummation of the Merger, Assertio intends to effect a reorganization merger (the “Assertio Reorganization”) pursuant to which Assertio Merger Sub will merge with and into Assertio, with Assertio surviving the merger and becoming a wholly-owned subsidiary of Parent. Parent will assume Assertio’s listing on the Nasdaq Stock Market (Nasdaq).

The terms of the Merger Agreement provide that, unless otherwise specified in the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of Zyla (the Zyla Common Stock) will be canceled and automatically converted into the right to receive as merger consideration (the Merger Consideration) 2.5 shares (the Exchange Ratio) of common stock, par value $0.0001 per share, of Parent (the Parent Common Stock).     

The Merger and the Merger Agreement have been approved by the board of directors of each of Zyla (the Zyla Board), Assertio (the Assertio Board) and Parent (the Parent Board). Completion of the Merger is conditioned upon the adoption and approval of the Merger Agreement by (1) the holders of at least a majority of the outstanding shares of Zyla Common Stock (the Zyla Stockholder Approval) and (2) by the affirmative vote of the majority of the total votes cast to approve the issuance of the Merger Consideration by the holders of the outstanding shares of common stock of Assertio (the Assertio Stockholder Approval). Completion of the Merger is also subject to other customary closing conditions. The Merger is expected to close in the second quarter of 2020.
Basis of Presentation
 
The unaudited condensed consolidated financial statements and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2020 are not necessarily indicative of results to be expected for the entire year ending December 31, 2020 or future operating periods.
 
The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2020 (the 2019 Form 10-K). The balance sheet as of December 31, 2019 has been derived from the audited financial statements at that date, as filed in the Company’s 2019 Form 10-K.

In connection with the preparation of the financial statements for the three months ended March 31, 2020, the Company evaluated whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to the entity's ability to continue as a going concern within twelve months after the date of the issuance of these financial statements noting that there did not appear to be evidence of substantial doubt of the entity's ability to continue as a going concern.
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Depomed Bermuda Ltd (Depo Bermuda), Depo NF Sub, LLC (Depo NF Sub) and Depo DR Sub, LLC (Depo DR Sub). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
 
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as sales discounts and returns, depreciable and amortizable lives, share-based compensation assumptions and taxes on income. Although management believes these estimates are based upon reasonable assumptions

8

within the bounds of its knowledge of the Company’s business and operations, actual results could differ materially from these estimates.
Segment Information

The Company maintains one operating segment and has operations solely in the United States. To date, substantially all of the Company’s revenues from product sales are related to sales in the United States.

Revenue Recognition
 
The Company adopted ASC 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective transition method. There was no adjustment to the Company’s opening balance of accumulated deficit resulting from the adoption of this guidance.

Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation, when (or as) the performance obligation is satisfied. The Company assesses the term of the contract based upon the contractual period in which the Company and Collegium have enforceable rights and obligations.

Variable consideration arising from sales or usage-based royalties, promised in exchange for a license of the Company’s Intellectual Property, is recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.
 
The Company recognizes a contract asset relating to its conditional right to consideration for completed performance obligations. Accounts receivable are recorded when the right to consideration becomes unconditional. A contract liability is recorded for payments received in advance of the related performance obligation being satisfied under the contract.

Product Sales
 
The Company sells commercial products to wholesale distributors and specialty pharmacies. Product sales revenue is recognized when title has transferred to the customer and the customer has assumed the risks and rewards of ownership, which typically occurs on delivery to the customer. The Company’s performance obligation is to deliver product to the customer, and the performance obligation is completed upon delivery. The transaction price consists of a fixed invoice price and variable product sales allowances, which include rebates, discounts and returns. Product sales revenues are recorded net of applicable sales tax and reserves for these product sales allowances. Receivables related to product sales are typically collected one to two months after delivery.
 
Product Sales Allowances—The Company considers products sales allowances to be variable consideration and estimates and recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on actual or estimated amounts owed on the related sales. These estimates take into consideration the terms of the Company’s agreements with customers, historical product returns, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. The Company uses the most likely method in estimating product sales allowances. If actual future results vary from the Company’s estimates, the Company may need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment. The Company’s sales allowances include:
 
Product Returns—The Company allows customers to return product for credit with respect to that product within six months before and up to 12 months after its product expiration date. The Company estimates product returns and associated credit on NUCYNTA ER and NUCYNTA, Gralise, CAMBIA, Zipsor and Lazanda. Estimates for returns are based on historical return trends by product or by return trends of similar products, taking into consideration the shelf life of the product at the time

9

of shipment, shipment and prescription trends, estimated distribution channel inventory levels and consideration of the introduction of competitive products. The Company did not assume financial responsibility for returns of NUCYNTA ER and NUCYNTA previously sold by Janssen Pharma or Lazanda product previously sold by Archimedes Pharma US Inc. Under the Commercialization Agreement with Collegium for NUCYNTA ER and NUCYNTA and the divestiture of Lazanda to Slán, the Company is only financially responsible for product returns for product that were sold by the Company, which are identified by specific lot numbers.
 
The shelf life of NUCYNTA ER and NUCYNTA is 24 months to 36 months from the date of tablet manufacture. The shelf life of Gralise is 24 months to 36 months from the date of tablet manufacture. The shelf life of CAMBIA is 24 months to 48 months from the manufacture date. The shelf life of Zipsor is 36 months from the date of tablet manufacture. The shelf life of Lazanda is 24 to 36 months from the manufacture date. Because of the shelf life of the Company’s products and its return policy of issuing credits with respect to product that is returned within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when the Company issues credit on a returned product. Accordingly, the Company may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments.
 
Wholesaler and Pharmacy Discounts—The Company offers contractually determined discounts to certain wholesale distributors and specialty pharmacies that purchase directly from it. These discounts are either taken off invoice at the time of shipment or paid to the customer on a quarterly basis one to two months after the quarter in which product was shipped to the customer.

Prompt Pay Discounts—The Company offers cash discounts to its customers (generally 2% of the sales price) as an incentive for prompt payment. Based on the Company’s experience, the Company expects its customers to comply with the payment terms to earn the cash discount.
 
Patient Discount Programs—The Company offers patient discount co-pay assistance programs in which patients receive certain discounts off their prescriptions at participating retail and specialty pharmacies. The discounts are reimbursed by the Company approximately one month after the prescriptions subject to the discount are filled.
 
Medicaid Rebates—The Company participates in Medicaid rebate programs, which provide assistance to certain low income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, the Company pays a rebate to each participating state, generally two to three months after the quarter in which prescriptions subject to the rebate are filled.
 
Chargebacks—The Company provides discounts to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract with the Department of Veterans Affairs. These federal entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current retail price and the price the federal entity paid for the product.
 
Managed Care Rebates—The Company offers discounts under contracts with certain managed care providers. The Company generally pays managed care rebates one to three months after the quarter in which prescriptions subject to the rebate are filled.
 
Medicare Part D Coverage Gap Rebates — The Company participates in the Medicare Part D Coverage Gap Discount Program under which it provides rebates on prescriptions that fall within the “donut hole” coverage gap. The Company generally pays Medicare Part D Coverage Gap rebates two to three months after the quarter in which prescriptions subject to the rebate are filled.

Commercialization Agreement

The Company derived revenue under the Commercialization Agreement with Collegium whereby the Company granted Collegium the right to commercialize the NUCYNTA franchise of products in the U.S. The Company entered into the Commercialization Agreement in December 2017, which became effective in January 2018, and amended the agreement in August 2018 and in November 2018. The Company viewed its performance obligations as a series of distinct goods or services that are substantially the same and that have the same pattern of transfer. Prior to the November 2018 amendment, the consideration related to the license and facilitation services was fixed and recognized ratably over the contract term. Following the November 2018 amendment, the royalty payments represent variable consideration that are subject to the sales-based royalty exception for licenses of intellectual property and are recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.

10


In addition, the Company was responsible for royalty payments to a third party related to sales of NUCYNTA. Prior to the November 2018 amendment, Collegium became primarily responsible for these royalties in connection with the Commercialization Agreement; however, a portion of these payments remained the responsibility of the Company. Following the November 2018 amendment, effective January 1, 2019, Collegium became responsible for the third-party royalty payments entirely. As the Company was not actively commercializing NUCYNTA, such royalties were recorded by the Company on a systematic basis in proportion to the underlying net product sales, subject to the sales-based royalty exemption for license of intellectual property, and were included as gross-to-net adjustments in the related revenue line in the Company’s Statements of Comprehensive Income. Such amounts, over the course of the calendar year, had no net impact.

In connection with the Commercialization Amendment, Collegium issued the Company a warrant to purchase up to 1,041,667 shares of Collegium common stock at an exercise price of $19.20 per share (Warrant). The Warrant is exercisable for a period of four years and contains customary terms, including with regard to net exercise. The Warrant was valued at $8.8 million as of the date of the Commercialization Amendment and is considered to be a component of the fixed consideration associated with the Commercialization Agreement. This Warrant is included in Investments on the Company’s Consolidated Balance Sheet, however, as it is non-cash it does not impact investing cash flows.

Effective as of February 13, 2020, the Company divested its rights, title and interest in and to its NUCYNTA franchise of products in the U.S. to Collegium. In connection with the sale, the Commercialization Agreement terminated at closing with certain specified provisions of the Commercialization Agreement surviving in accordance with the terms of the purchase agreement.

Royalties
 
For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

We currently have the right to receive royalties based on sales of CAMBIA in Canada, which are recognized as revenue when the related sales occur as there are no continuing performance obligations by the Company under those agreements.

Milestones

For arrangements that include milestones, the Company recognizes such revenue using the most likely method. As part of adopting ASC 606, the Company evaluated whether the future milestones should have been included as part of the transaction price in periods before January 1, 2018. The Company concluded that because of development and regulatory risks at the time, it was probable that a significant revenue reversal could have occurred. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.

Leases

The Company adopted ASC 842, Leases (ASC 842), on January 1, 2019 using the modified retrospective approach with cumulative effect. There was no adjustment to the Company's opening balance of accumulated deficit resulting from the adoption of this guidance. In addition, the Company elected the package of practical expedients, which among other things, allowed for the carryforward of the historical lease classification. The Company did not elect the hindsight practical expedient to determine the reasonably certain lease term for existing leases. Prior to the adoption of ASC 842, the Company accounted for its operating leases in accordance with ASC 840. Under ASC 840, only capital leases were recognized on the balance sheet and therefore the Company’s operating leases were reflected in the financial statement footnotes. The adoption of ASC 842 did not materially affect the Company’s consolidated comprehensive income.

11


The Company assesses contracts for lease arrangements at inception. Operating right-of-use (ROU) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease. Operating leases are included in other long term assets, other current liabilities, and other long term liabilities in the Consolidated Balance Sheet.

The Company accounts for operating leases with an initial term of 12 months or less on a straight-line basis over the lease term in the Consolidated Statements of Comprehensive Income.
 
Stock Based Compensation

The Company’s stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs), and purchases under the Company’s employee stock purchase plan (ESPP). The Company accounts for forfeitures as they occur for each type of award. Stock-based compensation expense related to restricted stock unit awards (RSUs) is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period.

The stock-based compensation expense related to PSUs is estimated at grant date based on the fair value of the award. The PSU awards are measured exclusively to the relative total shareholder return (TSR) performance, which is measured against the three-year TSR of a custom index of companies. The actual number of shares awarded is adjusted to between zero and 200% of the target award amount based upon achievement in each of the three independent successive one-year tranches. TSR relative to peers is considered a market condition under applicable authoritative guidance. For PSUs granted with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo model, and expense is recognized ratably over the requisite service period regardless of whether or not the market condition is satisfied. The Monte Carlo valuation model considers a variety of potential future share prices for Assertio and our peer companies in a selected market index.

The Company uses the Black-Scholes option valuation model to determine the fair value of stock options and ESPP shares. The determination of the fair value of stock-based payment awards on the date of grant using an option valuation model is affected by our stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate and expected dividends over the expected term of the award. The Company uses historical option exercise data to estimate the expected term of the options. The Company estimates the volatility of our common stock price by using the historical volatility over the expected term of the options. The Company bases the risk-free interest rate on U.S. Treasury zero coupon issues with terms similar to the expected term of the options as of the date of grant. The Company does not anticipate paying any cash dividends in the foreseeable future, and therefore, uses an expected dividend yield of zero in the option valuation model. Stock-based compensation expense related to the ESPP and options is recognized on a straight-line basis over its respective term.
 
Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 Financial Instruments-Credit Losses (ASU 2016-13 or Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted this standard on January 1, 2020 and updated its internal controls to include certain forward-looking considerations in the current process of developing and recognizing credit losses for in scope financial assets, which primarily included accounts receivable and a $3.5 million investment in a company engaged in medical research. ASC 326 had an immaterial impact to our allowance for credit losses reported in accounts receivable on our Condensed Consolidated Balance Sheet upon adoption. The investment is structured as a long-term loan receivable with a convertible feature and carried at amortized cost with accruing interest. To calculate the expected credit loss allowance, the Company utilized a probability-of-default method (PDM). This process estimates the probability of the loan being successfully paid back or converted into equity based on the ability of the investee to obtain FDA acceptance of its research. Using a PDM, we calculated an expected credit loss allowance at March 31, 2020 of $1.9 million, which was recorded in Other (expense) income in the Company’s Consolidated Statement of Comprehensive Income and included in Investments, net in the Company’s Consolidated Balance Sheet. Our expected credit losses can vary from period to period based on several factors, such as progress of the medical research and FDA submission, and overall economic environment and the ability of the investee to fund its operations. The primary factor that contributed to our provision

12

for expected credit losses in the first quarter of 2020 was an evaluation of probability of default to exist based on the outlook of the macro environment due to the COVID-19 pandemic and its impact to delay the FDA acceptance process combined with the investee’s ability to fund its operations and raise capital if required.

In June 2018, the FASB issued ASU 2018-18 Collaborative Arrangements (ASU 2018-18), which clarifies the interaction between ASC 808, Collaborative Arrangements (ASC 808) and ASC 606, Revenue from Contracts with Customers (ASC 606). The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The Company adopted the standard as of January 1, 2020 and have applied modified retrospective transition method to the date of initial application of ASC 606. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Accounting for Cloud Computing Arrangements (Subtopic 350-40), which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. Effective January 1, 2020, the Company adopted the standard using the prospective approach to eligible costs incurred on or after the date of adoption. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement Disclosure Framework (ASU 2018-03), which is part of a broader disclosure framework project by the FASB to improve the effectiveness of disclosures by more clearly communicating the information to the user. The Company adopted the standard as of January 1, 2020 and included these disclosures in the condensed consolidated financial statements. The additional elements of this release did not impact the Company's condensed consolidated financial statements.
 
In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASU 2019-02): Simplifying the Accounting for Income Taxes which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and by clarifying and amending existing guidance in order to improve consistent application of and simplify GAAP for other areas of Topic 740. ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company early adopted the standard effective January 1, 2020. The new standard was applied to the presentation of the Company’s reacquisition of $0.3 million and $16.5 million in equity component of the 2021 and 2024 Notes, respectively, as a result of the private purchase in February 2020.

Recently Issued Accounting Standards

In March 2020, the FASB issued ASU 2020-04 Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional expedients and exceptions to the US GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures.


    



13

NOTE 2. REVENUE
 
Disaggregated Revenue
 
The following table summarizes revenue from contracts with customers for the three months ended March 31, 2020 and 2019 (in thousands):
 
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Product sales, net
 
 
 
 
CAMBIA
 
$
6,274

 
$
8,808

Zipsor
 
2,331

 
4,231

Gralise
 
547

 
13,278

Total neurology product sales, net
 
9,152

 
26,317

NUCYNTA and Lazanda product sales adjustments
 
100

 
133

Total product sales, net
 
9,252

 
26,450

Commercialization agreement, net
 
11,258

 
30,856

Royalties and milestone revenue
 
407

 
623

Total revenues
 
$
20,917

 
$
57,929

 

Product Sales

For the three months ended March 31, 2020, neurology product sales consisted primarily of sales from CAMBIA and Zipsor. The Company completed the sale of Gralise to Alvogen on January 10, 2020, and therefore ceased recognizing product sales related to Gralise effective the transaction close date.  

The Company ceased recognizing product sales related to NUCYNTA in January 2018 as discussed below under Commercialization Agreement. The Company divested and ceased recognizing product sales related to Lazanda in November 2017. Product sales related to NUCYNTA and Lazanda during the three months ended March 31, 2020 and 2019 relate to sales reserve estimate adjustments related to sales recognized in prior periods. 

 
Commercialization Agreement
 
In December 2017, the Company and Collegium entered into the Commercialization Agreement (Commercialization Agreement), pursuant to which the Company granted Collegium the right to commercialize the NUCYNTA franchise of pain products in the U.S.  Pursuant to the Commercialization Agreement, Collegium assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing. In November 2018 the Company entered into an amendment to the Commercialization Agreement (Commercialization Amendment). Prior to the November 2018 amendment, the consideration related to the license and facilitation services was fixed and recognized ratably over the contract term. Following the November 2018 amendment, the royalty payments represented variable consideration that are subject to the sales-based royalty exception for licenses of intellectual property and are recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.
Effective as of February 13, 2020, the Company divested its rights, title and interest in and to its NUCYNTA franchise of products in the U.S. to Collegium. In connection with the sale, the Commercialization Agreement terminated at closing with certain specified provisions of the Commercialization Agreement surviving in accordance with the terms of the purchase agreement.    

For the three months ended March 31, 2020, the Company recognized net revenue from the Commercialization Agreement of $11.3 million. This included variable royalty revenue for the three months ended March 31, 2020 of $13.1 million offset by the amortization of the $1.8 million net contract asset in connection with the termination of the Commercialization Agreement as a result of the divestiture of NUCYNTA to Collegium.


14

During the three ended March 31, 2019, the Company recognized $1.0 million of net expense related to the third-party royalties which were paid by Collegium on behalf of Assertio. Collegium paid the full royalty owed to the third-party in 2019 and such amounts, over the course of the calendar year, had no net impact to the Company’s Consolidated Statement of Comprehensive Income.

Contract Assets
 
The following table presents changes in the Company’s contract assets as of March 31, 2020 (in thousands):
 
Balance as of
 
 
 
 
 
Balance as of
 
December 31, 2019
 
Additions
 
Deductions
 
March 31,
2020
Contract asset - Collegium, net
1,896

 
—

 
(1,896
)
 
—



The Collegium contract asset, net represented the conditional right to consideration for completed performance under the Commercialization Agreement arising from the transfer of inventory to Collegium on the date of closing of the agreement in January 2018 net of the contract liability of $10.0 million resulting from the upfront payment received and the $8.8 million of warrants received in connection with the Commercialization Amendment. In connection with the divestiture of NUCYNTA to Collegium the Company amortized the remaining balance of the contract asset in the first quarter of 2020.

Royalties & Milestones

In November 2010, we entered into a license agreement with Tribute Pharmaceuticals Canada Ltd. (now Nuvo Pharmaceuticals, Inc.) granting them the rights to commercially market CAMBIA in Canada. Nuvo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We receive royalties on net sales on a quarterly basis as well as certain one-time contingent milestone payments upon the occurrence of certain events. During the three months ended March 31, 2020 and 2019, we recognized $0.4 million and $0.6 million of revenue related to CAMBIA in Canada, respectively.
    
NOTE 3. ACCOUNTS RECEIVABLES, NET
 
Accounts receivables, net, consist of the following (in thousands): 
 
March 31,
2020
 
December 31,
2019
Receivables related to product sales, net
$
12,427

 
$
38,353

Receivables from Collegium
—

 
4,104

Other
525

 
287

Total accounts receivable, net
$
12,952

 
$
42,744

 

As of March 31, 2020 and 2019, allowances for cash discounts for prompt payment were $0.4 million and $1.2 million, respectively.

NOTE 4.  INVENTORIES, NET
 
Inventories, net, consist of raw materials, work in process and finished goods and are stated at the lower of cost or market and consist of the following (in thousands): 
 
March 31,
2020
 
December 31, 2019
Raw materials
$
29

 
$
1,065

Work-in-process
153

 
426

Finished goods
336

 
1,921

Total
$
518

 
$
3,412




15

Inventory, net as of March 31, 2020 decreased as compared to December 31, 2019 as a result of the divestiture of Gralise in January 2020.

As of March 31, 2020 and 2019, inventory reserves were $0.1 million and $0.4 million, respectively.

NOTE 5.  INTANGIBLE ASSETS
 
The gross carrying amounts and net book values of intangible assets were as follows (in thousands): 
 
 
March 31, 2020
 
December 31, 2019
Product rights
 
Remaining Useful Life (In years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Disposition
 
Net Book Value
 
Gross Carrying Amount
 
Accumulated Amortization
 
Impairment
 
Net Book Value
NUCYNTA
 
—
 
$
830,188

 
$
(461,119
)
 
$
(369,069
)
 
$
—

 
$
1,019,978

 
$
(455,192
)
 
$
(189,790
)
 
$
374,996

CAMBIA
 
3.7
 
51,360

 
(32,311
)
 
—

 
19,049

 
51,360

 
(31,027
)
 
—

 
20,333

Zipsor
 
2.0
 
27,250

 
(22,628
)
 
—

 
4,622

 
27,250

 
(22,044
)
 
—

 
5,206

Total
 
 
 
$
908,798

 
$
(516,058
)
 
$
(369,069
)
 
$
23,671

 
$
1,098,588

 
$
(508,263
)
 
$
(189,790
)
 
$
400,535



Amortization expense was $7.8 million and $25.4 million for the three months ended March 31, 2020 and 2019, respectively.
    
In February 2020, the Company divested its remaining rights, title and interest in and to the NUCYNTA franchise of products from the Company. As a result, the Company derecognized the remaining carrying value of $369.1 million of the NUCYNTA product rights.

Based on finite-lived intangible assets recorded as of March 31, 2020, and assuming the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): 
Year Ending December 31,
 
Estimated Amortization Expense
2020 (remainder)
 
$
5,605

2021
 
7,473

2022
 
5,668

Thereafter
 
4,925

Total
 
$
23,671


NOTE 6.  ACCRUED LIABILITIES
 
Accrued liabilities consist of the following (in thousands): 
 
March 31,
2020
 
December 31,
2019
Accrued compensation
$
4,913

 
$
6,188

Accrued consent fees
4,500

 
—

Accrued taxes payable
2,241

 
295

Accrued restructuring costs
1,332

 
3,763

Other accrued liabilities
11,730

 
8,702

Total accrued liabilities
$
24,716

 
$
18,948

 
NOTE 7.  STOCK-BASED COMPENSATION


16

The Company’s stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs), and purchases under the Company’s employee stock purchase plan (ESPP).
 
The following table presents stock‑based compensation expense recognized in the Company’s Consolidated Statements of Comprehensive Income (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cost of sales
$
23

 
$
—

Research and development expense
163

 
273

Selling, general and administrative expense
1,748

 
2,429

Restructuring
—

 
—

Total
$
1,934

 
$
2,702


 
At March 31, 2020, the Company had $0.9 million of total unrecognized compensation expense related to stock option grants that will be recognized over an average vesting period of 1.22 years and $14.6 million of total unrecognized compensation expense related to RSUs and PSUs that will be recognized over an average vesting period of 2.24 years.
 
During the three months ended March 31, 2020 the Company granted 3.6 million RSUs at an average fair market value of $1.05 per share. The Company did not grant any PSUs or options during three months ended March 31, 2020.

17

NOTE 8.  DEBT
 
Senior Notes
 
On April 2, 2015, the Company issued $575.0 million aggregate principal amount of senior secured notes (the Senior Notes) for aggregate gross proceeds of approximately $562.0 million pursuant to a Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement), among the Company and Deerfield Private Design Fund III, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., BioPharma Secured Investments III Holdings Cayman LP, Inteligo Bank Ltd. and Phemus Corporation (collectively, the Purchasers) and Deerfield Private Design Fund III, L.P., as collateral agent. The Company used $550.0 million of the net proceeds received upon the sale of the Senior Notes to fund a portion of the Purchase Price paid to Janssen Pharma in connection with the NUCYNTA acquisition.
 
The Senior Notes had a maturity date of April 14, 2021 (unless earlier prepaid or repurchased), were secured by substantially all of the assets of the Company and any subsidiary guarantors, and bore interest at the rate equal to the lesser of (i) 9.75% over the three month London Inter-Bank Offer Rate (LIBOR), subject to a floor of 1.0% and (ii) 11.95% (through the third anniversary of the purchase date) and 12.95% (thereafter). The interest rate was determined at the first business day of each fiscal quarter, commencing with the first such date following April 2, 2015. The interest rate for the three months ended March 31, 2020 and 2019 was 11.65% and 12.54%, respectively.

As of February 13, 2020, the Company had repaid in full all outstanding indebtedness, and terminated all commitments and obligations, under its Note Purchase Agreement. The Company used proceeds from the sale of Gralise and NUCYNTA to repay the outstanding principal of $162.5 million. In addition, the Company paid approximately $4.9 million and $4.4 million in prepayment premiums and accrued exit fees, respectively, plus accrued but unpaid interest. In connection with the termination of the Note Purchase Agreement, the Company was released from all security interests, liens and encumbrances under the Note Purchase Agreement.

During the three months ended March 31, 2020, the Company recognized a loss on debt extinguishment of $8.2 million, composed of the $4.9 million prepayment fee and $3.3 million of unamortized debt discount and debt issuance costs, recognized as part of Loss on debt extinguishment in the Company’s Consolidated Statement of Comprehensive Income.

The following is a summary of the carrying value of the Senior Notes as of December 31, 2019 (in thousands): 
 
 
December 31,
2019
Principal amount of the Senior Notes
 
$
162,500

Unamortized debt discount balance
 
(4,035
)
Unamortized debt issuance costs
 
(2,022
)
Total Senior Notes
 
$
156,443


Debt discount and debt issuance costs were amortized as interest expense using the effective interest method. The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands): 
 
Three Months Ended March 31,
 
2020
 
2019
Contractual interest expense
$
1,648

 
$
8,206

Amortization of debt discount and debt issuance costs
2,699

 
1,357

Total interest expense Senior Notes
$
4,347

 
$
9,563

 
    
    
2.50% Convertible Senior Notes Due 2021
 
On September 9, 2014, the Company issued $345.0 million aggregate principal amount of 2.50% Convertible Senior Notes Due 2021 (the 2021 Notes) which mature on September 1, 2021 and bear interest at the rate of 2.50% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning March 1, 2015.

On August 13, 2019, the Company exchanged (the Convertible Note Exchange) $200.0 million aggregate principal amount of the 2021 Notes for a combination of (a) its new $120.0 million aggregate principal amount of 5.00% Convertible

18

Senior Notes due August 15, 2024 (the 2024 Notes), (b) an aggregate cash payment of $30.0 million, and (c) an aggregate of 15.8 million shares of the Company’s common stock. The Company did not receive any cash proceeds from the issuance of the 2024 Notes or the issuance of the shares of its common stock. Upon completion of the Convertible Note Exchange, the aggregate principal amount of the 2021 Notes was reduced by $200.0 million to $145.0 million, the unamortized debt discount and debt issuance costs was reduced by $26.1 million to $18.9 million and the carrying amount of the equity component was reduced by $6.2 million to $112.8 million.

On February 19, 2020, the Company entered into separate, privately negotiated purchase agreements (Purchase Agreements) with a limited number of holders of the Company’s currently outstanding 2021 Notes and 2024 Notes. The Company used proceeds from the sale of Gralise and NUCYNTA to repurchase $102.5 million aggregate principal amount of 2021 Notes for a cash payment plus accrued but unpaid interest.

The repurchase of the 2021 Notes was accounted for in accordance with ASC 470-50, Debt Modifications and Extinguishments (ASC 470-50). During the three months ended March 31, 2020, the Company recognized a $10.3 million loss on debt extinguishment, which represented the difference between the carrying value and the fair value of the 2021 Notes just prior to the repurchase plus transaction costs. The Company also recognized reacquisition of $0.3 million in additional paid-in capital related to the equity component of the 2021 Notes based on the excess of the fair value of total considerations provided against the fair value of the 2021 Notes just prior to the repurchase. As a result of the transaction, the aggregate principal amount of the 2021 Notes was reduced to $42.5 million, the unamortized debt discount and debt issuance costs was reduced by $10.3 million to $4.3 million and the carrying amount of the equity component was reduced by $0.3 million to $112.5 million.

The closing price of the Company’s common stock did not exceed 130% of the $19.24 conversion price, for the required period during the quarter ended March 31, 2020. As a result, the 2021 Notes were not convertible as of March 31, 2020.

The following is a summary of the liability component of the 2021 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31,
2019
Principal amount of the 2021 Notes
$
42,465

 
$
145,000

Unamortized discount of the liability component
(3,767
)
 
(14,963
)
Unamortized debt issuance costs
(184
)
 
(725
)
Total 2021 Notes
$
38,514

 
$
129,312



The debt discount and debt issuance costs are being amortized as interest expense using the effective interest method. The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Stated coupon interest
$
607

 
$
2,156

Amortization of debt discount and debt issuance costs
1,469

 
4,807

Total interest expense 2021 Notes
$
2,076

 
$
6,963

 

5.00% Convertible Senior Notes Due 2024

On August 13, 2019, as part of the Convertible Note Exchange, the Company issued $120.0 million aggregate principal of 2024 Notes which mature on August 14, 2024 and bear interest at a rate of 5.0%, payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2020.

On February 19, 2020, the Company entered into separate, privately negotiated purchase agreements (Purchase Agreements) with a limited number of holders of the Company’s currently outstanding 2021 Notes and 2024 Notes. The Company used proceeds from the sale of Gralise and NUCYNTA to repurchase $85.5 million aggregate principal amount of 2024 Notes for a cash payment plus accrued but unpaid interest.

The repurchase of the 2024 Notes was accounted for in accordance with ASC 470-50, Debt Modifications and Extinguishments (ASC 470-50). During the three months ended March 31, 2020 the Company recognized a $21.3 million loss

19

on debt extinguishment, which represented the difference between the carrying value and the fair value of the 2024 Notes just prior to the repurchase plus transaction costs. The Company also recognized reacquisition of $16.8 million in additional paid-in capital related to the equity component of the 2024 Notes based on the excess of the fair value of total considerations provided against the fair value of the 2024 Notes just prior to the repurchase. As a result of the transaction, the aggregate principal amount of the 2024 Notes was reduced to $34.5 million, the unamortized debt discount and debt issuance costs was reduced by $38.1 million to $15.4 million and the carrying amount of the equity component was reduced by $16.5 million to $16.1 million.
    
The 2024 Notes are not convertible or redeemable as of March 31, 2020. The following is a summary of the liability component of the 2024 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31, 2019
Principal amount of the 2024 Notes
$
34,522

 
$
120,000

Unamortized discount of the liability component
(14,373
)
 
(51,701
)
Unamortized debt issuance costs
(797
)
 
(2,796
)
Total 2024 Notes
$
19,352

 
$
65,503



The debt discount and debt issuance costs are being amortized as interest expense using the effective interest method. The following is a summary of interest expense for the 2024 Notes for three months ended March 31, 2020 (in thousands):
 
Three Months Ended March 31, 2020
Stated coupon interest
$
1,047

Amortization of debt discount and debt issuance costs
1,219

Total interest expense 2024 Notes
$
2,266



On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. As a result of the Company’s intention to settle in cash the total remaining outstanding aggregate principal, the liability component of the 2021 Notes and 2024 Notes are classified as part of Convertible notes, current portion on the Company’s Consolidated Balance Sheet as of March 31, 2020.

NOTE 9.  LEASES

The Company has non-cancelable operating leases for its office and laboratory facilities, automobiles used by its sales force, and certain operating leases for office equipment.

The Company relocated its corporate headquarters from Newark, California to Lake Forest, Illinois in 2018 and subsequently entered into two subleases which, together, account for the entirety of the Newark facility. Each sublease contained abated rent periods resulting in reduced operating lease cash flows through May 2019. Operating lease costs and sublease income related to the Newark facility are accounted for in Other in the Consolidated Statements of Comprehensive Income. The Company has the right to renew the term of the Lake Forest lease for one period of five years, provided that written notice is made to the Landlord no later than twelve months prior to the expiration of the initial term of the Lease. 

Lease expense during the period included the following (in thousands):
 
 
 
Three Months Ended March 31,
 
Financial Statement Classification
 
2020
 
2019
Operating lease cost
Selling, general and administrative expenses
 
$
157

 
$
187

Operating lease cost
Other
 
148

 
148

Total lease cost
 
 
$
305

 
$
335

 
 
 
 
 
 
Sublease Income
Other
 
$
347

 
$
362




20

NOTE 10.  COMMITMENTS AND CONTINGENCIES

 
Purchase and Other Commitments

As of March 31, 2020 and December 31, 2019, the Company had non‑cancelable purchase orders and minimum purchase obligations related to manufacturing agreements of approximately $0.7 million and $3.6 million, respectively. Additionally, the Company had non‑cancelable purchase orders related to consulting services of approximately $1.8 million and $2.4 million as of March 31, 2020 and December 31, 2019, respectively.


Legal Matters

Glumetza Antitrust Litigation
Antitrust class actions and related direct antitrust actions have been filed in the Northern District of California against the Company and several other defendants relating to the drug Glumetza®. The named class representatives in the currently pending actions include Meijer, Inc., Bi-Lo, LLC, Winn-Dixie Logistics, Inc., City of Providence, and KPH Healthcare Services, Inc. These class representatives seek to represent a putative class of direct purchasers of Glumetza. In addition, several retailers, including CVS Pharmacy, Inc., Rite Aid Corporation, Walgreen Co., the Kroger Co., the Albertsons Companies, Inc., H-E-B, L.P., and Hy-Vee, Inc., have filed substantially similar direct antitrust claims based on alleged assignments of claims from direct purchaser wholesalers. On December 23, 2019, the Company filed a motion to dismiss all claims in the actions. That motion was heard by the District Court on February 20, 2020. On March 5, 2015 the District Court issued an order denying the motion to dismiss. However, based on the order on the motion, claims previously filed by a putative class of end payor plaintiffs were voluntarily dismissed.

These antitrust cases arise out of a Settlement and License Agreement (the Settlement) that the Company, Santarus, Inc. (Santarus) and Lupin Limited (Lupin) entered into in February 2012 that resolved patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs allege, among other things, that the Settlement violated the antitrust laws because it allegedly included a “reverse payment” that caused Lupin to delay its entry in the market with a generic version of Glumetza. The alleged “reverse payment” is an alleged commitment on the part of the settling parties not to launch an authorized generic version of Glumetza for a certain period. The antitrust plaintiffs allege that the Company and its co-defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus) are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza® due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.

The parties are currently conducting discovery, and briefing a motion by the direct purchasers seeking class certification. The Company intends to defend itself vigorously in these matters.

Securities Class Action Lawsuit and Related Matters

On August 23, 2017, the Company, its current chief executive officer and president, its former chief executive officer and president, and its former chief financial officer were named as defendants in a purported federal securities law class action filed in the U.S. District Court for the Northern District of California (the District Court). The action (Huang v. Depomed et al., No. 4:17-cv-4830-JST, N.D. Cal.) alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 relating to certain prior disclosures of the Company about its business, compliance, and operational policies and practices concerning the sales and marketing of its opioid products and contends that the conduct supporting the alleged violations affected the value of Company common stock and is seeking damages and other relief. In an amended complaint filed on February 6, 2018, the lead plaintiff (referred to in its pleadings as the Depomed Investor Group), which seeks to represent a class consisting of all purchasers of Company common stock between July 29, 2015 and August 7, 2017, asserted the same claims arising out of the same and similar disclosures against the Company and the same individuals as were involved in the original complaint. The Company and the individuals filed a motion to dismiss the amended complaint on April 9, 2018. On March 18, 2019, the District Court granted the motion to dismiss without prejudice, and the plaintiffs filed a second amended complaint on May 2, 2019. The second amended complaint asserted the same claims arising out of the same and similar disclosures against the Company and the same individuals as were involved in the original complaint. The Company and the individuals filed a motion to dismiss the second amended complaint on June 17, 2019. The lead plaintiff filed an opposition to the motion on August 1, 2019. The Company and the individuals filed a reply in support of their motion to

21

dismiss on August 30, 2019. The District Court held oral argument on December 18, 2019. On March 11, 2020, the District Court granted the motion to dismiss the second amended complaint. On April 9, 2020, the plaintiffs filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. The Company believes that the action is without merit and intends to contest it vigorously.

In addition, five shareholder derivative actions were filed on behalf of the Company against its officers and directors for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the federal securities laws. The claims arise out of the same factual allegations as the class action. The first derivative action was filed in the Superior Court of California, Alameda County on September 29, 2017 (Singh v. Higgins et al., RG17877280). The second and third actions were filed in the Northern District of California on November 10, 2017 (Solak v. Higgins et al., No. 3:17-cv-6546-JST) and November 15, 2017 (Ross v. Fogarty et al., No. 3:17-cv-6592- JST). The fourth action was filed in the District of Delaware on December 21, 2018 (Lutz v. Higgins et al, No. 18-2044-CFC). The fifth derivative action was filed in the Superior Court of California, Alameda County on January 28, 2019 (Youse v. Higgins et al, No. HG19004409). On December 7, 2017, the plaintiffs in Solak v. Higgins, et al. voluntarily dismissed the first federal derivative action. The Ross, Singh, and Lutz actions were stayed on January 18, 2018, January 23, 2018, and January 11, 2019, respectively, pending the resolution of the motion to dismiss in the securities class action. On May 28, 2019, during a brief lift of the stay in the Singh and Youse actions while the parties’ motion to consolidate was pending, after having been ordered to respond to the Singh and Youse complaints, the Company did so by filing demurrers. On July 12, 2019, the Singh and Youse actions were consolidated, and the consolidated matter was stayed pending the resolution of the motion to dismiss in the federal class action. The plaintiffs have indicated that they intend to file an amended consolidated complaint. The Company believes that these actions are without merit and intends to contest them vigorously.

Opioid-Related Request and Subpoenas

As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, the Company received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information from the Company regarding its historical commercialization of opioid products. The Company voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, the Company has received and responded to subpoenas from the U.S. Department of Justice (DOJ) seeking documents and information regarding its historical sales and marketing of opioid products. The Company has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding the Company’s historical sales and marketing of opioid products. In addition, the Company received and responded to a subpoena from the State of California Department of Insurance (CDI) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also seeks information on Gralise, a non-opioid product formerly in the Company’s portfolio. Most recently, the Company received a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company also from time to time receives and complies with subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

Multidistrict Opioid Litigation
A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but most of the lawsuits include federal and state statutory claims as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.
For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (MDL Court) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been transferred to the MDL Court. The Company is currently involved in a subset of the lawsuits that have been transferred to the MDL Court. The Company is also involved in other federal lawsuits that have not yet been transferred to the MDL Court pending a determination of whether those lawsuits should proceed in state or other originating court. Plaintiffs may file additional lawsuits in which the Company may be named. Plaintiffs in the pending federal cases involving the Company include individuals, county and municipal governmental entities,

22

employee benefit plans, health clinics and health insurance providers who assert federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. These lawsuits are in the earliest stages of proceedings, and the Company intends to defend itself vigorously in these matters.
State Opioid Litigation
Related to the cases in the MDL Court noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. The Company is currently named in a subset of those cases, including cases in Alabama, Florida, Illinois, Missouri, Pennsylvania, Texas and Utah. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving the Company, plaintiffs are asserting state common law and statutory claims against the defendants similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking past and future damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. These lawsuits are likewise in their earliest stages, and the Company intends to defend itself vigorously in these matters.
Insurance Litigation
On January 15, 2019, the Company was named as a defendant in a declaratory judgment action filed by Navigators Specialty Insurance Company (Navigators) in the U.S. District Court for the Northern District of California (Case No. 3:19-cv-255). Navigators is the Company’s primary product liability insurer. Navigators is seeking declaratory judgment that opioid litigation claims noticed by the Company (as further described above under “Multidistrict Opioid Litigation” and “State Opioid Litigation”) are not covered by the Company’s life sciences liability policies with Navigators. The Company filed a counterclaim on February 28, 2019. Navigators filed an answer on April 11, 2019. This litigation is ongoing. The parties expect to file summary judgment briefing relating to Navigators’ duty to defend the opioid litigation in the third quarter of 2020, and to receive a ruling in 2021.
General
The Company cannot reasonably predict the outcome of the legal proceedings described above, nor can the Company estimate the amount of loss, range of loss or other adverse consequence, if any, that may result from these proceedings or the amount of any gain in the event the Company prevails in litigation involving a claim for damages. As such the Company is not currently able to estimate the impact of the above litigation on its financial position or results of operations.
The Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to further litigation in federal and state courts relating to opioid drugs. Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth above, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.

23

NOTE 11.  RESTRUCTURING CHARGES

The Company continually evaluates its operations to identify opportunities to streamline operations and optimize operating efficiencies as an anticipation to changes in the business environment. In November 2019, the Company announced an acceleration of cost-saving initiatives that included a decision to discontinue its relationship with its contract sales organization, a reduction in the use of certain outside vendors and consultants, and the reorganization of certain functions resulting in a reduction of staff at its headquarters office and remote positions during the fourth quarter of 2019. The 2019 cost-saving initiative was substantially complete as of December 31, 2019. As a result, $3.9 million of severance and benefits costs for the reduction of staff were recognized during the year ended December 31, 2019. The Company does not expect to incur future costs related to the 2019 cost-saving initiative.

Selected information relating to accrued restructuring, severance costs and one-time termination costs is as follows (in thousands):
 
Employee compensation costs
Balance at December 31, 2019
$
3,763

Cash paid
(2,431
)
Balance at March 31, 2020
$
1,332


 
As of March 31, 2020, the full $1.3 million accrued restructuring liability balance was classified as a current liability in the Consolidated Balance Sheet.

NOTE 12.  NET INCOME (LOSS) PER SHARE

Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated by dividing the net income by the weighted-average number of shares of common stock outstanding during the period, plus potentially dilutive common shares, consisting of stock options and convertible debt. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock options and equivalents. The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt. For purposes of this calculation, options to purchase stock are considered to be potential common shares and are only included in the calculation of diluted net (loss) income per share when their effect is dilutive. Basic and diluted earnings per common share are calculated as follows (in thousands, except for per share amounts):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Basic net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Basic net income (loss) per share
 
$
0.58

 
$
(0.22
)
 
 
 
 
 
Diluted net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Add: effect of dilutive stock options, awards, and equivalents
 
111

 
—

Denominator for diluted income (loss) per share
 
71,051

 
64,239

Diluted net income (loss) per share
 
$
0.58

 
$
(0.22
)

 
The following table sets forth outstanding potentially dilutive common shares that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):

24

 
 
Three Months Ended March 31,
 
 
2020
 
2019
2.5% Convertible Notes debt 2021
 
5,111

 
17,931

5.0% Convertible Notes debt 2024
 
26,248

 
—

Stock options, awards and equivalents
 
7,144

 
6,103

Total potentially dilutive common shares
 
38,503

 
24,034




25

NOTE 13.  FAIR VALUE

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
 
•
Level 1: Quoted prices in active markets for identical assets or liabilities.
•
Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 (in thousands):
March 31, 2020
 
Financial Statement Classification
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
Collegium warrants
 
Investments, net
 
$
—

 
$
6,483

 
$
—

 
$
6,483

Total
 
 
 
$
—

 
$
6,483

 
$
—

 
$
6,483

December 31, 2019
 
Financial Statement Classification
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
Collegium warrants
 
Investments, net
 
$
—

 
$
9,629

 
$
—

 
$
9,629

Total
 
 
 
$
—

 
$
9,629

 
$
—

 
$
9,629



The fair value of the warrants to purchase Collegium’s common stock was calculated using the Black-Scholes option pricing model. As of March 31, 2020, the significant inputs included the fair value of Collegium’s common stock of $16.33, an expected term of 2.61 years and a risk-free rate of 0.27%. The expected term was based on the remaining contractual period of 2.61 years, and the volatility was determined using Collegium’s historical common stock volatility over the expected term. For the three months ended March 31, 2020, the Company recorded a loss of $3.1 million in Other for the change in fair value of the Collegium warrants
 
The Company estimates the fair value of its convertible notes based on a market approach which represents a Level 2 valuation. The estimated fair value of the 2.50% Convertible Senior Notes Due 2021, which the Company issued on September 9, 2014, was approximately $42.2 million (par value $42.5 million) and $108.1 million (par value $145.0 million) as of March 31, 2020 and December 31, 2019, respectively. The estimated fair value of the 5.00% Convertible Senior Notes Due 2024, which the Company issued on August 13, 2019, was approximately $34.3 million (par value $34.5 million) and $81.6 million (par value $120.0 million) as of March 31, 2020 and December 31, 2019, respectively. The principal amount of the Senior Notes approximates their fair value as of December 31, 2019 and represented a Level 2 valuation. The Senior Notes were fully repaid as of March 31, 2020. When determining the estimated fair value of the Company’s debt, the Company uses a commonly accepted valuation methodology and market-based risk measurements that are indirectly observable, such as credit risk. 
 
There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the three months ended March 31, 2020 and 2019.


26

NOTE 14.  INCOME TAXES
 
As of March 31, 2020, our net deferred tax assets are fully offset by a valuation allowance. The valuation allowance is determined in accordance with the provisions of ASC 740, Income taxes, which require an assessment of both negative and positive evidence when measuring the need for a valuation allowance.  Based on the weight of available evidence, the Company recorded a full valuation allowance against the Company’s net deferred assets beginning in the fourth quarter of 2016. The Company continued to provide a full valuation allowance against the Company’s net deferred assets in subsequent quarters. The Company reassesses the need for a valuation allowance on a quarterly basis.  If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.
 
On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, a massive tax-and-spending package intended to provide additional economic relief to address the impact of the COVID-19 pandemic. The CARES Act, among other business tax provisions, included legislative changes and updates to IRC sections 172, 163(j), and 168, resulting in impacting net operating losses, interest disallowance, and depreciation for qualified improvement property. The Company’s intention to carryback 2020 taxable loss to 2018 and 2019 resulted in the release of valuation allowance which was recorded to beginning deferred tax asset balance.  For the three months ended March 31, 2020, the Company recorded an expense from income taxes of approximately $2.0 million, which represents an effective tax rate of 4.7%. The difference between the income tax expense of $2.0 million and the tax at the statutory rate of 21.0% to date on current year operations is principally due to the partial release of valuation allowance recorded against the beginning of year deferred tax asset related the NOL carryback to the 2018 and 2019 tax years now permitted by the CARES Act.
 
For the three months ended March 31, 2019, the Company recorded an expense from income taxes of approximately $0.2 million that represents an effective tax rate of (1.5)%.  The difference between the recorded provision for income taxes and the income tax benefit based on the statutory federal tax rate of 21.0% was primarily attributable to the impact of the valuation allowance.
 
The Company files income tax returns in the United States federal jurisdiction and in various states, and the tax returns filed for the years 1997 through 2017 and the applicable statutes of limitation have not expired with respect to those returns. Because of net operating losses and unutilized R&D credits, substantially all of the Company’s tax years remain open to examination. The Company exhausted all the federal research and development credit in the 2018 tax return. Although the NOL carryback from CARES Act will result in making R&D credit utilized in 2018 available for future use, the percentage of unrecognized tax benefit against the R&D credit remains reserved, and the rest will be offset by valuation allowance.  Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense by the Company. At March 31, 2020 the Company did not have any accrued interest and penalties associated with unrecognized tax benefits.

NOTE 15. ACQUISITIONS AND DISPOSITIONS

Sale of Gralise

On December 12, 2019, the Company entered into a purchase agreement with Golf Acquiror LLC, an affiliate of Alvogen, Inc. (Alvogen) to divest its rights, title and interest in and to Gralise, including certain related assets, to Alvogen. The transaction subsequently closed on January 10, 2020. At closing, the Company received $78.6 million, including a $75.0 million base purchase price and a preliminary positive inventory adjustment equal to $3.6 million. In addition, the Company is entitled to receive 75% of Alvogen’s first $70.0 million of Gralise net sales after closing, a total of $52.5 million, as contingent consideration. Alvogen has also assumed, pursuant to the terms of the Asset Purchase Agreement, certain contracts, liabilities and obligations of the Company relating to Gralise, including those related to manufacturing and supply, post-market commitments and clinical development costs.

Pursuant to ASC 205-20, Presentation of Financial Statements— Discontinued Operations, Gralise did not meet the criteria of a discontinued operation as it was not considered a component of an entity that comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the Company, nor did it represent a strategic shift of the Company. The Company accounted for the divestiture under ASC 610-20 Other Income - Derecognition of Nonfinancial Assets. The Company recognized a gain of $127.5 million in Other income on the Company’s Consolidated Statements of Comprehensive Income composed of the $78.6 million in upfront consideration received and $52.5 million in contingent consideration deemed to be probable, net of $3.6 million in inventory transferred. The net remaining contingent consideration receivable as of March 31, 2020 is recognized and presented separately as a current asset on the

27

Company’s Consolidated Balance Sheet. In addition, the Company recognized co-promotion service income of approximately $1.3 million during the three months ended March 31, 2020. Co-promotion services were completed as of March 31, 2020.


Termination of Slán Agreements

On November 7, 2017, the Company entered into an agreement with Slán Medicinal Holdings Limited (Slán) under which it (i) acquired from Slán certain rights to market the specialty drug, long-acting cosyntropin in the U.S. and (ii) divested to Slán all of its rights to Lazanda® (fentanyl) nasal spray CII. As consideration for this acquisition, the Company provided the seller all of the rights and obligations, as defined under the arrangement, associated with Lazanda and together with $5.0 million in cash to Slán.

As outlined in the Slán Agreements, each party would support the development, including clinical development, of the licensed product and efforts to obtain regulatory approval of the initial NDA. Subsequent to approval of the initial NDA, Assertio and Slán would share in the net sales of long-acting cosyntropin for a 10-year period (after which time the product will revert back to Slán). As of December 31, 2019, the Company had $2.0 million of reimbursable development expenses in Prepaid and other current assets on the Company’s consolidated balance sheet.

On February 6, 2020, the Company entered into an amended agreement with Eolas Pharma Teoranta (Eolas), an affiliate of Slán. Pursuant to the amendment the license granted to the Company for the commercialization of long-acting cosyntropin was terminated and the Company received $2.0 million in settlement of the December 31, 2019 receivable for reimbursable development expenses. Additionally, the Company may receive up to $10.0 million in future payments based upon commercial sales of long-acting cosyntropin if Eolas successfully obtains regulatory approval for and commercializes the product.


Sale of NUCYNTA
    
On February 6, 2020, the Company entered into a purchase agreement with Collegium, to divest its remaining rights, title and interest in and to the NUCYNTA franchise of products from the Company, and assumed certain contracts, liabilities and obligations of the Company relating to the NUCYNTA products, including those related to manufacturing and supply, post-market commitments and clinical development costs. The transaction subsequently closed on February 13, 2020.

The Company received $367.9 million in net proceeds, which consisted of $375.0 million in base purchase price, plus $6.0 million in preliminary positive inventory value and less $13.1 million for royalties paid to the Company by Collegium between January 1, 2020 and February 11, 2010 pursuant to the Final Commercialization Agreement Payment Value of the Asset Purchase Agreement. In connection with the sale, the Company entered into a third-party consent agreement which requires two lump sum payments of $4.5 million each payable in 2021 and 2022 subject to Collegium achieving certain net sales in 2020 and 2021, respectively.

Since January 9, 2018, Collegium has been responsible for the commercialization of NUCYNTA in the U.S., including sales and marketing, and the Company received royalties based on certain net sales thresholds, in accordance with the Commercialization Agreement. The Commercialization Agreement terminated at closing with certain specified provisions of the Commercialization Agreement surviving in accordance with the terms of the Purchase Agreement.

Pursuant to ASC 205-20, the divestiture of NUCYNTA did not meet the criteria of a discontinued operation as it was not considered a strategic shift. The Company accounted for the divestiture under ASC 610-20 Other Income - Derecognition of Nonfinancial Assets. During the three months ended March 31, 2020, the Company recognized a net loss of $15.8 million in Other income which was comprised of the $367.9 million in consideration received less the $369.1 million carrying value of the NUCYNTA intangible derecognized, $5.6 million in net book value of inventory transferred, and $9.0 million in accrued third-party consent fees.

NOTE 16. SUBSEQUENT EVENTS

On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, the Company announced the completion and

28

final results for its cash tender offers which the Company settled approximately $76.7 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes with only $0.3 million of 2021 notes remaining.


    

29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
FORWARD-LOOKING INFORMATION
 
Statements made in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, those relating to:
•
the potential impacts of the ongoing COVID-19 pandemic on the Company’s liquidity, capital resources, operations and business and those of the third parties on which it relies, including suppliers and distributors;
•
our ability to successfully pursue business development, strategic partnerships, and investment opportunities to build and grow for the future;
•
the commercial success and market acceptance of our products;
•
the outcome of our opioid-related investigations, our opioid-related litigation brought by state and local governmental entities and private parties, and our insurance, antitrust and other litigation, and the costs and expenses associated therewith;
•
any additional patent infringement or other litigation, investigation or proceeding that may be instituted related to us or any of our products, product candidates or products we may acquire;
•
our ability to generate sufficient cash flow from our business to make payments on our indebtedness, our ability to restructure or refinance our indebtedness and our compliance with the terms and conditions of the agreements governing our indebtedness;
•
our common stock regaining compliance with Nasdaq’s minimum closing bid requirement of at least $1.00 per share;
•
our and our collaborative partners’ compliance or non-compliance with legal and regulatory requirements related to the development or promotion of pharmaceutical products in the U.S.;
•
our plans to acquire, in-license or co-promote other products, and/or acquire companies;
•
the timing and results of our and our collaborative partners’ research and development efforts including clinical studies relating to our and our collaborative partners’ product candidates;
•
our ability to raise additional capital, if necessary;
•
our ability to successfully develop and execute our sales and marketing strategies;
•
variations in revenues obtained from commercialization and collaborative agreements, including contingent milestone payments, royalties, license fees and other contract revenues, including non-recurring revenues, and the accounting treatment with respect thereto;
•
our collaborative partners’ compliance or non-compliance with obligations under our collaboration agreements; and
•
our ability to attract and retain key executive leadership.
This document also contains statements about our agreement to effect an all-stock, strategic combination with Zyla Life Sciences (Zyla) resulting in a new combined company (collectively, the Proposed Merger). Many factors could cause actual results to differ materially from these forward-looking statements with respect to the Proposed Merger, including (1) the completion of the Proposed Merger on anticipated terms and timing, including obtaining shareholder approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s operations and other conditions to the completion of the Proposed Merger; (2) the risk that the conditions to the closing of the Proposed Merger are not satisfied, including the risk that required approvals for the Proposed Merger from the stockholders of Assertio or Zyla are not obtained; (3) the occurrence of any event, change or other circumstances that either could give rise to the right of one or both of Assertio or Zyla to terminate the merger agreement; (4)

30

the risk of litigation relating to the Proposed Merger; (5) uncertainties as to the timing of the consummation of the Proposed Merger and the ability of each party to consummate the Proposed Merger; (6) risks related to disruption of management time from ongoing business operations due to the Proposed Merger; (7) unexpected costs, charges or expenses resulting from the Proposed Merger; (8) the ability of the Assertio and Zyla to retain and hire key personnel; (9) competitive responses to the Proposed Merger and the impact of competitive services; (10) certain restrictions during the pendency of the Proposed Merger that may impact Assertio’s or Zyla’s ability to pursue certain business opportunities or strategic transaction; (11) potential adverse changes to business relationships resulting from the announcement or completion of the Proposed Merger; (12) the combined company’s ability to achieve the growth prospects and synergies expected from the Proposed Merger, as well as delays, challenges and expenses associated with integrating the combined company’s existing businesses; (13) negative effects of this announcement or the consummation of the Proposed Merger on the market price of Assertio’s or Zyla’s common stock, credit ratings and operating results; (14) legislative, regulatory and economic developments, including changing business conditions in the industries in which Assertio and Zyla operate and (15) natural disasters or calamities, epidemics, pandemics or disease outbreaks (including COVID-19) or any escalation or worsening of the foregoing. These risks, as well as other risks associated with the Proposed Merger, are more fully discussed in the joint proxy statement/prospectus that is included in the registration statement on Form S-4 that was filed with the U.S. Securities and Exchange Commission in connection with the Proposed Merger. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements
Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described and incorporated by reference in the “RISK FACTORS” section and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Quarterly Report on Form 10-Q, even if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward-looking statement.
COMPANY OVERVIEW
 
Assertio Therapeutics, Inc. (Assertio or the Company) is a leading diversified, specialty pharmaceutical company focused on distinctive products that offer enhanced therapeutic options for patients in need, while maintaining the highest ethical standards in all our business practices.

As of March 31, 2020, the Company’s specialty pharmaceutical business consisted primarily of CAMBIA®(diclofenac potassium for oral solution), a nonsteroidal anti-inflammatory drug for the acute treatment of migraine attacks, acquired by the Company in December 2013; and Zipsor® (diclofenac potassium liquid filled capsules), a nonsteroidal anti-inflammatory drug for the treatment of mild to moderate acute pain, acquired by the Company in June 2012, both marketed in the U.S.

In 2017, the Company announced that it was in the process of transforming into a leading diversified, specialty pharmaceutical company with a goal of rapidly deleveraging its balance sheet, growing its core business, and opportunistically building for the future via business development. The Company continues to position itself to actively pursue business development, strategic partnerships, and investment opportunities to build and grow for the future. As part of this transformational initiative, the Company executed on several strategic transactions:

On January 10, 2020, the Company completed the sale of Gralise® (gabapentin) to Golf Acquiror LLC, an affiliate to Alvogen, Inc. (Alvogen), for total value of $127.5 million. This included $75.0 million in cash at closing, and the balance payable as 75% of Alvogen’s first $70.0 million of Gralise net sales after the closing. Alvogen also paid the Company for certain inventories relating to Gralise.

On February 13, 2020, the Company entered into a definitive agreement to divest its remaining rights, title and interest in and to the NUCYNTA franchise to Collegium for $375.0 million in cash, less royalties, paid to the Company in 2020. Pursuant to the agreement, Collegium assumed certain contracts, liabilities and obligations of the Company relating to the NUCYNTA products, including those related to manufacturing and supply, post-market commitments and clinical development costs. Collegium also paid the Company for certain inventories relating to the products.

On February 13, 2020, the Company had repaid in full its outstanding aggregate principal amount of senior secured notes (Senior Notes) pursuant to a Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement) and all subsequent amendments to the Note Purchase Agreement.


31

On February 19, 2020, the Company entered into separate, privately negotiated agreements with a limited number of holders of the Company’s 2021 Notes and 2024 Notes to repurchase approximately $188.0 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, the Company announced the completion and final results for its cash tender offers which the Company settled approximately $76.7 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

Merger Agreement

On March 16, 2020, the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Zyla Life Sciences (Zyla), Assertio Holdings, Inc., a newly created wholly-owned subsidiary of Assertio (Parent), Assertio Merger Sub, Inc., a newly created wholly-owned subsidiary of Parent (Assertio Merger Sub), and Zebra Merger Sub, Inc., a newly created wholly-owned subsidiary of Parent (Merger Sub). The Merger Agreement provides that, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Zyla (the Merger), with Zyla surviving the Merger and becoming a wholly-owned subsidiary of Parent. Prior to the consummation of the Merger, Assertio intends to effect a reorganization merger (the “Assertio Reorganization”) pursuant to which Assertio Merger Sub will merge with and into Assertio, with Assertio surviving the merger and becoming a wholly-owned subsidiary of Parent. Parent will assume Assertio’s listing on the Nasdaq Stock Market (Nasdaq).
 
The terms of the Merger Agreement provide that, unless otherwise specified in the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of Zyla (the Zyla Common Stock) will be canceled and automatically converted into the right to receive as merger consideration (the Merger Consideration) 2.5 shares (the Exchange Ratio) of common stock, par value $0.0001 per share, of Parent (the Parent Common Stock).     

The Merger and the Merger Agreement have been approved by the board of directors of each of Zyla (the Zyla Board), Assertio (the Assertio Board) and Parent (the Parent Board). Completion of the Merger is conditioned upon the adoption and approval of the Merger Agreement by (1) the holders of at least a majority of the outstanding shares of Zyla Common Stock (the Zyla Stockholder Approval) and (2) by the affirmative vote of the majority of the total votes cast to approve the issuance of the Merger Consideration by the holders of the outstanding shares of common stock of Assertio (the Assertio Stockholder Approval). Completion of the Merger is also subject to other customary closing conditions. The Merger is expected to close in the second quarter of 2020.

On March 16, 2020, the Company announced it entered into a definitive merger agreement with Zyla Life Sciences (Zyla). Zyla is a specialty pharmaceutical company focused on marketing its portfolio of medicines for pain and inflammation, and is committed on delivering differentiated products to patients and healthcare providers. Under the term of the agreement, upon the effective time of the merger (the Merger), the newly combined company will retain the Assertio name and trade on Nasdaq under the ASRT ticker. The Merger will create a leading commercial pharmaceutical company with neurology, inflammation and pain products. The combined company will have a leading portfolio of branded non-steroidal anti-inflammatory drugs (NSAIDs) commonly used by neurologists, orthopedic surgeons, internists, women’s health providers, podiatrists and paid care specialists. The Merger is expected to close in the second quarter of 2020, subject to approval by Assertio stockholders and by Zyla stockholders and the satisfaction of other customary closing conditions.

Impact of COVID-19 on our Business
We are closely monitoring the impact of the outbreak of COVID-19 on all aspects of our business, including how it will impact our customers, employees, supply chain, and distribution network. Our first priority remains the health and safety of our employees and their families. All our employees are currently operating under remote work arrangements and will continue to do so until government authorities allow opening of operation facilities. While COVID-19 did not have a material adverse effect on our reported results for our first quarter, we are unable to predict the ultimate impact that it may have on our business, future results of operations, financial position or cash flows. While shelter-in-place orders remain in effect, the Company would expect fewer patients to visit physicians for conditions treated by the Company’s products, as well as fewer elective surgeries and fewer visits to pharmacies to have prescriptions filled. As a result, the Company could see a negative impact in product sales during the peak of the pandemic, which is expected to be in the second quarter of 2020, although the degree of this impact is not currently estimable. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including

32

new information which may emerge concerning the severity of the outbreak and actions by government authorities to contain the outbreak or treat its impact.

OUR BUSINESS OPERATIONS
 
For the quarter ended March 31, 2020, our business operations consisted primarily of the following:

Products

CAMBIA (Diclofenac Potassium for Oral Solution)

CAMBIA is a non‑steroidal anti‑inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. We acquired CAMBIA in December 2013 from Nautilus Neurosciences, Inc. (Nautilus). We began shipping and recognizing product sales on CAMBIA in December 2013. CAMBIA product sales were $6.3 million and $8.8 million for the three months ended March 31, 2020 and 2019, respectively.
   
Zipsor (Diclofenac Potassium) Liquid Filled Capsules
 
Zipsor is an NSAID indicated for relief of mild to moderate acute pain in adults. Zipsor uses proprietary ProSorb®
delivery technology to deliver a finely dispersed, rapidly absorbed formulation of diclofenac. We acquired Zipsor in June 2012 from Xanodyne Pharmaceuticals, Inc. (Xanodyne). We began shipping and recognizing product sales on Zipsor in June 2012. Zipsor product sales were $2.3 million and $4.2 million for the three months ended March 31, 2020 and 2019, respectively.

Gralise (Gabapentin)
 
Gralise is our proprietary, once‑daily formulation of gabapentin indicated for management of PHN, a persistent pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection. We made Gralise commercially available in October 2011, following its FDA approval in January 2011. Effective as of January 10, 2020, we divested our rights, title and interest in and to Gralise to Alvogen. Gralise product sales were $0.5 million and $13.3 million for the three months ended March 31, 2020 and 2019, respectively.
      
NUCYNTA ER (Tapentadol Extended Release Tablets) and NUCYNTA IR (NUCYNTA) (Tapentadol)
 
NUCYNTA ER is an extended release version of tapentadol that is indicated for the management of pain severe enough to require daily, around‑the‑clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and for which alternate treatment options are inadequate. NUCYNTA is an immediate release version of tapentadol that is indicated for the management of moderate to severe acute pain in adults. We acquired the U.S. rights to NUCYNTA ER and NUCYNTA from Janssen Pharmaceuticals, Inc. (Janssen Pharma) and began shipping and recognizing product sales on NUCYNTA ER and NUCYNTA in April 2015. We began commercial promotion of NUCYNTA ER and NUCYNTA in June 2015.
 
In December 2017, we entered into a Commercialization Agreement with Collegium, which we amended in November 2018. Pursuant to the Commercialization Agreement, we granted Collegium the right to commercialize the NUCYNTA franchise of pain products in the United States. Collegium assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing. We received a royalty on all NUCYNTA revenues based on certain net sales thresholds, with a minimum royalty of $132.0 million for the year ended December 31, 2018. Beginning in 2019, we received royalties based on certain annual NUCYNTA net sales thresholds for future years. Effective as of February 13, 2020, we divested our rights, title and interest in and to our NUCYNTA franchise to Collegium.


Collaboration and License Agreements

Nuvo Pharmaceuticals, Inc. (Nuvo) In November 2010, we entered into a license agreement with Tribute Pharmaceuticals Canada Ltd. (now Nuvo Pharmaceuticals, Inc.) granting them the rights to commercially market CAMBIA in Canada. Nuvo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We receive royalties on net sales on a quarterly basis as well as certain one-time contingent milestone payments upon the occurrence of certain events. We recognized $0.4 million and $0.6 million of revenue related to CAMBIA in Canada during the three months ended March 31, 2020 and March 31, 2019, respectively. The revenue recognized in the three months ended March 31, 2019

33

included a $0.3 million one-time amendment fee to support the continued collaboration with our partner in Canada following their acquisition.

Ironwood Pharmaceuticals, Inc. (Ironwood) In July 2011, we entered into a collaboration and license agreement with Ironwood granting Ironwood a license for worldwide rights to certain patents and other intellectual property rights to our Acuform drug delivery technology for IW 3718, an Ironwood product candidate under evaluation for refractory GERD. There was no revenue recognized related to the Ironwood Agreement during the three months ended March 31, 2020 and March 31, 2019. We expect to receive additional contingent milestone payments upon the occurrence of certain development milestones and royalties on net sales of the product, if approved.     

Segment Information

We maintain one operating segment and have operations solely in the United States. To date, substantially all of our revenues from product sales are related to sales in the United States.


CRITICAL ACCOUNTING POLICIES
 
Critical accounting policies are those that require significant judgment and/or estimates by management at the time that the financial statements are prepared such that materially different results might have been reported if other assumptions had been made. We consider certain accounting policies related to revenue recognition, accrued liabilities and use of estimates to be critical policies. These estimates form the basis for making judgments about the carrying value of assets and liabilities. There have been no changes to our critical accounting policies since we filed our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 10, 2020 (the 2019 Form 10-K). The description of our critical accounting policies is incorporated herein by reference to our 2019 Form 10-K.

34

RESULTS OF OPERATIONS
 
Revenues
 
Total revenues by products are summarized in the following table (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Product sales, net
 
 
 
 
CAMBIA
 
$
6,274

 
$
8,808

Zipsor
 
2,331

 
4,231

Gralise (1)
 
547

 
13,278

Total neurology product sales, net
 
9,152

 
26,317

NUCYNTA and Lazanda product sales adjustments (2)
 
100

 
133

Total product sales, net
 
9,252

 
26,450

Commercialization agreement, net
 
11,258

 
30,856

Royalties and milestone revenue
 
407

 
623

Total revenues
 
$
20,917

 
$
57,929

(1)
On January 10, 2020, the Company completed the sale of Gralise to Alvogen.
(2)
In 2017 we granted Collegium the rights to commercialize our NUCYNTA franchise in the US. On February 13, 2020 we completed the sale of NUCYNTA to Collegium. We divested Lazanda in November 2017. We continue to recognize sales reserve estimate adjustments related to sales recognized for NUCYNTA and Lazanda in prior periods.

Product Sales
 
CAMBIA net product sales for the three months ended March 31, 2020 decreased $2.5 million to $6.3 million, as compared to the three months ended March 31, 2019, primarily due to unfavorable payer mix and increased patient discount programs.
 
Zipsor net product sales for the three months ended March 31, 2020 decreased $1.9 million to $2.3 million, as compared to the three months ended March 31, 2019, primarily due to lower volume and increased patient discount programs.

We ceased recording product sales and related costs for Gralise effective the closing of the transaction to divest our rights, title and interest in and to Gralise to Alvogen on January10, 2020. Product sales for the three months ended March 31, 2020 reflect sales through January 10, 2020.

We ceased recording product sales and related costs for NUCYNTA after commencing the Commercialization Agreement with Collegium on January 8, 2018. Product sales for the three months ended March 31, 2020 and 2019 reflect adjustments made for previously recorded sales reserve estimates.

We ceased recording revenues and related costs associated with Lazanda after we divested the product to Slán in November 2017. Product sales for the three months ended March 31, 2020 and 2019 reflect adjustments made for previously recorded sales reserve estimates.

Commercialization Agreement

We recognized revenue as a result of the Commercialization Agreement for the three months ended March 31, 2020 and 2019 as follows (in thousands):

35

 
 
Three Months Ended March 31,
 
 
2020
 
2019
Royalty revenue
 
$
13,071

 
$
32,098

Contract liability amortization (1)
 
237

 
688

Contract asset amortization, net (1)
 
(1,846
)
 
(887
)
Third-party royalty, net
 
—

 
(1043
)
Expense reimbursement (1)
 
(204
)
 
—

Total commercialization revenue
 
$
11,258

 
$
30,856

(1) The contract liability amortization represents the recognition of revenue related to the warrants received in November 2018. During the three months ended March 31, 2020 we amortized the remaining $1.8 million of the net contract assets in connection with the termination of the Commercialization Agreement as a result of the divestiture of NUCYNTA to Collegium.

For the three months ended March 31, 2020 and 2019, we recognized variable royalty revenue from the Commercialization Agreement of $13.1 million and $32.1 million, respectively. We ceased recognizing commercialization revenue and related costs for NUCYNTA effective the closing of the transaction to divest our rights, title and interest in and to the NUCYNTA franchise to Collegium on February 13, 2020. Other components of revenue recognized under the Commercialization Agreement include the amortization of contract assets arising from the transfer of inventory to Collegium net of contract liabilities arising from the warrants and prepayments received, and variable consideration revenue for reimbursement of certain shared costs. During the three months ended March 31, 2020 we amortized the remaining $1.8 million of the net contract asset in connection with the termination of the Commercialization Agreement as a result of the divestiture of NUCYNTA to Collegium. During the three months ended March 31, 2019, we recognized $1.0 million of net expense related to the third-party royalties which were paid by Collegium on behalf of Assertio. In accordance with the termination of the Commercialization Agreement, the Company did not incur third-party royalty obligations for the three months ended March 31, 2020.

Royalties & Milestones

In November 2010, we entered into a license agreement with Tribute Pharmaceuticals Canada Ltd. (now Nuvo Pharmaceuticals, Inc.) granting them the rights to commercially market CAMBIA in Canada. We receive royalties on net sales as well as certain one-time contingent milestone payments. During the three months ended March 31, 2020 and 2019, we recognized $0.4 million and $0.6 million of revenue related to CAMBIA in Canada, respectively.


Cost of Sales
 
Cost of sales consists of costs of the active pharmaceutical ingredient, contract manufacturing and packaging costs, royalties payable to third‑parties, inventory write‑downs, a product quality testing, internal employee costs related to the manufacturing process, distribution costs and shipping costs related to our product sales. Cost of sales excludes the amortization of intangible assets described separately below under “Intangible Assets.”
 
Cost of sales decreased by $1.2 million from $2.6 million to $1.4 million in the three months ended March 31, 2020 as compared to the same period in 2019 primarily due to the divestiture of Gralise to Alvogen. We ceased recognizing product sales and related costs for Gralise effective the closing of the transaction to divest our rights, title and interest in and to Gralise to Alvogen on January 10, 2020.

The cost of sales as a percentage of sales for CAMBIA, Zipsor and Gralise, combined for the three months ended March 31, 2020 and 2019 was approximately 15.3% and 10.0%, respectively. The increase is primarily due to the divestiture of Gralise which carried a lower costs of sales rate. 


Research and Development Expenses
 
Our research and development expenses currently include salaries, clinical trial costs, consultant fees, supplies, manufacturing costs for research and development programs and allocations of corporate costs. It is difficult to predict the scope and magnitude of future research and development expenses for our product candidates in research and development, as it is difficult to determine the nature, timing and extent of clinical trials and studies and the FDA’s requirements for a particular

36

drug. As potential products proceed through the development process, each step is typically more extensive, and therefore more expensive, than the previous step. Therefore, success in development generally results in increasing expenditures until actual product approval.

Research and development expenses decreased by $0.8 million from $1.8 million to $1.0 million in the three months ended March 31, 2020 as compared to the same period in 2019, primarily due to lower clinical and manufacturing costs due to the divestiture of Gralise and NUCYNTA and timing of clinical trials.
 

Selling, General and Administrative Expenses
 
Selling, general and administrative expenses primarily consist of personnel, contract personnel, marketing and promotion expenses associated with our commercial products, personnel expenses to support our administrative and operating activities, facility costs, and professional expenses, such as legal fees.

Selling, general, and administrative expenses increased by $2.3 million from $25.0 million to $27.3 million in the three months ended March 31, 2020 as compared to the same periods in 2019. The increase is primarily due to one-time transaction-related costs associated with the divestiture of NUCYNA, divestiture of Gralise, and the proposed merger with Zyla, partially offset by a decrease in marketing expenses as a result of the divestiture of Gralise and no additional costs incurred related to contract sales organization in 2020.

In connection with the Multidistrict Opioid Litigation, the State Opioid Litigation and the Opioid-Related Requests and Subpoenas described in “Note 10. Commitments and Contingencies - Legal Matters” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, we expect to incur additional costs and expenses related to our ongoing opioid-related litigation and investigations, which may be significant and which may increase in future periods.


Intangible Assets

Amortization of intangible assets for the three months ended March 31, 2020 and 2019 was comprised of (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Amortization of intangible assets - NUCYNTA
 
5,927

 
23,575

Amortization of intangible assets - CAMBIA
 
1,284

 
1,284

Amortization of intangible assets - Zipsor
 
584

 
585

Total
 
$
7,795

 
$
25,444

 
The amortization expense during the three months ended March 31, 2020 decreased as compared to the same period in 2019 due to the divestiture of the Company’s rights, title and interest in to the NUCYNTA franchise of products to Collegium in February 2020. As a result, the Company derecognized the remaining carrying value of the NUCYNTA product rights and ceased recognizing related amortization.
 

Restructuring Charges

We did not incur any incremental restructuring charges during three months ended March 31, 2020 and 2019 related to our previously announced restructuring plans.


Other Income (Expense)
 
Other income and expense for the three months ended March 31, 2020 and 2019 was comprised of (in thousands):

37

 
 
Three Months Ended March 31,
 
 
2020
 
2019
Gain on sale of Gralise
 
$
127,505

 
$
—

Loss on extinguishment of convertible notes
 
(31,608
)
 
—

Loss on sale of NUCYNTA
 
(15,755
)
 
—

Interest expense
 
(8,674
)
 
(16,554
)
Loss on prepayment of Senior Notes
 
(8,233
)
 
—

Change in fair value of Collegium warrants
 
(3,146
)
 
(1,629
)
Other
 
(179
)
 
1,020

Total other income (expense)
 
$
59,910

 
$
(17,163
)

Other income (expense) increased by $77.1 million from $(17.2) million to $59.9 million for the three months ended March 31, 2020 as compared to the same period in 2019 primarily due to the gain on the sale of Gralise offset by the loss on debt extinguishment as a result of the repurchase of the 2021 Notes and 2024 Notes and settlement of the Senior Notes, and the loss on the sale of NUCYNTA during the three months ended March 31, 2020.

The interest expense for the three months ended March 31, 2020 and 2019 was comprised of (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Interest payable on Senior Notes
 
$
1,648

 
$
8,206

Interest payable on Convertible Notes
 
1,654

 
2,156

Amortization of debt discounts and issuance costs relating to Senior Notes and Convertible Notes
 
5,387

 
6,164

Other
 
(15
)
 
28

Total interest expense
 
$
8,674

 
$
16,554

 
For the three months ended March 31, 2020, total interest expense decreased by $7.9 million primarily due to lower interest expense as a result of the settlement of the remaining principal of our Senior Notes and the repurchase of a portion of our 2021 and 2014 Notes in the first quarter of 2020.

Income Tax Provision
 
In the three months ended March 31, 2020, we recorded an expense from income taxes of approximately $2.0 million that represents an effective tax rate of 4.7% on income from continuing operations. The difference between income tax provision of $2.0 million and the tax at the statutory rate of 21.0% on current year operations is principally due to the valuation allowance recorded against the beginning of year deferred tax asset related the NOL carryback to the 2018 and 2019 tax years now permitted by the CARES Act.

In the three months ended March 31, 2019, we recorded an expense from income taxes of approximately $0.2 million, that represents an effective tax rate of (1.5)%. The difference for the three months ended March 31, 2019 between the income tax provision of $0.2 million, and the tax at the statutory rate of 21.0% on current year operations is principally due to the change in valuation allowance.


38

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents increased by $63.9 million from $42.1 million to $106.0 million during the three months ended March 31, 2020 is primarily attributable to upfront consideration of $368.0 million and $81.1 million received from the sales of NUCYNTA and Gralise, respectively, partially offset by the settlement of the $162.5 million remaining outstanding principal of our Senior Notes and repurchase of $188.0 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.
 
Since inception and through December 31, 2019, we have financed our product development efforts and operations primarily from product sales, private and public sales of equity securities, including convertible debt securities, the proceeds of secured borrowings, the sale of rights to future royalties and milestones to PDL, upfront license, milestone and termination fees from collaborative and license partners.

In April 2015, we issued $575.0 million aggregate principal amount of senior secured notes (Senior Notes) for aggregate gross proceeds of approximately $562.0 million. In connection with the divestiture of Gralise and NUCYNTA we used proceeds to repay the outstanding principal of $162.5 million as of December 31, 2019 and as a result the Company had repaid in full all outstanding indebtedness, and terminated all commitments and obligations, under its Note Purchase Agreement as of March 31, 2020. In connection with the termination of the Note Purchase Agreement, the Company was released from all security interests, liens and encumbrances under the Note Purchase Agreement. We were in compliance with our covenants with respect to the Senior Notes through the period of the effective payoff on February 13, 2020.

In September 2014, we issued $345.0 million aggregate principal amount of convertible notes due 2021 (the 2021 Notes) resulting in net proceeds to us of $334.2 million. In August 2019, we exchanged $200.0 million aggregate principal amount of the 2021 Notes for a combination of (a) its new $120.0 million aggregate principal amount of 5.00% Convertible Senior Notes due August 15, 2024 (the 2024 Notes), (b) an aggregate cash payment of $30.0 million, and (c) an aggregate of 15.8 million shares of our common stock. We did not receive any cash proceeds from the issuance of the 2024 Notes or the issuance of the shares of our common stock. On February 19, 2020, the Company utilized proceeds from the sale of Gralise and NUCYNTA to repurchase approximately $188.0 million aggregate principal amount of 2021 Notes and 2024 Notes. On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, upon close of the tender offer, the Company repurchased substantially all of the remaining outstanding $77.0 million aggregate principal amount of 2021 Notes and 2024 Notes, with only $0.3 million of 2021 Notes remaining.
 
We may incur operating losses in future years. We believe that our existing cash will be sufficient to fund our operations for the next twelve months from the date of this filing. We base this expectation on our current operating plan, which may change as a result of many factors.
 
Our cash needs may vary materially from our current expectations because of numerous factors, including:

•
acquisitions or licenses of complementary businesses, products, technologies or companies;
•
sales of our marketed products;
•
expenditures related to our commercialization of our products;
•
milestone and royalty revenue we receive under our collaborative development arrangements;
•
interest and principal payments on our current and future indebtedness;
•
financial terms of definitive license agreements or other commercial agreements we may enter into
•
changes in the focus and direction of our business strategy and/or research and development programs; and
•
effects of the COVID-19 pandemic on our operations.

The inability to raise any additional capital that may be required to fund our future operations or product acquisitions and strategic transactions which we may pursue could have a material adverse effect on our company.

The following table summarizes our cash flow activities (in thousands):

39

 
 
Three Months Ended March 31,
 
 
2020
 
2019
Net cash (used in) provided by operating activities
 
$
(25,063
)
 
$
27,195

Net cash provided by (used in) investing activities
 
449,036

 
(13
)
Net cash used in financing activities
 
(360,107
)
 
(28,440
)
Net increase (decrease) in cash and cash equivalents
 
$
63,866

 
$
(1,258
)

Cash Flows from Operating Activities
 
The decrease in operating cash flows during the three months ended March 31, 2020 compared to the same period in 2019 is primarily due to the cash used in operations after impact of adjustments to reconcile net income and changes in the working capital accounts.
 
Cash Flows from Investing Activities
 
Net cash provided by (used in) investing activities increased during the three months ended March 31, 2020 compared to the same period in 2019 is primarily due to the $368.0 million and $81.1 million in cash consideration received for the sales of NUCYNTA and Gralise, respectively.

Cash Flows from Financing Activities
 
Net cash used in financing activities decreased during the three months ended March 31, 2020 compared to the same period in 2019 is primarily due to the settlement of the $162.5 million remaining outstanding principal of our Senior Notes and repurchase of $188.0 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.
 
Off-Balance Sheet Arrangements
 
There were no off-balance sheet arrangements during the quarter ended March 31, 2020.


40

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Interest Rate Risk
 
We previously were subject to interest rate fluctuation exposure through our senior secured notes (Senior Notes), pursuant to the Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement) and all subsequent amendments to the Note Purchase Agreement, which bear a variable interest rate. As of February 13, 2020, the Company repaid in full its outstanding aggregate principal amount of Senior Notes. The remaining convertible senior notes outstanding are fixed rate instruments, and therefore, any significant changes in interest rates would not have a material impact on our financial position and results of operations.

Foreign Currency Risk

We have not had any significant transactions in foreign currencies, nor did we have any significant balances that were due or payable in foreign currencies at March 31, 2020. Accordingly, significant changes in foreign currency rates would not have a material impact on our financial position and results of operations.
ITEM 4. CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective.

We review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.
 
Changes in Internal Controls
 
There were no changes in our internal controls over financial reporting during the three months ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

41

PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
 
For a description of our material pending legal proceedings, see “Note 10. Commitments and Contingencies - Legal Matters” of the notes to unaudited consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
ITEM 1A.    RISK FACTORS
 
We are subject to various risks and uncertainties that could have a material impact on our business, results of operations and financial condition, including those described in: (i) Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019; and (ii) “Chapter I — The Merger” — “Risk Factors” — “Risks Relating to the Merger” in the joint proxy statement/prospectus included in the registration statement on Form S-4 filed with the SEC on April 20, 2020 in connection with the Proposed Merger (which risk factors are incorporated herein by reference). Except as set forth below, there have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2019, and our Form S-4 filed on April 20, 2020 in connection with the Proposed Merger. In addition to other information in this report, the following risk factors (together with those referenced in our Annual Report on Form 10-K for the year ended December 31, 2019, and our Form S-4 filed on April 20, 2020 in connection with the Proposed Merger) should be considered carefully in evaluating an investment in our securities. If any of these risks or uncertainties actually occurs, our business, results of operations or financial condition would be materially and adversely affected. The risks and uncertainties referenced above and described below are not the only ones facing us. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial may also become important factors that may harm our business, results of operations and financial condition.

The COVID-19 pandemic has been affecting the Company’s business and operations and may continue to affect these operations for a sustained period.

The ongoing COVID-19 pandemic has required the Company’s sales representatives to work from home and has prevented them from the usual practice of calling on physicians and healthcare providers in a healthcare setting. Additionally, while shelter-in-place orders remain in effect, the Company would expect fewer patients to visit physicians for conditions treated by the Company’s products, as well as fewer elective surgeries and fewer visits to pharmacies to have prescriptions filled. As a result, the Company could see a negative impact in product sales during the peak of the pandemic, which is expected to be in the second quarter of 2020, although the degree of this impact is not currently estimable.

As the shelter-in-place orders are lifted and the Company’s employees are permitted to return to their normal job functions, the longer term impact of the pandemic on the Company’s business is also unknown. The potential economic impact brought by the pandemic is difficult to assess or predict, and the impact of the pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s liquidity. The ultimate impact of the pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which it relies, including suppliers and distributors.

Our common stock may be delisted from the Nasdaq Global Select Market if we are unable to regain compliance with Nasdaq's continued listing standards.

On April 22, 2020, the Company received notification (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq) indicating that the Company’s common stock is subject to potential delisting from the Nasdaq Global Select Market because, for a period of 30 consecutive business days, the bid price of the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 5450(a)(1) (the Bid Price Rule). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Notice to regain compliance. However, due to recent market conditions, the Notice indicated that Nasdaq has determined to toll the compliance period for the Bid Price Rule through June 30, 2020. As a result, the compliance period for the Bid Price Rule will be reinstated on July 1, 2020 (the Reinstatement Date). Accordingly, the Company has until December 28, 2020 (the Compliance Date), which is 180 calendar days from the Reinstatement Date, to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 for a minimum of ten consecutive business days on or before the Compliance Date.

42


If the Company fails to regain compliance with the Bid Price Rule before December 28, 2020 but meets all of the other applicable standards for initial listing on the Nasdaq Global Select Market with the exception of the minimum bid price, then the Company may be eligible to have an additional 180 calendar days, or until June 26, 2021, to regain compliance with the Bid Price Rule.

Any delisting of our common stock would likely adversely affect the market liquidity and market price of our common stock and our ability to obtain financing for the continuation of our operations and/or result in the loss of confidence by investors. Furthermore, the delisting of our common stock would give the holders of our convertible notes rights to require us to repurchase all or a portion of their notes at the prices set forth in the indenture governing the convertible notes.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
The Company did not sell any equity securities during the period covered by this Quarterly Report that were not registered under the Securities Act, except as previously disclosed in our Current Reports on Form 8-K.



43

ITEM 6. EXHIBITS
2.1
 
2.2
 
10.1
 
10.2
 
10.3
 
31.1
 
31.2
 
32.1
 
32.2
 
101
 
Interactive Data Files pursuant to Rule 405 of Regulation S-T
_______________________________________________________
(*)    Furnished herewith

44

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: May 11, 2020
ASSERTIO THERAPEUTICS, INC.
 
 
 
/s/ Arthur J. Higgins
 
Arthur J. Higgins
 
President and Chief Executive Officer
 
 
 
/s/ Daniel A. Peisert
 
Daniel A. Peisert
 
Senior Vice President and Chief Financial Officer


45
 EX-31.1 2 exhibit311-1q2020.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
 
I, Arthur J. Higgins, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Assertio Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 11, 2020
By:
/s/ Arthur J. Higgins
 
 
Arthur J. Higgins
 
 
President and Chief Executive Officer
(Principal Executive Officer)



 EX-31.2 3 exhibit312-1q2020.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
 
I, Daniel A. Peisert, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Assertio Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 11, 2020
By:
/s/ Daniel A. Peisert
 
 
Daniel A. Peisert
 
 
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)



 EX-32.1 4 exhibit321-1q2020.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Assertio Therapeutics, Inc. (the “Company”) for the quarterly period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Arthur J. Higgins, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 11, 2020
 
/s/ Arthur J. Higgins
 
 
Arthur J. Higgins
 
 
President and Chief Executive Officer
(Principal Executive Officer)



 EX-32.2 5 exhibit322-1q2020.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Assertio Therapeutics, Inc. (the “Company”) for the quarterly period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel A. Peisert, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 11, 2020
 
/s/ Daniel A. Peisert
 
 
Daniel A. Peisert
 
 
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)



 EX-101.SCH 6 asrt-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - ACCOUNTS RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - ACCOUNTS RECEIVABLES, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - ACCOUNTS RECEIVABLES, NET - Schedule of Accounts Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - ACCOUNTS RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - ACCRUED LIABILITIES - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - ACQUISITIONS AND DISPOSITIONS link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Sale of Gralise (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Sale of NUCYNTA (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Termination of Slan Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Legal Matters (Details) link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Purchase and Other Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - DEBT - Summary of Carrying Value of Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - DEBT - Summary of Interest Expense of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - DEBT - Summary of Interest Expense of Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - DEBT - Summary of Liability Component of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and net Book Values of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - INVENTORIES, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - INVENTORIES, NET - Schedule of Inventories, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - LEASES - Lease Cost Components (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - NET INCOME (LOSS) PER SHARE - Schedule of Earnings (Loss) Per Share and Dilutive Shares Information (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Commercialization Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Sales and Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 2401409 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted and Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - RESTRUCTURING CHARGES link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring and Severance Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - RESTRUCTURING CHARGES (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - REVENUE - Commercialization Agreement with Collegium (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - REVENUE - Royalties & Milestones (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - REVENUE - Summary of Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 asrt-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 asrt-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 asrt-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounts Payable and Accrued Liabilities, Current [Abstract] Accrued compensation Employee-related Liabilities, Current Accrued consent fees Accrued Consent Fees, Current Accrued Consent Fees, Current Accrued taxes payable Taxes Payable, Current Accrued restructuring costs Restructuring Reserve Other accrued liabilities Other Accrued Liabilities, Current Total accrued liabilities Accrued Liabilities, Current Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Convertible debt Convertible Debt [Member] Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories, net Inventory, Net Consideration receivable from sale of Gralise Disposal Group, Consideration Receivable, Current Disposal Group, Consideration Receivable, Current Prepaid and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Investments, net Long-term Investments Other long-term assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued rebates, returns and discounts Customer Refund Liability, Current Accrued liabilities Senior Notes, current portion Debt, Current Interest payable Interest Payable, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Senior Notes Long-term Debt Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholders' equity Liabilities and Equity Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies [Table] Information related to various accounting policies of the entity. Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] NUCYNTA ER and NUCYNTA Nucynta Er And Nucynta [Member] Pertaining to NUCYNTA ER and NUCYNTA. Gralise Gralise [Member] Represents information pertaining to Gralise, a product of the entity. CAMBIA C A M B I A [Member] Represents information pertaining to CAMBIA, a product of the entity. Zipsor Zipsor [Member] Represents information pertaining to Zipsor, a product of the entity. Lazanda Lazanda [Member] Represents information pertaining to Lazanda, a product of the entity. Summary Of Significant Accounting Policies Summary of Significant Accounting Policies [Line Items] Product Sales and Royalties Revenue from Contract with Customer [Abstract] Collection period after delivery Receivables, Collection Period Represents the typical collection period for receivables after product delivery, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Product return period prior to expiration Product Return Period Prior to Expiration Date Represents the period prior to expiration of a product within which the entity accepts return of unsalable product from customers. Period after expiration for accepting unsalable product (up to) Product Return Period after Expiration Date Represents the period after expiration of a product within which the entity accepts return of unsalable product from customers. Product shelf-life Product Shelf Life from Date of Manufacturing Represents the product shelf-life from the manufacturing date. Discount taken off period after the quarter in which product shipped to the customer Discount Taken Off Period after Quarter in which Product Shipped to Customer Represents the discount taken off period after the quarter in which product shipped to the customer under certain wholesaler and retail pharmacy discounts. Cash discount Cash Discount to Customer for Prompt Payment as Percentage of Sales Price Represents the cash discount that the entity offers to its customers as an incentive for prompt payment as a percentage of sales price. Discount reimbursement period after filling of prescription subject to discount Discount Reimbursement Period after Filling of Prescription Subject to Discount Represents the discount reimbursement period after filling of prescription subject to discount. Period after the quarter in which prescription is filled for paying rebate Period After Quarter in which Prescription is Filled for Paying Rebate Represents the period after the quarter in which prescription is filled for paying rebate to each participating state under the Medicaid rebate programs. Contract with customer, managed care rebate liability, period after quarter in which prescription is filled Contract With Customer, Managed Care Rebate Liability, Period After Quarter In Which Prescription Is Filled Contract With Customer, Managed Care Rebate Liability, Period After Quarter In Which Prescription Is Filled Contract with customer, Medicare Part D coverage gap rebate liability, period after quarter in which prescription is filled Contract With Customer, Medicare Part D Coverage Gap Rebate Liability, Period After Quarter In Which Prescription Is Filled Contract With Customer, Medicare Part D Coverage Gap Rebate Liability, Period After Quarter In Which Prescription Is Filled Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2014 Equity Incentive Plan 2014 [Member] Equity Incentive Plan 2014 [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Performance-based Restricted Stock Units Performance Based Restricted Stock Units [Member] Performance based restricted stock units. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Awards vesting by the end of the first year Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Payment Arrangement [Abstract] Schedule of stock-based compensation expense recognized for stock options, stock awards, restricted stock units and the Company's employee stock purchase program (ESPP) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Project [Axis] Project [Axis] Project [Domain] Project [Domain] Nuvo Pharmaceuticals Agreement Nuvo Pharmaceuticals Agreement [Member] Nuvo Pharmaceuticals Agreement [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Cambia Canada Cambia Canada [Member] Cambia Canada [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue recognized Contract with Customer, Liability, Revenue Recognized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Stock Based Compensation Share-based Payment Arrangement [Policy Text Block] Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Long-term Debt, Unclassified [Abstract] Summary of the carrying value of the Senior Notes Schedule of Long-term Debt Instruments [Table Text Block] Summary of interest expense for the Notes Schedule of Interest Expense [Table Text Block] Tabular disclosure of the amount of interest expense. Summary of the liability component of the Convertible Notes Schedule of Liability Components of Debt Instruments [Table Text Block] Tabular disclosure of the carrying amounts of the liability components of debt instruments. Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% [Member] Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% [Member] 2.5% Convertible Notes debt 2021 Convertible Senior Notes, 2.5% [Member] Convertible Senior Notes, 2.5% [Member] Convertible senior notes Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Tender offer to repurchase debt Debt Instrument, Tender Offer To Repurchase Debt Debt Instrument, Tender Offer To Repurchase Debt Repurchased aggregate principal amount Debt Instrument, Repurchased Face Amount Notes remaining Commitments and Contingencies Disclosure [Abstract] Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Manufacturing Manufacturing [Member] Manufacturing [Member] Consulting Services Consulting Services [Member] Consulting Services [Member] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Non-cancelable purchase obligations Purchase Obligation Number of operating segments Number of Operating Segments Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Commercialization Agreement And Amended Commercialization Agreement Commercialization Agreement And Amended Commercialization Agreement [Member] Commercialization Agreement And Amended Commercialization Agreement [Member] Collegium Pharmaceutical Inc Collegium Pharmaceutical Inc [Member] Represents information pertaining to the license and service agreement with collegium Pharmaceutical Inc. Royalties and milestones Royalties And Milestones [Member] Royalties And Milestones [Member] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Contract asset, amortization Capitalized Contract Cost, Amortization Expense related to third-party royalties Revenue Recognition, Third-Party Royalty Net Expense Revenue Recognition, Third-Party Royalty Net Expense Business Combinations [Abstract] ACQUISITIONS AND DISPOSITIONS Business Combination And Disposition Disclosure [Text Block] Business Combination And Disposition Disclosure [Text Block] Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance and Benefits Employee Severance [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] 2019 Cost Savings Initiative 2019 Cost Savings Initiative [Member] 2019 Cost Savings Initiative [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring charges Restructuring Charges Accrued restructuring liability Restructuring Reserve, Current Fair Value Disclosures [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Collegium warrants Warrant [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Investments, net Investments Total Assets, Fair Value Disclosure Schedule of accrued restructuring and severance costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Contractual interest expense Interest Expense, Debt, Excluding Amortization Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Total interest expense Senior Notes Interest Expense, Debt Receivables [Abstract] Allowance for cash discounts for prompt payment Accounts Receivable, Allowance For Cash Discount Accounts Receivable, Allowance For Cash Discount Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] NUCYNTA NUCYNTA [Member] NUCYNTA [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Third-Party Consent Agreement Third-Party Consent Agreement [Member] Third-Party Consent Agreement [Member] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Consideration received, including base purchase price, inventory adjustment and royalties received Disposal Group, Including Discontinued Operation, Consideration, Including Base Purchase Price And Inventory Adjustment Disposal Group, Including Discontinued Operation, Consideration, Including Base Purchase Price And Inventory Adjustment Proceeds from divestiture of businesses, base purchase price Disposal Group, Including Discontinued Operation, Consideration, Base Purchase Price Disposal Group, Including Discontinued Operation, Consideration, Base Purchase Price Proceeds from divestiture of businesses, inventory amount Disposal Group, Including Discontinued Operations, Inventory Adjustment Disposal Group, Including Discontinued Operations, Inventory Adjustment Royalties received Disposal Group, Including Discontinued Operations, Royalties Received Disposal Group, Including Discontinued Operations, Royalties Received Number of lump sum payments Disposal Group, Lump Sum Payment Obligation, Number Of Payments Disposal Group, Lump Sum Payment Obligation, Number Of Payments Lump sum payments obligation Disposal Group, Annual Lump Sum Payment Due In Years Two And Three Disposal Group, Annual Lump Sum Payment Due In Years Two And Three Gain (loss) on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Consideration received Disposal Group, Including Discontinued Operations, Upfront Consideration Received Disposal Group, Including Discontinued Operations, Upfront Consideration Received Contingent consideration deemed to be probable Disposal Group, Including Discontinued Operations, Contingent Consideration Deemed Probable Disposal Group, Including Discontinued Operations, Contingent Consideration Deemed Probable Accrued third-party consent fees Disposal Group, Including Discontinued Operations, Accrued Third-Party Consent Fees Disposal Group, Including Discontinued Operations, Accrued Third-Party Consent Fee Carrying value of intangible derecognized Disposal Group, Including Discontinued Operations, Carrying Value, Intangible Derecognized Disposal Group, Including Discontinued Operations, Carrying Value, Intangible Derecognized Inventory transfer Disposal Group, Including Discontinued Operations, Inventory Transfer Disposal Group, Including Discontinued Operations, Inventory Transfer Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Smaller Reporting Company Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Leases [Abstract] Schedule of lease cost components, Cash Flow information, and term and discount rate information Lease, Cost [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of the gross carrying amounts and net book values of our intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of the future amortization expenses of intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Product rights Product Rights [Member] Legal rights held to use a product. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortization of intangible assets Amortization of Intangible Assets Write-off of remaining carrying value, disposition Disposal Of Intangible Assets, Finite-lived Disposal Of Intangible Assets, Finite-lived Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] NUCYNTA Janssen Nucynta [Member] Represents activity related to NUCYNTA and related inventory. Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Three month LIBOR London Interbank Offered Rate (LIBOR) [Member] 5.0% Convertible Notes debt 2024 Convertible Senior Notes, 5.0% [Member] Convertible Senior Notes, 5.0% [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Aggregate principal amount Debt Instrument, Face Amount Proceeds from the issuance of debt Proceeds from Issuance of Debt Basis spread Debt Instrument, Basis Spread on Variable Rate Interest rate Debt Instrument, Interest Rate, Stated Percentage Interest rate through third anniversary of purchase date Debt Instrument, Interest Rate Through Third Anniversary, Percentage Maximum contractual interest rate for funds borrowed, under the debt agreement through third anniversary of the purchase date. Interest rate after third anniversary of purchase date Debt Instrument, Interest Rate After Third Anniversary, Percentage Maximum contractual interest rate for funds borrowed, under the debt agreement after third anniversary of the purchase date Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Payment of debt extinguishment Payment for Debt Extinguishment or Debt Prepayment Cost Payment accrued exit fees Payment For Debt Exit Fee Payment For Debt Exit Fee Loss on extinguishment of convertible notes Gain (Loss) on Extinguishment of Debt Debt prepayment fee Payment Of Debt Prepayment Cost Payment Of Debt Prepayment Cost Unamortized balances of debt discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt extinguishment, amount Extinguishment of Debt, Amount Extinguishment of debt, cash paid Extinguishment Of Debt, Cash Paid Extinguishment Of Debt, Cash Paid Reduction in carrying amount of equity component Debt Instrument, Convertible, Increase (Decrease) In Carrying Amount Of Equity Component Debt Instrument, Convertible, Increase (Decrease) In Carrying Amount of Equity Component Accretion of debt discount and debt issuance costs Carrying amount of equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Extinguishment of debt, shares issued (in shares) Stock Issued During Period, Shares, New Issues Reacquisition in additional paid-in capital, equity component Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Business days, period Debt Instrument Convertible Threshold Business Days Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. Consecutive trading-day period Debt Instrument Convertible Threshold Consecutive Trading Day Period Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. Conversion ratio Debt Instrument, Convertible, Conversion Ratio Earnings Per Share [Abstract] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Inventory Disclosure [Abstract] Inventory Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work-in-process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total Schedule of inventories, net Schedule of Inventory, Current [Table Text Block] 2020 (remainder) Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Thereafter Finite-Lived Intangible Assets, Amortization Expense, After Year Three Finite-Lived Intangible Assets, Amortization Expense, After Year Three Total Finite-Lived Intangible Assets, Net Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Zyla Life Sciences Zyla Life Sciences [Member] Zyla Life Sciences [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Parent Assertio, Parent [Member] Assertio, Parent [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Par value of common stock (in dollars per share) Common Stock, Par or Stated Value Per Share Exchange ratio (in shares) Business Acquisition, Equity Interest Issued Or Issuable, Share Exchange Ratio Business Acquisition, Equity Interest Issued Or Issuable, Share Exchange Ratio DEBT Long-term Debt [Text Block] Stock Options Share-based Payment Arrangement, Option [Member] Restricted Stock Units and Performance-based Restricted Stock Units Restricted Stock Units And Performance Based Restricted Stock Units [Member] Restricted Stock Units And Performance Based Restricted Stock Units [Member] RSUs Restricted Stock Units (RSUs) [Member] PSUs Total unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Average vesting period for recognition of unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total unrecognized compensation expense, non-options Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Award granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of revenue from contracts with customers Revenue from External Customers by Products and Services [Table Text Block] Summary of contract assets and liabilities Contract with Customer, Asset and Liability [Table Text Block] Schedule of accounts receivables, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Statement of Stockholders' Equity [Abstract] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Earnings (Deficit) Retained Earnings [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances (in shares) Common Stock, Shares, Issued Balances Issuance of common stock upon exercise of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock in conjunction with vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Reacquisition of equity component of 2021 Notes and 2024 Notes Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Shares withheld for payment of employee's withholding tax liability Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Net income (loss) Net Income (Loss) Attributable to Parent Balances (in shares) Balances Intangible assets Remaining Useful Life (In years) Finite-Lived Intangible Asset, Useful Life Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Disposition Impairment Impairment of Intangible Assets, Finite-lived New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Investment, long-term loan receivable Financing Receivable, before Allowance for Credit Loss Expected allowance for credit loss Financing Receivable, Expected Allowance For Credit Loss Financing Receivable, Expected Allowance For Credit Loss Reacquisition of equity component Principal amount of the Notes Long-term Debt, Gross Unamortized discount of the liability component Debt Instrument, Unamortized Discount Unamortized debt issuance costs Unamortized Debt Issuance Expense Total Senior Notes, Noncurrent Schedule of fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Other Other Expense (Income), Net [Member] Other Expense (Income), Net [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease cost Operating Lease, Cost Total lease cost Lease, Cost Sublease Income Sublease Income Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] REVENUE Revenue from Contract with Customer [Text Block] Inventory reserves Inventory Valuation Reserves Income Statement [Abstract] Product sales, net Product [Member] Commercialization agreement, net Commercialization Agreement [Member] Represents information pertaining to the commercialization agreement. Revenues: Revenues [Abstract] Costs and expenses: Operating Costs and Expenses [Abstract] Cost of sales (excluding amortization of intangible assets) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Selling, general and administrative expenses Selling, General and Administrative Expense Total costs and expenses Costs and Expenses (Loss) income from operations Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Gain (loss) on sale of assets Gain (Loss) on Disposition of Assets Loss on extinguishment of convertible notes Interest expense Interest Expense Loss on prepayment of Senior Notes Loss On Debt Prepayment Loss On Debt Prepayment Other Other Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) Net income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net income (loss) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Diluted net income (loss) per share (in dollars per share) Earnings Per Share, Diluted Shares used in computing basic net income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Basic Shares used in computing diluted net income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Diluted ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Employee compensation costs Accrued restructuring and severance costs rollforward Restructuring Reserve [Roll Forward] Balance at beginning of period Cash paid Payments for Restructuring Balance at end of period Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options, awards and equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Basic net income (loss) per share Earnings Per Share, Basic [Abstract] Net income (loss) Weighted average common shares outstanding (in shares) Basic net (loss) income per share (in dollars per share) Diluted net income (loss) per share Earnings Per Share, Diluted [Abstract] Add: effect of dilutive stock options, awards, and equivalents (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted income (loss) per share (in shares) Diluted net (loss) income per share (in dollars per share) Potentially dilutive common shares: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Total potentially dilutive common shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU 2014-09 Accounting Standards Update 2014-09 [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Adjustments Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Gain Contingencies [Table] Gain Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Securities Class Action Lawsuit and Related Matters Securities Class Action Lawsuit [Member] Represents information related to the securities calss action lawsuits. Multidistrict Opioid Litigation Multidistrict Opioid Litigation [Member] Information pertaining to Multidistrict Opioid Litigation. Legal matters Gain Contingencies [Line Items] Number of shareholder derivative actions filed Number of Shareholder Derivative Actions Filed Represents the number of shareholder derivative actions that were filed. Number of industry-wide opioid litigation cases (more than) Claims, Number, Industry-Wide Number of claims filed industry-wide. Contract asset - Collegium, net Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract asset, Beginning of Period Contract with Customer, Asset, after Allowance for Credit Loss Additions Contract with Customer Asset Net Current Additions The amount of additions, in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Deductions Contract with Customer, Asset, Deletions Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, from business combination. May include payments received during the period. Contract asset, End of Period Contract liability Contract with Customer, Liability Proceeds from issuance of warrants Proceeds from Issuance of Warrants FAIR VALUE Fair Value Disclosures [Text Block] Number of subleases Lessee, Operating Lease, Number Of Subleases Lessee, Operating Lease, Number Of Subleases Operating lease, number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Lease term Lessee, Operating Lease, Term of Contract Expense from income taxes Effective tax rate Effective Income Tax Rate Reconciliation, Percent Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Accrued interest and penalties associated with unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Stated coupon interest Statement of Cash Flows [Abstract] Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Gain (Loss) on sale of assets Gain (Loss) on Disposition of Intangible Assets Loss on prepayment of Senior Notes Depreciation and amortization Depreciation, Depletion and Amortization Recurring fair value measurement of assets and liabilities Fair Value Adjustment Of Assets And Liabilities Fair Value Adjustment Of Assets And Liabilities Stock-based compensation Share-based Payment Arrangement, Noncash Expense Provision for inventory and other assets Provision For Inventory And Other Assets Provision For Inventory And Other Assets Other Other Noncash Income (Expense) Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and other accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Excluding Employee Related Liabilities The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. Excludes employee related liabilities. Accrued rebates, returns and discounts Increase (Decrease) in Accrued Rebates, Returns and Discounts The increase (decrease) during the reporting period related to rebates, returns and discounts incurred but not paid. Interest payable Increase (Decrease) in Interest Payable, Net Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of assets Proceeds from Sale of Productive Assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Payments in connection with debt payment Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Shares withheld for payment of employee's withholding tax liability Payment, Tax Withholding, Share-based Payment Arrangement Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental Disclosure of Cash Flow Information Supplemental Cash Flow Information [Abstract] Net cash paid for income taxes Income Taxes Paid, Net Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Capital expenditures incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Schedule of accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Amended Commercialization Agreement Amended Commercialization Agreement [Member] Amended Commercialization Agreement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrant, number of shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant, exercise price per share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant, exercise period Class Of Warrant Or Right, Exercise Period Class Of Warrant Or Right, Exercise Period Warrants outstanding Warrants and Rights Outstanding Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total neurology product sales, net Neurology Product [Member] Neurology product. NUCYNTA and Lazanda product sales adjustments Commercialization agreement, net Commercialization Rights And Facilitation Services [Member] Pertaining to commercialization rights and facilitation services. Royalties and milestone revenue Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Principal amount of the Senior Notes Unamortized debt discount balance Unamortized debt issuance costs Schedule of Cash and Cash Equivalents and Marketable Securities [Table] Schedule of Cash and Cash Equivalents and Marketable Securities [Table] Schedule of cash and cash equivalent balances and investments in marketable securities. Receivables from Collegium Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Level 2 Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Warrant, fair value price (in dollars per share) Class Of Warrant Or Right, Fair Value Price Of Warrants Or Rights Class Of Warrant Or Right, Fair Value Price Of Warrants Or Rights Warrant, expected term Class Of Warrant Or Right, Expected Term Class Of Warrant Or Right, Expected Term Warrant, risk-free rate Class Of Warrant Or Right, Risk-Free Rate Class Of Warrant Or Right, Risk-Free Rate Warrant, remaining contractual period Class Of Warrant Or Right, Remaining Contractual Period Class Of Warrant Or Right, Remaining Contractual Period Fair value adjustment, recorded loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Estimated fair value of debt Debt Instrument, Fair Value Disclosure Par value of debt Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Receivable Type [Axis] Receivable Type [Axis] Receivable [Domain] Receivable [Domain] Receivables related to product sales, net Product Sales Receivable [Member] Product Sales Receivable [Member] Other Collaborative Partners Receivable [Member] Collaborative Partners Receivable [Member] ACCOUNTS RECEIVABLES, NET Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts receivables Accounts Receivable, after Allowance for Credit Loss [Abstract] Accounts receivables, net INVENTORIES, NET Inventory Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Schedule of calculation of basic and diluted earnings per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of anti-dilutive securities excluded from computation of diluted net (loss) income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cost of sales Cost of Sales [Member] Research and development expense Research and Development Expense [Member] Selling, general and administrative expense Restructuring Restructuring Charges [Member] Stock-based compensation Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Share-based Payment Arrangement, Expense INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] Sale of disposal group, total value Disposal Group, Including Discontinued Operation, Consideration Sale of disposal group, cash received Proceeds from Divestiture of Businesses Consideration receivable as percentage of net sales after closing Disposal Group, Including Discontinued Operations, Consideration, Percentage Of Net Sales After Closing Disposal Group, Including Discontinued Operations, Consideration, Percentage Of Net Sales After Closing Threshold for consideration receivable on net sales after closing Disposal Group, Including Discontinued Operation, Consideration, Threshold For Net Sales After Closing Disposal Group, Including Discontinued Operation, Consideration, Threshold For Net Sales After Closing Consideration received, including base purchase price and inventory adjustment Consideration received, base purchase price Consideration received, inventory adjustment upon disposal Net sale after closing, contingent consideration Disposal Group, Including Discontinued Operation, Consideration, Amount Of Net Sales After Closing Disposal Group, Including Discontinued Operation, Consideration, Amount Of Net Sales After Closing Recognized gain Upfront consideration received Co-promotion service income RESTRUCTURING CHARGES Restructuring, Impairment, and Other Activities Disclosure [Text Block] License Agreement License Agreement [Member] Pertaining to the license agreement. Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Slan Slan [Member] This member stands for the information related to Slan and cosyntropin. License fee received in cash License Fee The amount of the license fee incurred during the period. Term of license agreement Collaborative Agreement, Term Of License Agreement The period of time the license agreement last following the first commercial sale in the U.S. Reimbursable development expenses Reimbursable Development Expenses Reimbursable Development Expenses Reimbursable development expenses, received Collaborative Arrangement, Termination, Reimbursable Development Expenses Received Collaborative Arrangement, Termination, Reimbursable Development Expenses Received Possible future payments to be received, based upon commercial sales, if circumstances met Collaborative Arrangement, Termination, Future Payments To Be Received, If Circumstances Met Collaborative Arrangement, Termination, Future Payments To Be Received, If Circumstances Met ACCOUNTS RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] LEASES Lessor, Operating Leases [Text Block] LEASES Lessee, Operating Leases [Text Block] EX-101.PRE 10 asrt-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R28.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense recognized for stock options, stock awards, restricted stock units and the Company's employee stock purchase program (ESPP)
The following table presents stock‑based compensation expense recognized in the Company’s Consolidated Statements of Comprehensive Income (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cost of sales
$
23

 
$
—

Research and development expense
163

 
273

Selling, general and administrative expense
1,748

 
2,429

Restructuring
—

 
—

Total
$
1,934

 
$
2,702
XML 13 R20.htm IDEA: XBRL DOCUMENT v3.20.1
ACQUISITIONS AND DISPOSITIONS
 3 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
ACQUISITIONS AND DISPOSITIONS ACQUISITIONS AND DISPOSITIONS

Sale of Gralise

On December 12, 2019, the Company entered into a purchase agreement with Golf Acquiror LLC, an affiliate of Alvogen, Inc. (Alvogen) to divest its rights, title and interest in and to Gralise, including certain related assets, to Alvogen. The transaction subsequently closed on January 10, 2020. At closing, the Company received $78.6 million, including a $75.0 million base purchase price and a preliminary positive inventory adjustment equal to $3.6 million. In addition, the Company is entitled to receive 75% of Alvogen’s first $70.0 million of Gralise net sales after closing, a total of $52.5 million, as contingent consideration. Alvogen has also assumed, pursuant to the terms of the Asset Purchase Agreement, certain contracts, liabilities and obligations of the Company relating to Gralise, including those related to manufacturing and supply, post-market commitments and clinical development costs.

Pursuant to ASC 205-20, Presentation of Financial Statements— Discontinued Operations, Gralise did not meet the criteria of a discontinued operation as it was not considered a component of an entity that comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the Company, nor did it represent a strategic shift of the Company. The Company accounted for the divestiture under ASC 610-20 Other Income - Derecognition of Nonfinancial Assets. The Company recognized a gain of $127.5 million in Other income on the Company’s Consolidated Statements of Comprehensive Income composed of the $78.6 million in upfront consideration received and $52.5 million in contingent consideration deemed to be probable, net of $3.6 million in inventory transferred. The net remaining contingent consideration receivable as of March 31, 2020 is recognized and presented separately as a current asset on the
Company’s Consolidated Balance Sheet. In addition, the Company recognized co-promotion service income of approximately $1.3 million during the three months ended March 31, 2020. Co-promotion services were completed as of March 31, 2020.


Termination of Slán Agreements

On November 7, 2017, the Company entered into an agreement with Slán Medicinal Holdings Limited (Slán) under which it (i) acquired from Slán certain rights to market the specialty drug, long-acting cosyntropin in the U.S. and (ii) divested to Slán all of its rights to Lazanda® (fentanyl) nasal spray CII. As consideration for this acquisition, the Company provided the seller all of the rights and obligations, as defined under the arrangement, associated with Lazanda and together with $5.0 million in cash to Slán.

As outlined in the Slán Agreements, each party would support the development, including clinical development, of the licensed product and efforts to obtain regulatory approval of the initial NDA. Subsequent to approval of the initial NDA, Assertio and Slán would share in the net sales of long-acting cosyntropin for a 10-year period (after which time the product will revert back to Slán). As of December 31, 2019, the Company had $2.0 million of reimbursable development expenses in Prepaid and other current assets on the Company’s consolidated balance sheet.

On February 6, 2020, the Company entered into an amended agreement with Eolas Pharma Teoranta (Eolas), an affiliate of Slán. Pursuant to the amendment the license granted to the Company for the commercialization of long-acting cosyntropin was terminated and the Company received $2.0 million in settlement of the December 31, 2019 receivable for reimbursable development expenses. Additionally, the Company may receive up to $10.0 million in future payments based upon commercial sales of long-acting cosyntropin if Eolas successfully obtains regulatory approval for and commercializes the product.


Sale of NUCYNTA
    
On February 6, 2020, the Company entered into a purchase agreement with Collegium, to divest its remaining rights, title and interest in and to the NUCYNTA franchise of products from the Company, and assumed certain contracts, liabilities and obligations of the Company relating to the NUCYNTA products, including those related to manufacturing and supply, post-market commitments and clinical development costs. The transaction subsequently closed on February 13, 2020.

The Company received $367.9 million in net proceeds, which consisted of $375.0 million in base purchase price, plus $6.0 million in preliminary positive inventory value and less $13.1 million for royalties paid to the Company by Collegium between January 1, 2020 and February 11, 2010 pursuant to the Final Commercialization Agreement Payment Value of the Asset Purchase Agreement. In connection with the sale, the Company entered into a third-party consent agreement which requires two lump sum payments of $4.5 million each payable in 2021 and 2022 subject to Collegium achieving certain net sales in 2020 and 2021, respectively.

Since January 9, 2018, Collegium has been responsible for the commercialization of NUCYNTA in the U.S., including sales and marketing, and the Company received royalties based on certain net sales thresholds, in accordance with the Commercialization Agreement. The Commercialization Agreement terminated at closing with certain specified provisions of the Commercialization Agreement surviving in accordance with the terms of the Purchase Agreement.

Pursuant to ASC 205-20, the divestiture of NUCYNTA did not meet the criteria of a discontinued operation as it was not considered a strategic shift. The Company accounted for the divestiture under ASC 610-20 Other Income - Derecognition of Nonfinancial Assets. During the three months ended March 31, 2020, the Company recognized a net loss of $15.8 million in Other income which was comprised of the $367.9 million in consideration received less the $369.1 million carrying value of the NUCYNTA intangible derecognized, $5.6 million in net book value of inventory transferred, and $9.0 million in accrued third-party consent fees.
XML 14 R24.htm IDEA: XBRL DOCUMENT v3.20.1
ACCOUNTS RECEIVABLES, NET (Tables)
 3 Months Ended
Mar. 31, 2020
Receivables [Abstract]  
Schedule of accounts receivables, net
Accounts receivables, net, consist of the following (in thousands): 
 
March 31,
2020
 
December 31,
2019
Receivables related to product sales, net
$
12,427

 
$
38,353

Receivables from Collegium
—

 
4,104

Other
525

 
287

Total accounts receivable, net
$
12,952

 
$
42,744
XML 15 R62.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES - Lease Cost Components (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Lessee, Lease, Description [Line Items]    
Total lease cost $ 305 $ 335
Selling, general and administrative expenses    
Lessee, Lease, Description [Line Items]    
Operating lease cost 157 187
Other    
Lessee, Lease, Description [Line Items]    
Operating lease cost 148 148
Sublease Income $ 347 $ 362
XML 16 R66.htm IDEA: XBRL DOCUMENT v3.20.1
RESTRUCTURING CHARGES - Schedule of Accrued Restructuring and Severance Costs (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
USD ($)
Accrued restructuring and severance costs rollforward  
Balance at beginning of period $ 3,763
Balance at end of period 1,332
Employee compensation costs  
Accrued restructuring and severance costs rollforward  
Balance at beginning of period 3,763
Cash paid (2,431)
Balance at end of period $ 1,332
XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R45.htm IDEA: XBRL DOCUMENT v3.20.1
REVENUE - Royalties & Milestones (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Nuvo Pharmaceuticals Agreement | Cambia Canada    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue recognized $ 0.4 $ 0.6
XML 19 R41.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted and Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Jan. 01, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Investment, long-term loan receivable   $ 3,500
Expected allowance for credit loss $ 1,900  
Convertible debt    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Reacquisition of equity component 16,814  
2.5% Convertible Notes debt 2021 | Convertible debt    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Reacquisition of equity component 300  
5.0% Convertible Notes debt 2024 | Convertible debt    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Reacquisition of equity component $ 16,800  
EXCEL 20 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 21 R49.htm IDEA: XBRL DOCUMENT v3.20.1
INVENTORIES, NET - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Mar. 31, 2019
Inventory Disclosure [Abstract]    
Inventory reserves $ 0.1 $ 0.4
XML 22 R73.htm IDEA: XBRL DOCUMENT v3.20.1
ACQUISITIONS AND DISPOSITIONS - Sale of NUCYNTA (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations
$ in Millions
 1 Months Ended 3 Months Ended
Feb. 11, 2020
USD ($)
Mar. 31, 2020
USD ($)
Feb. 13, 2020
USD ($)
payment
Jan. 10, 2020
USD ($)
Gralise        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Consideration received, including base purchase price, inventory adjustment and royalties received       $ 78.6
Proceeds from divestiture of businesses, base purchase price       75.0
Proceeds from divestiture of businesses, inventory amount       $ 3.6
Gain (loss) on disposal   $ 127.5    
Consideration received   78.6    
Contingent consideration deemed to be probable   52.5    
Inventory transfer   3.6    
NUCYNTA        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Consideration received, including base purchase price, inventory adjustment and royalties received     $ 367.9  
Proceeds from divestiture of businesses, base purchase price     375.0  
Proceeds from divestiture of businesses, inventory amount     $ 6.0  
Royalties received $ 13.1      
Number of lump sum payments | payment     2  
Gain (loss) on disposal   (15.8)    
Consideration received   367.9    
Accrued third-party consent fees   9.0    
Carrying value of intangible derecognized   369.1    
Inventory transfer   $ 5.6    
NUCYNTA | Third-Party Consent Agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Lump sum payments obligation     $ 4.5  
XML 23 R58.htm IDEA: XBRL DOCUMENT v3.20.1
DEBT - Summary of Interest Expense of Senior Notes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Debt Instrument [Line Items]    
Amortization of debt discount and debt issuance costs $ 5,387 $ 6,164
Senior Notes    
Debt Instrument [Line Items]    
Contractual interest expense 1,648 8,206
Amortization of debt discount and debt issuance costs 2,699 1,357
Total interest expense Senior Notes $ 4,347 $ 9,563
XML 24 R50.htm IDEA: XBRL DOCUMENT v3.20.1
INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and net Book Values of Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Intangible assets    
Gross Carrying Amount $ 908,798 $ 1,098,588
Accumulated Amortization (516,058) (508,263)
Disposition (369,069)  
Impairment   (189,790)
Total 23,671 400,535
NUCYNTA | Product rights    
Intangible assets    
Gross Carrying Amount 830,188 1,019,978
Accumulated Amortization (461,119) (455,192)
Disposition (369,069)  
Impairment   (189,790)
Total $ 0 374,996
CAMBIA | Product rights    
Intangible assets    
Remaining Useful Life (In years) 3 years 8 months 12 days  
Gross Carrying Amount $ 51,360 51,360
Accumulated Amortization (32,311) (31,027)
Total $ 19,049 20,333
Zipsor | Product rights    
Intangible assets    
Remaining Useful Life (In years) 2 years  
Gross Carrying Amount $ 27,250 27,250
Accumulated Amortization (22,628) (22,044)
Total $ 4,622 $ 5,206
XML 25 R54.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION - Schedule of Stock Based Compensation Expense Recognized (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock-based compensation    
Total $ 1,934 $ 2,702
Cost of sales    
Stock-based compensation    
Total 23 0
Research and development expense    
Stock-based compensation    
Total 163 273
Selling, general and administrative expense    
Stock-based compensation    
Total 1,748 2,429
Restructuring    
Stock-based compensation    
Total $ 0 $ 0
XML 26 R35.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Agreement (Details) - Forecast - Subsequent Event - Zyla Life Sciences
 3 Months Ended
Jun. 30, 2020
$ / shares
shares
Common Stock  
Business Acquisition, Equity Interests Issued or Issuable [Line Items]  
Exchange ratio (in shares) | shares 2.5
Zyla Life Sciences  
Business Acquisition, Equity Interests Issued or Issuable [Line Items]  
Par value of common stock (in dollars per share) $ 0.001
Parent  
Business Acquisition, Equity Interests Issued or Issuable [Line Items]  
Par value of common stock (in dollars per share) $ 0.0001
XML 27 R31.htm IDEA: XBRL DOCUMENT v3.20.1
RESTRUCTURING CHARGES (Tables)
 3 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
Schedule of accrued restructuring and severance costs
Selected information relating to accrued restructuring, severance costs and one-time termination costs is as follows (in thousands):
 
Employee compensation costs
Balance at December 31, 2019
$
3,763

Cash paid
(2,431
)
Balance at March 31, 2020
$
1,332
XML 28 R39.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Commercialization Agreement (Details) - Contract asset - Collegium, net - Amended Commercialization Agreement
$ / shares in Units, $ in Millions
Nov. 08, 2018
USD ($)
$ / shares
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Warrant, number of shares (in shares) | shares 1,041,667
Warrant, exercise price per share (in dollars per share) | $ / shares $ 19.20
Warrant, exercise period 4 years
Warrants outstanding | $ $ 8.8
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION

The Company’s stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs), and purchases under the Company’s employee stock purchase plan (ESPP).
 
The following table presents stock‑based compensation expense recognized in the Company’s Consolidated Statements of Comprehensive Income (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cost of sales
$
23

 
$
—

Research and development expense
163

 
273

Selling, general and administrative expense
1,748

 
2,429

Restructuring
—

 
—

Total
$
1,934

 
$
2,702


 
At March 31, 2020, the Company had $0.9 million of total unrecognized compensation expense related to stock option grants that will be recognized over an average vesting period of 1.22 years and $14.6 million of total unrecognized compensation expense related to RSUs and PSUs that will be recognized over an average vesting period of 2.24 years.
 
During the three months ended March 31, 2020 the Company granted 3.6 million RSUs at an average fair market value of $1.05 per share. The Company did not grant any PSUs or options during three months ended March 31, 2020.
XML 31 R9.htm IDEA: XBRL DOCUMENT v3.20.1
INVENTORIES, NET
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
 
Inventories, net, consist of raw materials, work in process and finished goods and are stated at the lower of cost or market and consist of the following (in thousands): 
 
March 31,
2020
 
December 31, 2019
Raw materials
$
29

 
$
1,065

Work-in-process
153

 
426

Finished goods
336

 
1,921

Total
$
518

 
$
3,412



Inventory, net as of March 31, 2020 decreased as compared to December 31, 2019 as a result of the divestiture of Gralise in January 2020.

As of March 31, 2020 and 2019, inventory reserves were $0.1 million and $0.4 million, respectively.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.20.1
RESTRUCTURING CHARGES
 3 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
RESTRUCTURING CHARGES RESTRUCTURING CHARGES

The Company continually evaluates its operations to identify opportunities to streamline operations and optimize operating efficiencies as an anticipation to changes in the business environment. In November 2019, the Company announced an acceleration of cost-saving initiatives that included a decision to discontinue its relationship with its contract sales organization, a reduction in the use of certain outside vendors and consultants, and the reorganization of certain functions resulting in a reduction of staff at its headquarters office and remote positions during the fourth quarter of 2019. The 2019 cost-saving initiative was substantially complete as of December 31, 2019. As a result, $3.9 million of severance and benefits costs for the reduction of staff were recognized during the year ended December 31, 2019. The Company does not expect to incur future costs related to the 2019 cost-saving initiative.

Selected information relating to accrued restructuring, severance costs and one-time termination costs is as follows (in thousands):
 
Employee compensation costs
Balance at December 31, 2019
$
3,763

Cash paid
(2,431
)
Balance at March 31, 2020
$
1,332


 
As of March 31, 2020, the full $1.3 million accrued restructuring liability balance was classified as a current liability in the Consolidated Balance Sheet.
XML 33 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating Activities    
Net income (loss) $ 41,230 $ (14,301)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities    
Loss on extinguishment of convertible notes 31,608 0
Loss on prepayment of Senior Notes 8,233 0
Depreciation and amortization 8,068 25,990
Accretion of debt discount and debt issuance costs 5,387 6,164
Recurring fair value measurement of assets and liabilities 3,147 28
Stock-based compensation 1,934 2,702
Provision for inventory and other assets 1,554 359
Other (14) 1,297
Changes in assets and liabilities:    
Accounts receivable 29,792 (6,278)
Inventories (2,381) (40)
Prepaid and other assets 3,289 30,592
Accounts payable and other accrued liabilities (10,510) (12,361)
Accrued rebates, returns and discounts (26,584) (4,105)
Interest payable (8,071) (2,852)
Net cash (used in) provided by operating activities (25,063) 27,195
Investing Activities    
Purchases of property and equipment (9) (13)
Net cash provided by (used in) investing activities 449,036 (13)
Financing Activities    
Proceeds from issuance of common stock 0 25
Shares withheld for payment of employee's withholding tax liability (272) (216)
Net cash used in financing activities (360,107) (28,440)
Net increase (decrease) in cash and cash equivalents 63,866 (1,258)
Cash and cash equivalents at beginning of year 42,107 110,949
Cash and cash equivalents at end of period 105,973 109,691
Supplemental Disclosure of Cash Flow Information    
Net cash paid for income taxes 100 0
Cash paid for interest 10,842 13,213
Capital expenditures incurred but not yet paid 0 130
Senior Notes    
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities    
Loss on extinguishment of convertible notes 8,200  
Accretion of debt discount and debt issuance costs 2,699 1,357
Financing Activities    
Payments in connection with debt payment (171,775) (28,249)
Convertible debt    
Financing Activities    
Payments in connection with debt payment (188,060) 0
Gralise    
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities    
Gain (Loss) on sale of assets (127,500) 0
Investing Activities    
Proceeds from sale of assets 81,087 0
NUCYNTA    
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities    
Gain (Loss) on sale of assets 15,755 0
Investing Activities    
Proceeds from sale of assets $ 367,958 $ 0
XML 34 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2020
May 06, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 001-13111  
Entity Registrant Name ASSERTIO THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 94-3229046  
Entity Address, Address Line One 100 South Saunders Road  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town Lake Forest  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60045  
City Area Code 224  
Local Phone Number 419-7106  
Title of 12(b) Security Common Stock, $0.0001 par value  
Trading Symbol ASRT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Smaller Reporting Company false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   81,375,075
Entity Central Index Key 0001005201  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
XML 35 R72.htm IDEA: XBRL DOCUMENT v3.20.1
ACQUISITIONS AND DISPOSITIONS - Termination of Slan Agreements (Details) - License Agreement - Slan - USD ($)
$ in Millions
Feb. 06, 2020
Nov. 07, 2017
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
License fee received in cash   $ 5.0  
Term of license agreement   10 years  
Reimbursable development expenses     $ 2.0
Reimbursable development expenses, received $ 2.0    
Possible future payments to be received, based upon commercial sales, if circumstances met $ 10.0    
XML 36 R51.htm IDEA: XBRL DOCUMENT v3.20.1
INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets $ 7,795 $ 25,444
Write-off of remaining carrying value, disposition 369,069  
NUCYNTA | Product rights    
Finite-Lived Intangible Assets [Line Items]    
Write-off of remaining carrying value, disposition $ 369,069  
XML 37 R55.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION - Narrative (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2020
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Options granted (in dollars per share) 0
Stock Options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total unrecognized compensation expense | $ $ 0.9
Average vesting period for recognition of unrecognized compensation expense 1 year 2 months 19 days
Restricted Stock Units and Performance-based Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Average vesting period for recognition of unrecognized compensation expense 2 years 2 months 26 days
Total unrecognized compensation expense, non-options | $ $ 14.6
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award granted (in shares) 3,600,000
Granted (in dollars per share) | $ / shares $ 1.05
PSUs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award granted (in shares) 0
XML 38 R59.htm IDEA: XBRL DOCUMENT v3.20.1
DEBT - Summary of Liability Component of Convertible Notes (Details) - Convertible debt - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
2.5% Convertible Notes debt 2021    
Debt Instrument [Line Items]    
Principal amount of the Notes $ 42,465 $ 145,000
Unamortized discount of the liability component (3,767) (14,963)
Unamortized debt issuance costs (184) (725)
Total 38,514 129,312
5.0% Convertible Notes debt 2024    
Debt Instrument [Line Items]    
Principal amount of the Notes 34,522 120,000
Unamortized discount of the liability component (14,373) (51,701)
Unamortized debt issuance costs (797) (2,796)
Total $ 19,352 $ 65,503
XML 39 R38.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Sales and Royalties (Details)
 3 Months Ended
Mar. 31, 2020
Product Sales and Royalties  
Product return period prior to expiration 6 months
Period after expiration for accepting unsalable product (up to) 12 months
Cash discount 2.00%
Discount reimbursement period after filling of prescription subject to discount 1 month
Zipsor  
Product Sales and Royalties  
Product shelf-life 36 months
Minimum  
Product Sales and Royalties  
Collection period after delivery 1 month
Discount taken off period after the quarter in which product shipped to the customer 1 month
Period after the quarter in which prescription is filled for paying rebate 2 months
Contract with customer, managed care rebate liability, period after quarter in which prescription is filled 1 month
Contract with customer, Medicare Part D coverage gap rebate liability, period after quarter in which prescription is filled 2 months
Minimum | NUCYNTA ER and NUCYNTA  
Product Sales and Royalties  
Product shelf-life 24 months
Minimum | Gralise  
Product Sales and Royalties  
Product shelf-life 24 months
Minimum | CAMBIA  
Product Sales and Royalties  
Product shelf-life 24 months
Minimum | Lazanda  
Product Sales and Royalties  
Product shelf-life 24 months
Maximum  
Product Sales and Royalties  
Collection period after delivery 2 months
Product return period prior to expiration 6 months
Period after expiration for accepting unsalable product (up to) 12 months
Discount taken off period after the quarter in which product shipped to the customer 2 months
Period after the quarter in which prescription is filled for paying rebate 3 months
Contract with customer, managed care rebate liability, period after quarter in which prescription is filled 3 months
Contract with customer, Medicare Part D coverage gap rebate liability, period after quarter in which prescription is filled 3 months
Maximum | NUCYNTA ER and NUCYNTA  
Product Sales and Royalties  
Product shelf-life 36 months
Maximum | Gralise  
Product Sales and Royalties  
Product shelf-life 36 months
Maximum | CAMBIA  
Product Sales and Royalties  
Product shelf-life 48 months
Maximum | Lazanda  
Product Sales and Royalties  
Product shelf-life 36 months
XML 40 R34.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Organization (Details) - USD ($)
Feb. 13, 2020
Jan. 10, 2020
Apr. 08, 2020
Mar. 11, 2020
Feb. 19, 2020
Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% | Convertible debt          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Repurchased aggregate principal amount         $ 188,000,000.0
Tender offer to repurchase debt       $ 77,000,000.0  
Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% | Convertible debt | Subsequent Event          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Repurchased aggregate principal amount     $ 76,700,000    
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Gralise          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Sale of disposal group, total value   $ 127,500,000      
Sale of disposal group, cash received   $ 75,000,000.0      
Consideration receivable as percentage of net sales after closing   75.00%      
Threshold for consideration receivable on net sales after closing   $ 70,000,000.0      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | NUCYNTA          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Sale of disposal group, cash received $ 375,000,000.0        
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Schedule of lease cost components, Cash Flow information, and term and discount rate information
Lease expense during the period included the following (in thousands):
 
 
 
Three Months Ended March 31,
 
Financial Statement Classification
 
2020
 
2019
Operating lease cost
Selling, general and administrative expenses
 
$
157

 
$
187

Operating lease cost
Other
 
148

 
148

Total lease cost
 
 
$
305

 
$
335

 
 
 
 
 
 
Sublease Income
Other
 
$
347

 
$
362
XML 42 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Convertible debt
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Convertible debt
Accumulated Earnings (Deficit)
Accumulated Other Comprehensive Loss
Balances (in shares) at Dec. 31, 2018     64,185        
Balances at Dec. 31, 2018 $ 220,335   $ 6 $ 402,934   $ (182,600) $ (5)
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock upon exercise of options (in shares)     14        
Issuance of common stock upon exercise of options 25     25      
Issuance of common stock in conjunction with vesting of restricted stock units (in shares)     132        
Stock-based compensation 2,702     2,702      
Shares withheld for payment of employee's withholding tax liability (216)     (216)      
Net income (loss) (14,301)         (14,301)  
Balances (in shares) at Mar. 31, 2019     64,331        
Balances at Mar. 31, 2019 208,545   $ 6 405,445   (196,901) (5)
Balances (in shares) at Dec. 31, 2019     80,888        
Balances at Dec. 31, 2019 57,958   $ 8 457,751   (399,801) 0
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock in conjunction with vesting of restricted stock units (in shares)     434        
Reacquisition of equity component of 2021 Notes and 2024 Notes   $ (16,814)     $ (16,814)    
Stock-based compensation 1,934     1,934      
Shares withheld for payment of employee's withholding tax liability (271)     (271)      
Net income (loss) 41,230         41,230  
Balances (in shares) at Mar. 31, 2020     81,322        
Balances at Mar. 31, 2020 $ 84,037   $ 8 $ 442,600   $ (358,571) $ 0
XML 43 R13.htm IDEA: XBRL DOCUMENT v3.20.1
DEBT
 3 Months Ended
Mar. 31, 2020
Long-term Debt, Unclassified [Abstract]  
DEBT DEBT
 
Senior Notes
 
On April 2, 2015, the Company issued $575.0 million aggregate principal amount of senior secured notes (the Senior Notes) for aggregate gross proceeds of approximately $562.0 million pursuant to a Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement), among the Company and Deerfield Private Design Fund III, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., BioPharma Secured Investments III Holdings Cayman LP, Inteligo Bank Ltd. and Phemus Corporation (collectively, the Purchasers) and Deerfield Private Design Fund III, L.P., as collateral agent. The Company used $550.0 million of the net proceeds received upon the sale of the Senior Notes to fund a portion of the Purchase Price paid to Janssen Pharma in connection with the NUCYNTA acquisition.
 
The Senior Notes had a maturity date of April 14, 2021 (unless earlier prepaid or repurchased), were secured by substantially all of the assets of the Company and any subsidiary guarantors, and bore interest at the rate equal to the lesser of (i) 9.75% over the three month London Inter-Bank Offer Rate (LIBOR), subject to a floor of 1.0% and (ii) 11.95% (through the third anniversary of the purchase date) and 12.95% (thereafter). The interest rate was determined at the first business day of each fiscal quarter, commencing with the first such date following April 2, 2015. The interest rate for the three months ended March 31, 2020 and 2019 was 11.65% and 12.54%, respectively.

As of February 13, 2020, the Company had repaid in full all outstanding indebtedness, and terminated all commitments and obligations, under its Note Purchase Agreement. The Company used proceeds from the sale of Gralise and NUCYNTA to repay the outstanding principal of $162.5 million. In addition, the Company paid approximately $4.9 million and $4.4 million in prepayment premiums and accrued exit fees, respectively, plus accrued but unpaid interest. In connection with the termination of the Note Purchase Agreement, the Company was released from all security interests, liens and encumbrances under the Note Purchase Agreement.

During the three months ended March 31, 2020, the Company recognized a loss on debt extinguishment of $8.2 million, composed of the $4.9 million prepayment fee and $3.3 million of unamortized debt discount and debt issuance costs, recognized as part of Loss on debt extinguishment in the Company’s Consolidated Statement of Comprehensive Income.

The following is a summary of the carrying value of the Senior Notes as of December 31, 2019 (in thousands): 
 
 
December 31,
2019
Principal amount of the Senior Notes
 
$
162,500

Unamortized debt discount balance
 
(4,035
)
Unamortized debt issuance costs
 
(2,022
)
Total Senior Notes
 
$
156,443


Debt discount and debt issuance costs were amortized as interest expense using the effective interest method. The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands): 
 
Three Months Ended March 31,
 
2020
 
2019
Contractual interest expense
$
1,648

 
$
8,206

Amortization of debt discount and debt issuance costs
2,699

 
1,357

Total interest expense Senior Notes
$
4,347

 
$
9,563

 
    
    
2.50% Convertible Senior Notes Due 2021
 
On September 9, 2014, the Company issued $345.0 million aggregate principal amount of 2.50% Convertible Senior Notes Due 2021 (the 2021 Notes) which mature on September 1, 2021 and bear interest at the rate of 2.50% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning March 1, 2015.

On August 13, 2019, the Company exchanged (the Convertible Note Exchange) $200.0 million aggregate principal amount of the 2021 Notes for a combination of (a) its new $120.0 million aggregate principal amount of 5.00% Convertible
Senior Notes due August 15, 2024 (the 2024 Notes), (b) an aggregate cash payment of $30.0 million, and (c) an aggregate of 15.8 million shares of the Company’s common stock. The Company did not receive any cash proceeds from the issuance of the 2024 Notes or the issuance of the shares of its common stock. Upon completion of the Convertible Note Exchange, the aggregate principal amount of the 2021 Notes was reduced by $200.0 million to $145.0 million, the unamortized debt discount and debt issuance costs was reduced by $26.1 million to $18.9 million and the carrying amount of the equity component was reduced by $6.2 million to $112.8 million.

On February 19, 2020, the Company entered into separate, privately negotiated purchase agreements (Purchase Agreements) with a limited number of holders of the Company’s currently outstanding 2021 Notes and 2024 Notes. The Company used proceeds from the sale of Gralise and NUCYNTA to repurchase $102.5 million aggregate principal amount of 2021 Notes for a cash payment plus accrued but unpaid interest.

The repurchase of the 2021 Notes was accounted for in accordance with ASC 470-50, Debt Modifications and Extinguishments (ASC 470-50). During the three months ended March 31, 2020, the Company recognized a $10.3 million loss on debt extinguishment, which represented the difference between the carrying value and the fair value of the 2021 Notes just prior to the repurchase plus transaction costs. The Company also recognized reacquisition of $0.3 million in additional paid-in capital related to the equity component of the 2021 Notes based on the excess of the fair value of total considerations provided against the fair value of the 2021 Notes just prior to the repurchase. As a result of the transaction, the aggregate principal amount of the 2021 Notes was reduced to $42.5 million, the unamortized debt discount and debt issuance costs was reduced by $10.3 million to $4.3 million and the carrying amount of the equity component was reduced by $0.3 million to $112.5 million.

The closing price of the Company’s common stock did not exceed 130% of the $19.24 conversion price, for the required period during the quarter ended March 31, 2020. As a result, the 2021 Notes were not convertible as of March 31, 2020.

The following is a summary of the liability component of the 2021 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31,
2019
Principal amount of the 2021 Notes
$
42,465

 
$
145,000

Unamortized discount of the liability component
(3,767
)
 
(14,963
)
Unamortized debt issuance costs
(184
)
 
(725
)
Total 2021 Notes
$
38,514

 
$
129,312



The debt discount and debt issuance costs are being amortized as interest expense using the effective interest method. The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Stated coupon interest
$
607

 
$
2,156

Amortization of debt discount and debt issuance costs
1,469

 
4,807

Total interest expense 2021 Notes
$
2,076

 
$
6,963

 

5.00% Convertible Senior Notes Due 2024

On August 13, 2019, as part of the Convertible Note Exchange, the Company issued $120.0 million aggregate principal of 2024 Notes which mature on August 14, 2024 and bear interest at a rate of 5.0%, payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2020.

On February 19, 2020, the Company entered into separate, privately negotiated purchase agreements (Purchase Agreements) with a limited number of holders of the Company’s currently outstanding 2021 Notes and 2024 Notes. The Company used proceeds from the sale of Gralise and NUCYNTA to repurchase $85.5 million aggregate principal amount of 2024 Notes for a cash payment plus accrued but unpaid interest.

The repurchase of the 2024 Notes was accounted for in accordance with ASC 470-50, Debt Modifications and Extinguishments (ASC 470-50). During the three months ended March 31, 2020 the Company recognized a $21.3 million loss
on debt extinguishment, which represented the difference between the carrying value and the fair value of the 2024 Notes just prior to the repurchase plus transaction costs. The Company also recognized reacquisition of $16.8 million in additional paid-in capital related to the equity component of the 2024 Notes based on the excess of the fair value of total considerations provided against the fair value of the 2024 Notes just prior to the repurchase. As a result of the transaction, the aggregate principal amount of the 2024 Notes was reduced to $34.5 million, the unamortized debt discount and debt issuance costs was reduced by $38.1 million to $15.4 million and the carrying amount of the equity component was reduced by $16.5 million to $16.1 million.
    
The 2024 Notes are not convertible or redeemable as of March 31, 2020. The following is a summary of the liability component of the 2024 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31, 2019
Principal amount of the 2024 Notes
$
34,522

 
$
120,000

Unamortized discount of the liability component
(14,373
)
 
(51,701
)
Unamortized debt issuance costs
(797
)
 
(2,796
)
Total 2024 Notes
$
19,352

 
$
65,503



The debt discount and debt issuance costs are being amortized as interest expense using the effective interest method. The following is a summary of interest expense for the 2024 Notes for three months ended March 31, 2020 (in thousands):
 
Three Months Ended March 31, 2020
Stated coupon interest
$
1,047

Amortization of debt discount and debt issuance costs
1,219

Total interest expense 2024 Notes
$
2,266



On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. As a result of the Company’s intention to settle in cash the total remaining outstanding aggregate principal, the liability component of the 2021 Notes and 2024 Notes are classified as part of Convertible notes, current portion on the Company’s Consolidated Balance Sheet as of March 31, 2020.
XML 44 R8.htm IDEA: XBRL DOCUMENT v3.20.1
ACCOUNTS RECEIVABLES, NET
 3 Months Ended
Mar. 31, 2020
Receivables [Abstract]  
ACCOUNTS RECEIVABLES, NET ACCOUNTS RECEIVABLES, NET
 
Accounts receivables, net, consist of the following (in thousands): 
 
March 31,
2020
 
December 31,
2019
Receivables related to product sales, net
$
12,427

 
$
38,353

Receivables from Collegium
—

 
4,104

Other
525

 
287

Total accounts receivable, net
$
12,952

 
$
42,744

 

As of March 31, 2020 and 2019, allowances for cash discounts for prompt payment were $0.4 million and $1.2 million, respectively.
XML 45 R17.htm IDEA: XBRL DOCUMENT v3.20.1
NET INCOME (LOSS) PER SHARE
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE NET INCOME (LOSS) PER SHARE

Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated by dividing the net income by the weighted-average number of shares of common stock outstanding during the period, plus potentially dilutive common shares, consisting of stock options and convertible debt. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock options and equivalents. The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt. For purposes of this calculation, options to purchase stock are considered to be potential common shares and are only included in the calculation of diluted net (loss) income per share when their effect is dilutive. Basic and diluted earnings per common share are calculated as follows (in thousands, except for per share amounts):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Basic net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Basic net income (loss) per share
 
$
0.58

 
$
(0.22
)
 
 
 
 
 
Diluted net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Add: effect of dilutive stock options, awards, and equivalents
 
111

 
—

Denominator for diluted income (loss) per share
 
71,051

 
64,239

Diluted net income (loss) per share
 
$
0.58

 
$
(0.22
)

 
The following table sets forth outstanding potentially dilutive common shares that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
2.5% Convertible Notes debt 2021
 
5,111

 
17,931

5.0% Convertible Notes debt 2024
 
26,248

 
—

Stock options, awards and equivalents
 
7,144

 
6,103

Total potentially dilutive common shares
 
38,503

 
24,034
XML 46 R21.htm IDEA: XBRL DOCUMENT v3.20.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS

On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, the Company announced the completion and
final results for its cash tender offers which the Company settled approximately $76.7 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes with only $0.3 million of 2021 notes remaining.
XML 47 R25.htm IDEA: XBRL DOCUMENT v3.20.1
INVENTORIES, NET (Tables)
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of inventories, net
Inventories, net, consist of raw materials, work in process and finished goods and are stated at the lower of cost or market and consist of the following (in thousands): 
 
March 31,
2020
 
December 31, 2019
Raw materials
$
29

 
$
1,065

Work-in-process
153

 
426

Finished goods
336

 
1,921

Total
$
518

 
$
3,412
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.20.1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2020
Long-term Debt, Unclassified [Abstract]  
Summary of the carrying value of the Senior Notes
The following is a summary of the carrying value of the Senior Notes as of December 31, 2019 (in thousands): 
 
 
December 31,
2019
Principal amount of the Senior Notes
 
$
162,500

Unamortized debt discount balance
 
(4,035
)
Unamortized debt issuance costs
 
(2,022
)
Total Senior Notes
 
$
156,443
Summary of interest expense for the Notes The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands): 
 
Three Months Ended March 31,
 
2020
 
2019
Contractual interest expense
$
1,648

 
$
8,206

Amortization of debt discount and debt issuance costs
2,699

 
1,357

Total interest expense Senior Notes
$
4,347

 
$
9,563

The following is a summary of interest expense for the three months ended March 31, 2020 and 2019 (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Stated coupon interest
$
607

 
$
2,156

Amortization of debt discount and debt issuance costs
1,469

 
4,807

Total interest expense 2021 Notes
$
2,076

 
$
6,963

 
The following is a summary of interest expense for the 2024 Notes for three months ended March 31, 2020 (in thousands):
 
Three Months Ended March 31, 2020
Stated coupon interest
$
1,047

Amortization of debt discount and debt issuance costs
1,219

Total interest expense 2024 Notes
$
2,266
Summary of the liability component of the Convertible Notes
The 2024 Notes are not convertible or redeemable as of March 31, 2020. The following is a summary of the liability component of the 2024 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31, 2019
Principal amount of the 2024 Notes
$
34,522

 
$
120,000

Unamortized discount of the liability component
(14,373
)
 
(51,701
)
Unamortized debt issuance costs
(797
)
 
(2,796
)
Total 2024 Notes
$
19,352

 
$
65,503


The following is a summary of the liability component of the 2021 Notes as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31,
2019
Principal amount of the 2021 Notes
$
42,465

 
$
145,000

Unamortized discount of the liability component
(3,767
)
 
(14,963
)
Unamortized debt issuance costs
(184
)
 
(725
)
Total 2021 Notes
$
38,514

 
$
129,312
XML 49 R63.htm IDEA: XBRL DOCUMENT v3.20.1
COMMITMENTS AND CONTINGENCIES - Purchase and Other Commitments (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Manufacturing    
Long-term Purchase Commitment [Line Items]    
Non-cancelable purchase obligations $ 0.7 $ 3.6
Consulting Services    
Long-term Purchase Commitment [Line Items]    
Non-cancelable purchase obligations $ 1.8 $ 2.4
XML 50 R67.htm IDEA: XBRL DOCUMENT v3.20.1
NET INCOME (LOSS) PER SHARE - Schedule of Earnings (Loss) Per Share and Dilutive Shares Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Basic net income (loss) per share    
Net income (loss) $ 41,230 $ (14,301)
Weighted average common shares outstanding (in shares) 70,940 64,239
Basic net (loss) income per share (in dollars per share) $ 0.58 $ (0.22)
Diluted net income (loss) per share    
Add: effect of dilutive stock options, awards, and equivalents (in shares) 111 0
Denominator for diluted income (loss) per share (in shares) 71,051 64,239
Diluted net (loss) income per share (in dollars per share) $ 0.58 $ (0.22)
Potentially dilutive common shares:    
Total potentially dilutive common shares (in shares) 38,503 24,034
Convertible debt | 2.5% Convertible Notes debt 2021    
Potentially dilutive common shares:    
Total potentially dilutive common shares (in shares) 5,111 17,931
Convertible debt | 5.0% Convertible Notes debt 2024    
Potentially dilutive common shares:    
Total potentially dilutive common shares (in shares) 26,248 0
Stock options, awards and equivalents    
Potentially dilutive common shares:    
Total potentially dilutive common shares (in shares) 7,144 6,103
XML 51 R48.htm IDEA: XBRL DOCUMENT v3.20.1
INVENTORIES, NET - Schedule of Inventories, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Inventory    
Raw materials $ 29 $ 1,065
Work-in-process 153 426
Finished goods 336 1,921
Total $ 518 $ 3,412
XML 52 R44.htm IDEA: XBRL DOCUMENT v3.20.1
REVENUE - Summary of Contract Assets and Liabilities (Details) - Contract asset - Collegium, net - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jan. 31, 2018
Mar. 31, 2020
Contract With Customer, Asset [Roll Forward]    
Contract asset, Beginning of Period   $ 1,896
Additions   0
Deductions   (1,896)
Contract asset, End of Period   $ 0
Contract liability $ 10,000  
Proceeds from issuance of warrants $ 8,800  
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) - Equity Incentive Plan 2014 - Performance-based Restricted Stock Units
 3 Months Ended
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Awards vesting by the end of the first year 0.00%
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Awards vesting by the end of the first year 200.00%
XML 54 R53.htm IDEA: XBRL DOCUMENT v3.20.1
ACCRUED LIABILITIES - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Accrued compensation $ 4,913 $ 6,188
Accrued consent fees 4,500 0
Accrued taxes payable 2,241 295
Accrued restructuring costs 1,332 3,763
Other accrued liabilities 11,730 8,702
Total accrued liabilities $ 24,716 $ 18,948
XML 55 R57.htm IDEA: XBRL DOCUMENT v3.20.1
DEBT - Summary of Carrying Value of Senior Notes (Details) - Senior Notes
$ in Thousands
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]  
Principal amount of the Senior Notes $ 162,500
Unamortized debt discount balance (4,035)
Unamortized debt issuance costs (2,022)
Total $ 156,443
XML 56 R74.htm IDEA: XBRL DOCUMENT v3.20.1
SUBSEQUENT EVENTS - Narrative (Details) - Convertible senior notes - USD ($)
Apr. 08, 2020
Mar. 31, 2020
Mar. 11, 2020
Feb. 19, 2020
Dec. 31, 2019
Subsequent Event [Line Items]          
Notes remaining   $ 0     $ 194,815,000
Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0%          
Subsequent Event [Line Items]          
Tender offer to repurchase debt     $ 77,000,000.0    
Repurchased aggregate principal amount       $ 188,000,000.0  
Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% | Subsequent Event          
Subsequent Event [Line Items]          
Repurchased aggregate principal amount $ 76,700,000        
2.5% Convertible Notes debt 2021          
Subsequent Event [Line Items]          
Repurchased aggregate principal amount       $ 102,500,000  
2.5% Convertible Notes debt 2021 | Subsequent Event          
Subsequent Event [Line Items]          
Notes remaining $ 300,000        
XML 57 R70.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Expense from income taxes $ 2,048,000 $ 210,000
Effective tax rate 4.70% (1.50%)
Federal statutory rate 21.00% 21.00%
Accrued interest and penalties associated with unrecognized tax benefits $ 0  
XML 58 R6.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization
 
Assertio Therapeutics, Inc. (Assertio or the Company) is a leading diversified, specialty pharmaceutical company focused on distinctive products that offer enhanced therapeutic options for patients in need, while maintaining the highest ethical standards in all our business practices.

As of March 31, 2020, the Company’s specialty pharmaceutical business consisted primarily of CAMBIA®(diclofenac potassium for oral solution), a nonsteroidal anti-inflammatory drug for the acute treatment of migraine attacks, acquired by the Company in December 2013; and Zipsor® (diclofenac potassium liquid filled capsules), a nonsteroidal anti-inflammatory drug for the treatment of mild to moderate acute pain, acquired by the Company in June 2012, both marketed in the U.S.

In 2017, the Company announced that it was in the process of transforming into a leading diversified, specialty pharmaceutical company with a goal of rapidly deleveraging its balance sheet, growing its core business, and opportunistically building for the future via business development. The Company continues to position itself to actively pursue business development, strategic partnerships, and investment opportunities to build and grow for the future. As part of this transformational initiative, the Company executed on several strategic transactions:

On December 4, 2017, the Company announced a commercialization agreement with Collegium Pharmaceutical, Inc. (Collegium), pursuant to which the Company granted Collegium the right to commercialize the NUCYNTA® franchise of products in the U.S. (the Commercialization Agreement). Pursuant to the Commercialization Agreement, Collegium assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing, and the Company received royalties on all NUCYNTA revenues based on certain net sales thresholds.

On January 10, 2020, the Company completed the sale of Gralise® (gabapentin) to Golf Acquiror LLC, an affiliate to Alvogen, Inc. (Alvogen), for total value of $127.5 million. This included $75.0 million in cash at closing, and the balance payable as 75% of Alvogen’s first $70.0 million of Gralise net sales after the closing. Alvogen also paid the Company for certain inventories relating to Gralise.

On February 13, 2020, the Company entered into a definitive agreement to divest its remaining rights, title and interest in and to the NUCYNTA franchise to Collegium for $375.0 million in cash, less royalties, paid to the Company in 2020. Pursuant to the agreement, Collegium assumed certain contracts, liabilities and obligations of the Company relating to the NUCYNTA products, including those related to manufacturing and supply, post-market commitments and clinical development costs. Collegium also paid the Company for certain inventories relating to the products.

On February 13, 2020, the Company had repaid in full its outstanding aggregate principal amount of senior secured notes (Senior Notes) pursuant to a Note Purchase Agreement dated March 12, 2015 (Note Purchase Agreement) and all subsequent amendments to the Note Purchase Agreement.

On February 19, 2020, the Company entered into separate, privately negotiated agreements with a limited number of holders of the Company’s 2021 Notes and 2024 Notes to repurchase $188.0 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

On March 11, 2020, the Company initiated a tender offer to repurchase any and all of the Company’s remaining $77.0 million of combined outstanding 2021 Notes and 2024 Notes. On April 8, 2020, the Company announced the completion and final results for its cash tender offers which the Company settled approximately $76.7 million aggregate principal amount of the outstanding 2021 Notes and 2024 Notes.

Merger Agreement

On March 16, 2020, the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Zyla Life Sciences (Zyla), Assertio Holdings, Inc., a newly created wholly-owned subsidiary of Assertio (Parent), Assertio Merger Sub, Inc., a newly created wholly-owned subsidiary of Parent (Assertio Merger Sub), and Zebra Merger Sub, Inc., a newly
created wholly-owned subsidiary of Parent (Merger Sub). The Merger Agreement provides that, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Zyla (the Merger), with Zyla surviving the Merger and becoming a wholly-owned subsidiary of Parent. Prior to the consummation of the Merger, Assertio intends to effect a reorganization merger (the “Assertio Reorganization”) pursuant to which Assertio Merger Sub will merge with and into Assertio, with Assertio surviving the merger and becoming a wholly-owned subsidiary of Parent. Parent will assume Assertio’s listing on the Nasdaq Stock Market (Nasdaq).

The terms of the Merger Agreement provide that, unless otherwise specified in the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of Zyla (the Zyla Common Stock) will be canceled and automatically converted into the right to receive as merger consideration (the Merger Consideration) 2.5 shares (the Exchange Ratio) of common stock, par value $0.0001 per share, of Parent (the Parent Common Stock).     

The Merger and the Merger Agreement have been approved by the board of directors of each of Zyla (the Zyla Board), Assertio (the Assertio Board) and Parent (the Parent Board). Completion of the Merger is conditioned upon the adoption and approval of the Merger Agreement by (1) the holders of at least a majority of the outstanding shares of Zyla Common Stock (the Zyla Stockholder Approval) and (2) by the affirmative vote of the majority of the total votes cast to approve the issuance of the Merger Consideration by the holders of the outstanding shares of common stock of Assertio (the Assertio Stockholder Approval). Completion of the Merger is also subject to other customary closing conditions. The Merger is expected to close in the second quarter of 2020.
Basis of Presentation
 
The unaudited condensed consolidated financial statements and the related footnote information of the Company have been prepared pursuant to the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company’s management, the accompanying interim unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the information for the periods presented. The results for the three months ended March 31, 2020 are not necessarily indicative of results to be expected for the entire year ending December 31, 2020 or future operating periods.
 
The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2020 (the 2019 Form 10-K). The balance sheet as of December 31, 2019 has been derived from the audited financial statements at that date, as filed in the Company’s 2019 Form 10-K.

In connection with the preparation of the financial statements for the three months ended March 31, 2020, the Company evaluated whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to the entity's ability to continue as a going concern within twelve months after the date of the issuance of these financial statements noting that there did not appear to be evidence of substantial doubt of the entity's ability to continue as a going concern.
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Depomed Bermuda Ltd (Depo Bermuda), Depo NF Sub, LLC (Depo NF Sub) and Depo DR Sub, LLC (Depo DR Sub). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
 
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as sales discounts and returns, depreciable and amortizable lives, share-based compensation assumptions and taxes on income. Although management believes these estimates are based upon reasonable assumptions
within the bounds of its knowledge of the Company’s business and operations, actual results could differ materially from these estimates.
Segment Information

The Company maintains one operating segment and has operations solely in the United States. To date, substantially all of the Company’s revenues from product sales are related to sales in the United States.

Revenue Recognition
 
The Company adopted ASC 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective transition method. There was no adjustment to the Company’s opening balance of accumulated deficit resulting from the adoption of this guidance.

Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation, when (or as) the performance obligation is satisfied. The Company assesses the term of the contract based upon the contractual period in which the Company and Collegium have enforceable rights and obligations.

Variable consideration arising from sales or usage-based royalties, promised in exchange for a license of the Company’s Intellectual Property, is recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.
 
The Company recognizes a contract asset relating to its conditional right to consideration for completed performance obligations. Accounts receivable are recorded when the right to consideration becomes unconditional. A contract liability is recorded for payments received in advance of the related performance obligation being satisfied under the contract.

Product Sales
 
The Company sells commercial products to wholesale distributors and specialty pharmacies. Product sales revenue is recognized when title has transferred to the customer and the customer has assumed the risks and rewards of ownership, which typically occurs on delivery to the customer. The Company’s performance obligation is to deliver product to the customer, and the performance obligation is completed upon delivery. The transaction price consists of a fixed invoice price and variable product sales allowances, which include rebates, discounts and returns. Product sales revenues are recorded net of applicable sales tax and reserves for these product sales allowances. Receivables related to product sales are typically collected one to two months after delivery.
 
Product Sales Allowances—The Company considers products sales allowances to be variable consideration and estimates and recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on actual or estimated amounts owed on the related sales. These estimates take into consideration the terms of the Company’s agreements with customers, historical product returns, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. The Company uses the most likely method in estimating product sales allowances. If actual future results vary from the Company’s estimates, the Company may need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment. The Company’s sales allowances include:
 
Product Returns—The Company allows customers to return product for credit with respect to that product within six months before and up to 12 months after its product expiration date. The Company estimates product returns and associated credit on NUCYNTA ER and NUCYNTA, Gralise, CAMBIA, Zipsor and Lazanda. Estimates for returns are based on historical return trends by product or by return trends of similar products, taking into consideration the shelf life of the product at the time
of shipment, shipment and prescription trends, estimated distribution channel inventory levels and consideration of the introduction of competitive products. The Company did not assume financial responsibility for returns of NUCYNTA ER and NUCYNTA previously sold by Janssen Pharma or Lazanda product previously sold by Archimedes Pharma US Inc. Under the Commercialization Agreement with Collegium for NUCYNTA ER and NUCYNTA and the divestiture of Lazanda to Slán, the Company is only financially responsible for product returns for product that were sold by the Company, which are identified by specific lot numbers.
 
The shelf life of NUCYNTA ER and NUCYNTA is 24 months to 36 months from the date of tablet manufacture. The shelf life of Gralise is 24 months to 36 months from the date of tablet manufacture. The shelf life of CAMBIA is 24 months to 48 months from the manufacture date. The shelf life of Zipsor is 36 months from the date of tablet manufacture. The shelf life of Lazanda is 24 to 36 months from the manufacture date. Because of the shelf life of the Company’s products and its return policy of issuing credits with respect to product that is returned within six months before and up to 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when the Company issues credit on a returned product. Accordingly, the Company may have to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustments.
 
Wholesaler and Pharmacy Discounts—The Company offers contractually determined discounts to certain wholesale distributors and specialty pharmacies that purchase directly from it. These discounts are either taken off invoice at the time of shipment or paid to the customer on a quarterly basis one to two months after the quarter in which product was shipped to the customer.

Prompt Pay Discounts—The Company offers cash discounts to its customers (generally 2% of the sales price) as an incentive for prompt payment. Based on the Company’s experience, the Company expects its customers to comply with the payment terms to earn the cash discount.
 
Patient Discount Programs—The Company offers patient discount co-pay assistance programs in which patients receive certain discounts off their prescriptions at participating retail and specialty pharmacies. The discounts are reimbursed by the Company approximately one month after the prescriptions subject to the discount are filled.
 
Medicaid Rebates—The Company participates in Medicaid rebate programs, which provide assistance to certain low income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, the Company pays a rebate to each participating state, generally two to three months after the quarter in which prescriptions subject to the rebate are filled.
 
Chargebacks—The Company provides discounts to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract with the Department of Veterans Affairs. These federal entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current retail price and the price the federal entity paid for the product.
 
Managed Care Rebates—The Company offers discounts under contracts with certain managed care providers. The Company generally pays managed care rebates one to three months after the quarter in which prescriptions subject to the rebate are filled.
 
Medicare Part D Coverage Gap Rebates — The Company participates in the Medicare Part D Coverage Gap Discount Program under which it provides rebates on prescriptions that fall within the “donut hole” coverage gap. The Company generally pays Medicare Part D Coverage Gap rebates two to three months after the quarter in which prescriptions subject to the rebate are filled.

Commercialization Agreement

The Company derived revenue under the Commercialization Agreement with Collegium whereby the Company granted Collegium the right to commercialize the NUCYNTA franchise of products in the U.S. The Company entered into the Commercialization Agreement in December 2017, which became effective in January 2018, and amended the agreement in August 2018 and in November 2018. The Company viewed its performance obligations as a series of distinct goods or services that are substantially the same and that have the same pattern of transfer. Prior to the November 2018 amendment, the consideration related to the license and facilitation services was fixed and recognized ratably over the contract term. Following the November 2018 amendment, the royalty payments represent variable consideration that are subject to the sales-based royalty exception for licenses of intellectual property and are recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.

In addition, the Company was responsible for royalty payments to a third party related to sales of NUCYNTA. Prior to the November 2018 amendment, Collegium became primarily responsible for these royalties in connection with the Commercialization Agreement; however, a portion of these payments remained the responsibility of the Company. Following the November 2018 amendment, effective January 1, 2019, Collegium became responsible for the third-party royalty payments entirely. As the Company was not actively commercializing NUCYNTA, such royalties were recorded by the Company on a systematic basis in proportion to the underlying net product sales, subject to the sales-based royalty exemption for license of intellectual property, and were included as gross-to-net adjustments in the related revenue line in the Company’s Statements of Comprehensive Income. Such amounts, over the course of the calendar year, had no net impact.

In connection with the Commercialization Amendment, Collegium issued the Company a warrant to purchase up to 1,041,667 shares of Collegium common stock at an exercise price of $19.20 per share (Warrant). The Warrant is exercisable for a period of four years and contains customary terms, including with regard to net exercise. The Warrant was valued at $8.8 million as of the date of the Commercialization Amendment and is considered to be a component of the fixed consideration associated with the Commercialization Agreement. This Warrant is included in Investments on the Company’s Consolidated Balance Sheet, however, as it is non-cash it does not impact investing cash flows.

Effective as of February 13, 2020, the Company divested its rights, title and interest in and to its NUCYNTA franchise of products in the U.S. to Collegium. In connection with the sale, the Commercialization Agreement terminated at closing with certain specified provisions of the Commercialization Agreement surviving in accordance with the terms of the purchase agreement.

Royalties
 
For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

We currently have the right to receive royalties based on sales of CAMBIA in Canada, which are recognized as revenue when the related sales occur as there are no continuing performance obligations by the Company under those agreements.

Milestones

For arrangements that include milestones, the Company recognizes such revenue using the most likely method. As part of adopting ASC 606, the Company evaluated whether the future milestones should have been included as part of the transaction price in periods before January 1, 2018. The Company concluded that because of development and regulatory risks at the time, it was probable that a significant revenue reversal could have occurred. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.

Leases

The Company adopted ASC 842, Leases (ASC 842), on January 1, 2019 using the modified retrospective approach with cumulative effect. There was no adjustment to the Company's opening balance of accumulated deficit resulting from the adoption of this guidance. In addition, the Company elected the package of practical expedients, which among other things, allowed for the carryforward of the historical lease classification. The Company did not elect the hindsight practical expedient to determine the reasonably certain lease term for existing leases. Prior to the adoption of ASC 842, the Company accounted for its operating leases in accordance with ASC 840. Under ASC 840, only capital leases were recognized on the balance sheet and therefore the Company’s operating leases were reflected in the financial statement footnotes. The adoption of ASC 842 did not materially affect the Company’s consolidated comprehensive income.

The Company assesses contracts for lease arrangements at inception. Operating right-of-use (ROU) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease. Operating leases are included in other long term assets, other current liabilities, and other long term liabilities in the Consolidated Balance Sheet.

The Company accounts for operating leases with an initial term of 12 months or less on a straight-line basis over the lease term in the Consolidated Statements of Comprehensive Income.
 
Stock Based Compensation

The Company’s stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs), and purchases under the Company’s employee stock purchase plan (ESPP). The Company accounts for forfeitures as they occur for each type of award. Stock-based compensation expense related to restricted stock unit awards (RSUs) is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period.

The stock-based compensation expense related to PSUs is estimated at grant date based on the fair value of the award. The PSU awards are measured exclusively to the relative total shareholder return (TSR) performance, which is measured against the three-year TSR of a custom index of companies. The actual number of shares awarded is adjusted to between zero and 200% of the target award amount based upon achievement in each of the three independent successive one-year tranches. TSR relative to peers is considered a market condition under applicable authoritative guidance. For PSUs granted with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo model, and expense is recognized ratably over the requisite service period regardless of whether or not the market condition is satisfied. The Monte Carlo valuation model considers a variety of potential future share prices for Assertio and our peer companies in a selected market index.

The Company uses the Black-Scholes option valuation model to determine the fair value of stock options and ESPP shares. The determination of the fair value of stock-based payment awards on the date of grant using an option valuation model is affected by our stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate and expected dividends over the expected term of the award. The Company uses historical option exercise data to estimate the expected term of the options. The Company estimates the volatility of our common stock price by using the historical volatility over the expected term of the options. The Company bases the risk-free interest rate on U.S. Treasury zero coupon issues with terms similar to the expected term of the options as of the date of grant. The Company does not anticipate paying any cash dividends in the foreseeable future, and therefore, uses an expected dividend yield of zero in the option valuation model. Stock-based compensation expense related to the ESPP and options is recognized on a straight-line basis over its respective term.
 
Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 Financial Instruments-Credit Losses (ASU 2016-13 or Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The Company adopted this standard on January 1, 2020 and updated its internal controls to include certain forward-looking considerations in the current process of developing and recognizing credit losses for in scope financial assets, which primarily included accounts receivable and a $3.5 million investment in a company engaged in medical research. ASC 326 had an immaterial impact to our allowance for credit losses reported in accounts receivable on our Condensed Consolidated Balance Sheet upon adoption. The investment is structured as a long-term loan receivable with a convertible feature and carried at amortized cost with accruing interest. To calculate the expected credit loss allowance, the Company utilized a probability-of-default method (PDM). This process estimates the probability of the loan being successfully paid back or converted into equity based on the ability of the investee to obtain FDA acceptance of its research. Using a PDM, we calculated an expected credit loss allowance at March 31, 2020 of $1.9 million, which was recorded in Other (expense) income in the Company’s Consolidated Statement of Comprehensive Income and included in Investments, net in the Company’s Consolidated Balance Sheet. Our expected credit losses can vary from period to period based on several factors, such as progress of the medical research and FDA submission, and overall economic environment and the ability of the investee to fund its operations. The primary factor that contributed to our provision
for expected credit losses in the first quarter of 2020 was an evaluation of probability of default to exist based on the outlook of the macro environment due to the COVID-19 pandemic and its impact to delay the FDA acceptance process combined with the investee’s ability to fund its operations and raise capital if required.

In June 2018, the FASB issued ASU 2018-18 Collaborative Arrangements (ASU 2018-18), which clarifies the interaction between ASC 808, Collaborative Arrangements (ASC 808) and ASC 606, Revenue from Contracts with Customers (ASC 606). The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The Company adopted the standard as of January 1, 2020 and have applied modified retrospective transition method to the date of initial application of ASC 606. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Accounting for Cloud Computing Arrangements (Subtopic 350-40), which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. Effective January 1, 2020, the Company adopted the standard using the prospective approach to eligible costs incurred on or after the date of adoption. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement Disclosure Framework (ASU 2018-03), which is part of a broader disclosure framework project by the FASB to improve the effectiveness of disclosures by more clearly communicating the information to the user. The Company adopted the standard as of January 1, 2020 and included these disclosures in the condensed consolidated financial statements. The additional elements of this release did not impact the Company's condensed consolidated financial statements.
 
In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASU 2019-02): Simplifying the Accounting for Income Taxes which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and by clarifying and amending existing guidance in order to improve consistent application of and simplify GAAP for other areas of Topic 740. ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company early adopted the standard effective January 1, 2020. The new standard was applied to the presentation of the Company’s reacquisition of $0.3 million and $16.5 million in equity component of the 2021 and 2024 Notes, respectively, as a result of the private purchase in February 2020.

Recently Issued Accounting Standards

In March 2020, the FASB issued ASU 2020-04 Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional expedients and exceptions to the US GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures.
XML 59 R19.htm IDEA: XBRL DOCUMENT v3.20.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
 
As of March 31, 2020, our net deferred tax assets are fully offset by a valuation allowance. The valuation allowance is determined in accordance with the provisions of ASC 740, Income taxes, which require an assessment of both negative and positive evidence when measuring the need for a valuation allowance.  Based on the weight of available evidence, the Company recorded a full valuation allowance against the Company’s net deferred assets beginning in the fourth quarter of 2016. The Company continued to provide a full valuation allowance against the Company’s net deferred assets in subsequent quarters. The Company reassesses the need for a valuation allowance on a quarterly basis.  If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.
 
On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, a massive tax-and-spending package intended to provide additional economic relief to address the impact of the COVID-19 pandemic. The CARES Act, among other business tax provisions, included legislative changes and updates to IRC sections 172, 163(j), and 168, resulting in impacting net operating losses, interest disallowance, and depreciation for qualified improvement property. The Company’s intention to carryback 2020 taxable loss to 2018 and 2019 resulted in the release of valuation allowance which was recorded to beginning deferred tax asset balance.  For the three months ended March 31, 2020, the Company recorded an expense from income taxes of approximately $2.0 million, which represents an effective tax rate of 4.7%. The difference between the income tax expense of $2.0 million and the tax at the statutory rate of 21.0% to date on current year operations is principally due to the partial release of valuation allowance recorded against the beginning of year deferred tax asset related the NOL carryback to the 2018 and 2019 tax years now permitted by the CARES Act.
 
For the three months ended March 31, 2019, the Company recorded an expense from income taxes of approximately $0.2 million that represents an effective tax rate of (1.5)%.  The difference between the recorded provision for income taxes and the income tax benefit based on the statutory federal tax rate of 21.0% was primarily attributable to the impact of the valuation allowance.
 
The Company files income tax returns in the United States federal jurisdiction and in various states, and the tax returns filed for the years 1997 through 2017 and the applicable statutes of limitation have not expired with respect to those returns. Because of net operating losses and unutilized R&D credits, substantially all of the Company’s tax years remain open to examination. The Company exhausted all the federal research and development credit in the 2018 tax return. Although the NOL carryback from CARES Act will result in making R&D credit utilized in 2018 available for future use, the percentage of unrecognized tax benefit against the R&D credit remains reserved, and the rest will be offset by valuation allowance.  Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense by the Company. At March 31, 2020 the Company did not have any accrued interest and penalties associated with unrecognized tax benefits.
XML 60 R2.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 105,973 $ 42,107
Accounts receivable, net 12,952 42,744
Inventories, net 518 3,412
Consideration receivable from sale of Gralise 50,019 0
Prepaid and other current assets 10,651 15,688
Total current assets 180,113 103,951
Property and equipment, net 3,233 3,497
Intangible assets, net 23,671 400,535
Investments, net 8,132 13,064
Other long-term assets 4,125 6,123
Total assets 219,274 527,170
Current liabilities:    
Accounts payable 4,982 16,193
Accrued rebates, returns and discounts 32,359 58,943
Accrued liabilities 24,716 18,948
Interest payable 304 8,375
Other current liabilities 2,066 2,094
Total current liabilities 122,293 184,553
Other long-term liabilities 12,944 13,401
Total liabilities 135,237 469,212
Commitments and contingencies
Shareholders’ equity:    
Common stock 8 8
Additional paid-in capital 442,600 457,751
Accumulated deficit (358,571) (399,801)
Total shareholders’ equity 84,037 57,958
Total liabilities and shareholders' equity 219,274 527,170
Senior Notes    
Current liabilities:    
Senior Notes, current portion 0 80,000
Senior Notes 0 76,443
Convertible debt    
Current liabilities:    
Senior Notes, current portion 57,866 0
Senior Notes $ 0 $ 194,815
XML 61 R11.htm IDEA: XBRL DOCUMENT v3.20.1
ACCRUED LIABILITIES
 3 Months Ended
Mar. 31, 2020
Accounts Payable and Accrued Liabilities, Current [Abstract]  
ACCRUED LIABILITIES ACCRUED LIABILITIES
 
Accrued liabilities consist of the following (in thousands): 
 
March 31,
2020
 
December 31,
2019
Accrued compensation
$
4,913

 
$
6,188

Accrued consent fees
4,500

 
—

Accrued taxes payable
2,241

 
295

Accrued restructuring costs
1,332

 
3,763

Other accrued liabilities
11,730

 
8,702

Total accrued liabilities
$
24,716

 
$
18,948
XML 62 R15.htm IDEA: XBRL DOCUMENT v3.20.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

 
Purchase and Other Commitments

As of March 31, 2020 and December 31, 2019, the Company had non‑cancelable purchase orders and minimum purchase obligations related to manufacturing agreements of approximately $0.7 million and $3.6 million, respectively. Additionally, the Company had non‑cancelable purchase orders related to consulting services of approximately $1.8 million and $2.4 million as of March 31, 2020 and December 31, 2019, respectively.


Legal Matters

Glumetza Antitrust Litigation
Antitrust class actions and related direct antitrust actions have been filed in the Northern District of California against the Company and several other defendants relating to the drug Glumetza®. The named class representatives in the currently pending actions include Meijer, Inc., Bi-Lo, LLC, Winn-Dixie Logistics, Inc., City of Providence, and KPH Healthcare Services, Inc. These class representatives seek to represent a putative class of direct purchasers of Glumetza. In addition, several retailers, including CVS Pharmacy, Inc., Rite Aid Corporation, Walgreen Co., the Kroger Co., the Albertsons Companies, Inc., H-E-B, L.P., and Hy-Vee, Inc., have filed substantially similar direct antitrust claims based on alleged assignments of claims from direct purchaser wholesalers. On December 23, 2019, the Company filed a motion to dismiss all claims in the actions. That motion was heard by the District Court on February 20, 2020. On March 5, 2015 the District Court issued an order denying the motion to dismiss. However, based on the order on the motion, claims previously filed by a putative class of end payor plaintiffs were voluntarily dismissed.

These antitrust cases arise out of a Settlement and License Agreement (the Settlement) that the Company, Santarus, Inc. (Santarus) and Lupin Limited (Lupin) entered into in February 2012 that resolved patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs allege, among other things, that the Settlement violated the antitrust laws because it allegedly included a “reverse payment” that caused Lupin to delay its entry in the market with a generic version of Glumetza. The alleged “reverse payment” is an alleged commitment on the part of the settling parties not to launch an authorized generic version of Glumetza for a certain period. The antitrust plaintiffs allege that the Company and its co-defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus) are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza® due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.

The parties are currently conducting discovery, and briefing a motion by the direct purchasers seeking class certification. The Company intends to defend itself vigorously in these matters.

Securities Class Action Lawsuit and Related Matters

On August 23, 2017, the Company, its current chief executive officer and president, its former chief executive officer and president, and its former chief financial officer were named as defendants in a purported federal securities law class action filed in the U.S. District Court for the Northern District of California (the District Court). The action (Huang v. Depomed et al., No. 4:17-cv-4830-JST, N.D. Cal.) alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 relating to certain prior disclosures of the Company about its business, compliance, and operational policies and practices concerning the sales and marketing of its opioid products and contends that the conduct supporting the alleged violations affected the value of Company common stock and is seeking damages and other relief. In an amended complaint filed on February 6, 2018, the lead plaintiff (referred to in its pleadings as the Depomed Investor Group), which seeks to represent a class consisting of all purchasers of Company common stock between July 29, 2015 and August 7, 2017, asserted the same claims arising out of the same and similar disclosures against the Company and the same individuals as were involved in the original complaint. The Company and the individuals filed a motion to dismiss the amended complaint on April 9, 2018. On March 18, 2019, the District Court granted the motion to dismiss without prejudice, and the plaintiffs filed a second amended complaint on May 2, 2019. The second amended complaint asserted the same claims arising out of the same and similar disclosures against the Company and the same individuals as were involved in the original complaint. The Company and the individuals filed a motion to dismiss the second amended complaint on June 17, 2019. The lead plaintiff filed an opposition to the motion on August 1, 2019. The Company and the individuals filed a reply in support of their motion to
dismiss on August 30, 2019. The District Court held oral argument on December 18, 2019. On March 11, 2020, the District Court granted the motion to dismiss the second amended complaint. On April 9, 2020, the plaintiffs filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. The Company believes that the action is without merit and intends to contest it vigorously.

In addition, five shareholder derivative actions were filed on behalf of the Company against its officers and directors for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the federal securities laws. The claims arise out of the same factual allegations as the class action. The first derivative action was filed in the Superior Court of California, Alameda County on September 29, 2017 (Singh v. Higgins et al., RG17877280). The second and third actions were filed in the Northern District of California on November 10, 2017 (Solak v. Higgins et al., No. 3:17-cv-6546-JST) and November 15, 2017 (Ross v. Fogarty et al., No. 3:17-cv-6592- JST). The fourth action was filed in the District of Delaware on December 21, 2018 (Lutz v. Higgins et al, No. 18-2044-CFC). The fifth derivative action was filed in the Superior Court of California, Alameda County on January 28, 2019 (Youse v. Higgins et al, No. HG19004409). On December 7, 2017, the plaintiffs in Solak v. Higgins, et al. voluntarily dismissed the first federal derivative action. The Ross, Singh, and Lutz actions were stayed on January 18, 2018, January 23, 2018, and January 11, 2019, respectively, pending the resolution of the motion to dismiss in the securities class action. On May 28, 2019, during a brief lift of the stay in the Singh and Youse actions while the parties’ motion to consolidate was pending, after having been ordered to respond to the Singh and Youse complaints, the Company did so by filing demurrers. On July 12, 2019, the Singh and Youse actions were consolidated, and the consolidated matter was stayed pending the resolution of the motion to dismiss in the federal class action. The plaintiffs have indicated that they intend to file an amended consolidated complaint. The Company believes that these actions are without merit and intends to contest them vigorously.

Opioid-Related Request and Subpoenas

As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, the Company received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information from the Company regarding its historical commercialization of opioid products. The Company voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, the Company has received and responded to subpoenas from the U.S. Department of Justice (DOJ) seeking documents and information regarding its historical sales and marketing of opioid products. The Company has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding the Company’s historical sales and marketing of opioid products. In addition, the Company received and responded to a subpoena from the State of California Department of Insurance (CDI) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also seeks information on Gralise, a non-opioid product formerly in the Company’s portfolio. Most recently, the Company received a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company also from time to time receives and complies with subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

Multidistrict Opioid Litigation
A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but most of the lawsuits include federal and state statutory claims as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.
For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (MDL Court) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been transferred to the MDL Court. The Company is currently involved in a subset of the lawsuits that have been transferred to the MDL Court. The Company is also involved in other federal lawsuits that have not yet been transferred to the MDL Court pending a determination of whether those lawsuits should proceed in state or other originating court. Plaintiffs may file additional lawsuits in which the Company may be named. Plaintiffs in the pending federal cases involving the Company include individuals, county and municipal governmental entities,
employee benefit plans, health clinics and health insurance providers who assert federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. These lawsuits are in the earliest stages of proceedings, and the Company intends to defend itself vigorously in these matters.
State Opioid Litigation
Related to the cases in the MDL Court noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. The Company is currently named in a subset of those cases, including cases in Alabama, Florida, Illinois, Missouri, Pennsylvania, Texas and Utah. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving the Company, plaintiffs are asserting state common law and statutory claims against the defendants similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking past and future damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. These lawsuits are likewise in their earliest stages, and the Company intends to defend itself vigorously in these matters.
Insurance Litigation
On January 15, 2019, the Company was named as a defendant in a declaratory judgment action filed by Navigators Specialty Insurance Company (Navigators) in the U.S. District Court for the Northern District of California (Case No. 3:19-cv-255). Navigators is the Company’s primary product liability insurer. Navigators is seeking declaratory judgment that opioid litigation claims noticed by the Company (as further described above under “Multidistrict Opioid Litigation” and “State Opioid Litigation”) are not covered by the Company’s life sciences liability policies with Navigators. The Company filed a counterclaim on February 28, 2019. Navigators filed an answer on April 11, 2019. This litigation is ongoing. The parties expect to file summary judgment briefing relating to Navigators’ duty to defend the opioid litigation in the third quarter of 2020, and to receive a ruling in 2021.
General
The Company cannot reasonably predict the outcome of the legal proceedings described above, nor can the Company estimate the amount of loss, range of loss or other adverse consequence, if any, that may result from these proceedings or the amount of any gain in the event the Company prevails in litigation involving a claim for damages. As such the Company is not currently able to estimate the impact of the above litigation on its financial position or results of operations.
The Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. The Company may also become party to further litigation in federal and state courts relating to opioid drugs. Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth above, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.
JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "asrt-331202010q.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 210, "dts": { "calculationLink": { "local": [ "asrt-20200331_cal.xml" ] }, "definitionLink": { "local": [ "asrt-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "asrt-331202010q.htm" ] }, "labelLink": { "local": [ "asrt-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "asrt-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "asrt-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 498, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 6, "http://www.assertiotx.com/20200331": 7, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 18 }, "keyCustom": 65, "keyStandard": 283, "memberCustom": 36, "memberStandard": 28, "nsprefix": "asrt", "nsuri": "http://www.assertiotx.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.assertiotx.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - INTANGIBLE ASSETS", "role": "http://www.assertiotx.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - ACCRUED LIABILITIES", "role": "http://www.assertiotx.com/role/AccruedLiabilities", "shortName": "ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.assertiotx.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - DEBT", "role": "http://www.assertiotx.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - LEASES", "role": "http://www.assertiotx.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.assertiotx.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - RESTRUCTURING CHARGES", "role": "http://www.assertiotx.com/role/RestructuringCharges", "shortName": "RESTRUCTURING CHARGES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - NET INCOME (LOSS) PER SHARE", "role": "http://www.assertiotx.com/role/NetIncomeLossPerShare", "shortName": "NET INCOME (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - FAIR VALUE", "role": "http://www.assertiotx.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - INCOME TAXES", "role": "http://www.assertiotx.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "asrt:BusinessCombinationAndDispositionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - ACQUISITIONS AND DISPOSITIONS", "role": "http://www.assertiotx.com/role/AcquisitionsAndDispositions", "shortName": "ACQUISITIONS AND DISPOSITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "asrt:BusinessCombinationAndDispositionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.assertiotx.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - REVENUE (Tables)", "role": "http://www.assertiotx.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - ACCOUNTS RECEIVABLES, NET (Tables)", "role": "http://www.assertiotx.com/role/AccountsReceivablesNetTables", "shortName": "ACCOUNTS RECEIVABLES, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - INVENTORIES, NET (Tables)", "role": "http://www.assertiotx.com/role/InventoriesNetTables", "shortName": "INVENTORIES, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://www.assertiotx.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - ACCRUED LIABILITIES (Tables)", "role": "http://www.assertiotx.com/role/AccruedLiabilitiesTables", "shortName": "ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.assertiotx.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - DEBT (Tables)", "role": "http://www.assertiotx.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "role": "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - LEASES (Tables)", "role": "http://www.assertiotx.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - RESTRUCTURING CHARGES (Tables)", "role": "http://www.assertiotx.com/role/RestructuringChargesTables", "shortName": "RESTRUCTURING CHARGES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)", "role": "http://www.assertiotx.com/role/NetIncomeLossPerShareTables", "shortName": "NET INCOME (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - FAIR VALUE (Tables)", "role": "http://www.assertiotx.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Feb19_us-gaap_DebtInstrumentAxis_asrt_ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Organization (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Jan10_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asrt_GraliseMember", "decimals": "-5", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q2QTD_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_BusinessAcquisitionAxis_asrt_ZylaLifeSciencesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "asrt:BusinessAcquisitionEquityInterestIssuedOrIssuableShareExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Agreement (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q2QTD_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_BusinessAcquisitionAxis_asrt_ZylaLifeSciencesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "asrt:BusinessAcquisitionEquityInterestIssuedOrIssuableShareExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Information (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2018Q1JAN01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "decimals": "INF", "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "asrt:ProductReturnPeriodPriorToExpirationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Sales and Royalties (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Sales and Royalties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "asrt:ProductReturnPeriodPriorToExpirationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2018Q4Nov08_srt_CounterpartyNameAxis_asrt_CollegiumPharmaceuticalIncMember_us-gaap_TypeOfArrangementAxis_asrt_AmendedCommercializationAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Commercialization Agreement (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Commercialization Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2018Q4Nov08_srt_CounterpartyNameAxis_asrt_CollegiumPharmaceuticalIncMember_us-gaap_TypeOfArrangementAxis_asrt_AmendedCommercializationAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY (Unaudited)", "role": "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_asrt_PerformanceBasedRestrictedStockUnitsMember_us-gaap_PlanNameAxis_asrt_EquityIncentivePlan2014Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_asrt_PerformanceBasedRestrictedStockUnitsMember_us-gaap_PlanNameAxis_asrt_EquityIncentivePlan2014Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Jan01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401409 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted and Issued Accounting Pronouncements (Details)", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted and Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Jan01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details)", "role": "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails", "shortName": "REVENUE - Schedule of Disaggregated Revenue from Contracts with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_asrt_NeurologyProductMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - REVENUE - Commercialization Agreement with Collegium (Details)", "role": "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "shortName": "REVENUE - Commercialization Agreement with Collegium (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1QTD_srt_CounterpartyNameAxis_asrt_CollegiumPharmaceuticalIncMember_us-gaap_TypeOfArrangementAxis_asrt_CommercializationAgreementAndAmendedCommercializationAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4_srt_CounterpartyNameAxis_asrt_CollegiumPharmaceuticalIncMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - REVENUE - Summary of Contract Assets and Liabilities (Details)", "role": "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails", "shortName": "REVENUE - Summary of Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4_srt_CounterpartyNameAxis_asrt_CollegiumPharmaceuticalIncMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_srt_CounterpartyNameAxis_asrt_CambiaCanadaMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_asrt_NuvoPharmaceuticalsAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - REVENUE - Royalties & Milestones (Details)", "role": "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails", "shortName": "REVENUE - Royalties & Milestones (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_srt_CounterpartyNameAxis_asrt_CambiaCanadaMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_asrt_NuvoPharmaceuticalsAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - ACCOUNTS RECEIVABLES, NET - Schedule of Accounts Receivables, Net (Details)", "role": "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails", "shortName": "ACCOUNTS RECEIVABLES, NET - Schedule of Accounts Receivables, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_TypeOfArrangementAxis_asrt_CommercializationAgreementMember", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "asrt:AccountsReceivableAllowanceForCashDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - ACCOUNTS RECEIVABLES, NET - Narrative (Details)", "role": "http://www.assertiotx.com/role/AccountsReceivablesNetNarrativeDetails", "shortName": "ACCOUNTS RECEIVABLES, NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "asrt:AccountsReceivableAllowanceForCashDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - INVENTORIES, NET - Schedule of Inventories, Net (Details)", "role": "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails", "shortName": "INVENTORIES, NET - Schedule of Inventories, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - INVENTORIES, NET - Narrative (Details)", "role": "http://www.assertiotx.com/role/InventoriesNetNarrativeDetails", "shortName": "INVENTORIES, NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and net Book Values of Intangible Assets (Details)", "role": "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS - Summary of Gross Carrying Amounts and net Book Values of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - INTANGIBLE ASSETS - Narrative (Details)", "role": "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "shortName": "INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details)", "role": "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS - Summary of Future Amortization Expense of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - ACCRUED LIABILITIES - Schedule of Accrued Liabilities (Details)", "role": "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "shortName": "ACCRUED LIABILITIES - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Based Compensation Expense Recognized (Details)", "role": "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Based Compensation Expense Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - DEBT - Narrative (Details)", "role": "http://www.assertiotx.com/role/DebtNarrativeDetails", "shortName": "DEBT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "D2019Q3Aug13-Aug13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - DEBT - Summary of Carrying Value of Senior Notes (Details)", "role": "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "shortName": "DEBT - Summary of Carrying Value of Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - DEBT - Summary of Interest Expense of Senior Notes (Details)", "role": "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails", "shortName": "DEBT - Summary of Interest Expense of Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_asrt_ConvertibleSeniorNotes2.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - DEBT - Summary of Liability Component of Convertible Notes (Details)", "role": "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "shortName": "DEBT - Summary of Liability Component of Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_asrt_ConvertibleSeniorNotes2.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - DEBT - Summary of Interest Expense of Convertible Notes (Details)", "role": "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "shortName": "DEBT - Summary of Interest Expense of Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DebtInstrumentAxis_asrt_ConvertibleSeniorNotes2.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "asrt:LesseeOperatingLeaseNumberOfSubleases", "reportCount": 1, "unique": true, "unitRef": "sublease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.assertiotx.com/role/LeasesNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "asrt:LesseeOperatingLeaseNumberOfSubleases", "reportCount": 1, "unique": true, "unitRef": "sublease", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - LEASES - Lease Cost Components (Details)", "role": "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails", "shortName": "LEASES - Lease Cost Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_asrt_ManufacturingMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Purchase and Other Commitments (Details)", "role": "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Purchase and Other Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_asrt_ManufacturingMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "D2017Q3Aug23_srt_LitigationCaseAxis_asrt_SecuritiesClassActionLawsuitMember", "decimals": "INF", "first": true, "lang": null, "name": "asrt:NumberOfShareholderDerivativeActionsFiled", "reportCount": 1, "unique": true, "unitRef": "action", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Legal Matters (Details)", "role": "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Legal Matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "D2017Q3Aug23_srt_LitigationCaseAxis_asrt_SecuritiesClassActionLawsuitMember", "decimals": "INF", "first": true, "lang": null, "name": "asrt:NumberOfShareholderDerivativeActionsFiled", "reportCount": 1, "unique": true, "unitRef": "action", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)", "role": "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "shortName": "RESTRUCTURING CHARGES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring and Severance Costs (Details)", "role": "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails", "shortName": "RESTRUCTURING CHARGES - Schedule of Accrued Restructuring and Severance Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember", "decimals": "-3", "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - NET INCOME (LOSS) PER SHARE - Schedule of Earnings (Loss) Per Share and Dilutive Shares Information (Details)", "role": "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "shortName": "NET INCOME (LOSS) PER SHARE - Schedule of Earnings (Loss) Per Share and Dilutive Shares Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)", "role": "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails", "shortName": "FAIR VALUE - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_CashAndCashEquivalentsAxis_us-gaap_WarrantMember_us-gaap_IncomeStatementLocationAxis_asrt_OtherExpenseIncomeNetMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - FAIR VALUE - Narrative (Details)", "role": "http://www.assertiotx.com/role/FairValueNarrativeDetails", "shortName": "FAIR VALUE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_CashAndCashEquivalentsAxis_us-gaap_WarrantMember_us-gaap_IncomeStatementLocationAxis_asrt_OtherExpenseIncomeNetMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - REVENUE", "role": "http://www.assertiotx.com/role/Revenue", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://www.assertiotx.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Sale of Gralise (Details)", "role": "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "shortName": "ACQUISITIONS AND DISPOSITIONS - Sale of Gralise (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Jan10_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asrt_GraliseMember", "decimals": "-5", "lang": null, "name": "asrt:DisposalGroupIncludingDiscontinuedOperationConsiderationAmountOfNetSalesAfterClosing", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "D2017Q4NOV07-NOV07_asrt_AssetAcquisitionAxis_asrt_SlanMember_us-gaap_TypeOfArrangementAxis_asrt_LicenseAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "asrt:LicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Termination of Slan Agreements (Details)", "role": "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails", "shortName": "ACQUISITIONS AND DISPOSITIONS - Termination of Slan Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "D2017Q4NOV07-NOV07_asrt_AssetAcquisitionAxis_asrt_SlanMember_us-gaap_TypeOfArrangementAxis_asrt_LicenseAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "asrt:LicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Jan10_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asrt_GraliseMember", "decimals": "-5", "first": true, "lang": null, "name": "asrt:DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingBasePurchasePriceAndInventoryAdjustment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - ACQUISITIONS AND DISPOSITIONS - Sale of NUCYNTA (Details)", "role": "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "shortName": "ACQUISITIONS AND DISPOSITIONS - Sale of NUCYNTA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q1Feb13_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asrt_NUCYNTAMember", "decimals": "-5", "lang": null, "name": "asrt:DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingBasePurchasePriceAndInventoryAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FI2020Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)", "role": "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails", "shortName": "SUBSEQUENT EVENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "I2020Q2Apr08_us-gaap_DebtInstrumentAxis_asrt_ConvertibleSeniorNotes2.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - ACCOUNTS RECEIVABLES, NET", "role": "http://www.assertiotx.com/role/AccountsReceivablesNet", "shortName": "ACCOUNTS RECEIVABLES, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - INVENTORIES, NET", "role": "http://www.assertiotx.com/role/InventoriesNet", "shortName": "INVENTORIES, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "asrt-331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "asrt_A2019CostSavingsInitiativeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Cost Savings Initiative [Member]", "label": "2019 Cost Savings Initiative [Member]", "terseLabel": "2019 Cost Savings Initiative" } } }, "localname": "A2019CostSavingsInitiativeMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_AccountsReceivableAllowanceForCashDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accounts Receivable, Allowance For Cash Discount", "label": "Accounts Receivable, Allowance For Cash Discount", "terseLabel": "Allowance for cash discounts for prompt payment" } } }, "localname": "AccountsReceivableAllowanceForCashDiscount", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_AccruedConsentFeesCurrent": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Consent Fees, Current", "label": "Accrued Consent Fees, Current", "terseLabel": "Accrued consent fees" } } }, "localname": "AccruedConsentFeesCurrent", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "asrt_AmendedCommercializationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended Commercialization Agreement [Member]", "label": "Amended Commercialization Agreement [Member]", "terseLabel": "Amended Commercialization Agreement" } } }, "localname": "AmendedCommercializationAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails" ], "xbrltype": "domainItemType" }, "asrt_AssertioParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assertio, Parent [Member]", "label": "Assertio, Parent [Member]", "terseLabel": "Parent" } } }, "localname": "AssertioParentMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "asrt_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "stringItemType" }, "asrt_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "domainItemType" }, "asrt_BusinessAcquisitionEquityInterestIssuedOrIssuableShareExchangeRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Share Exchange Ratio", "label": "Business Acquisition, Equity Interest Issued Or Issuable, Share Exchange Ratio", "terseLabel": "Exchange ratio (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableShareExchangeRatio", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "sharesItemType" }, "asrt_BusinessCombinationAndDispositionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination And Disposition Disclosure [Text Block]", "label": "Business Combination And Disposition Disclosure [Text Block]", "terseLabel": "ACQUISITIONS AND DISPOSITIONS" } } }, "localname": "BusinessCombinationAndDispositionDisclosureTextBlock", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositions" ], "xbrltype": "textBlockItemType" }, "asrt_CAMBIAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to CAMBIA, a product of the entity.", "label": "C A M B I A [Member]", "terseLabel": "CAMBIA" } } }, "localname": "CAMBIAMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_CambiaCanadaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cambia Canada [Member]", "label": "Cambia Canada [Member]", "terseLabel": "Cambia Canada" } } }, "localname": "CambiaCanadaMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "domainItemType" }, "asrt_CashDiscountToCustomerForPromptPaymentAsPercentageOfSalesPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the cash discount that the entity offers to its customers as an incentive for prompt payment as a percentage of sales price.", "label": "Cash Discount to Customer for Prompt Payment as Percentage of Sales Price", "terseLabel": "Cash discount" } } }, "localname": "CashDiscountToCustomerForPromptPaymentAsPercentageOfSalesPrice", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "percentItemType" }, "asrt_ClaimsNumberIndustryWideOpioid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims filed industry-wide.", "label": "Claims, Number, Industry-Wide", "terseLabel": "Number of industry-wide opioid litigation cases (more than)" } } }, "localname": "ClaimsNumberIndustryWideOpioid", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "integerItemType" }, "asrt_ClassOfWarrantOrRightExercisePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Period", "label": "Class Of Warrant Or Right, Exercise Period", "terseLabel": "Warrant, exercise period" } } }, "localname": "ClassOfWarrantOrRightExercisePeriod", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails" ], "xbrltype": "durationItemType" }, "asrt_ClassOfWarrantOrRightExpectedTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Expected Term", "label": "Class Of Warrant Or Right, Expected Term", "terseLabel": "Warrant, expected term" } } }, "localname": "ClassOfWarrantOrRightExpectedTerm", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "durationItemType" }, "asrt_ClassOfWarrantOrRightFairValuePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Fair Value Price Of Warrants Or Rights", "label": "Class Of Warrant Or Right, Fair Value Price Of Warrants Or Rights", "terseLabel": "Warrant, fair value price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightFairValuePriceOfWarrantsOrRights", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "perShareItemType" }, "asrt_ClassOfWarrantOrRightRemainingContractualPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Remaining Contractual Period", "label": "Class Of Warrant Or Right, Remaining Contractual Period", "terseLabel": "Warrant, remaining contractual period" } } }, "localname": "ClassOfWarrantOrRightRemainingContractualPeriod", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "durationItemType" }, "asrt_ClassOfWarrantOrRightRiskFreeRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Risk-Free Rate", "label": "Class Of Warrant Or Right, Risk-Free Rate", "terseLabel": "Warrant, risk-free rate" } } }, "localname": "ClassOfWarrantOrRightRiskFreeRate", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "percentItemType" }, "asrt_CollaborativeAgreementTermOfLicenseAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The period of time the license agreement last following the first commercial sale in the U.S.", "label": "Collaborative Agreement, Term Of License Agreement", "terseLabel": "Term of license agreement" } } }, "localname": "CollaborativeAgreementTermOfLicenseAgreement", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "durationItemType" }, "asrt_CollaborativeArrangementTerminationFuturePaymentsToBeReceivedIfCircumstancesMet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Termination, Future Payments To Be Received, If Circumstances Met", "label": "Collaborative Arrangement, Termination, Future Payments To Be Received, If Circumstances Met", "terseLabel": "Possible future payments to be received, based upon commercial sales, if circumstances met" } } }, "localname": "CollaborativeArrangementTerminationFuturePaymentsToBeReceivedIfCircumstancesMet", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_CollaborativeArrangementTerminationReimbursableDevelopmentExpensesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Termination, Reimbursable Development Expenses Received", "label": "Collaborative Arrangement, Termination, Reimbursable Development Expenses Received", "terseLabel": "Reimbursable development expenses, received" } } }, "localname": "CollaborativeArrangementTerminationReimbursableDevelopmentExpensesReceived", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_CollaborativePartnersReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Partners Receivable [Member]", "label": "Collaborative Partners Receivable [Member]", "terseLabel": "Other" } } }, "localname": "CollaborativePartnersReceivableMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "domainItemType" }, "asrt_CollegiumPharmaceuticalIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to the license and service agreement with collegium Pharmaceutical Inc.", "label": "Collegium Pharmaceutical Inc [Member]", "terseLabel": "Contract asset - Collegium, net", "verboseLabel": "Collegium Pharmaceutical Inc" } } }, "localname": "CollegiumPharmaceuticalIncMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "asrt_CommercializationAgreementAndAmendedCommercializationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercialization Agreement And Amended Commercialization Agreement [Member]", "label": "Commercialization Agreement And Amended Commercialization Agreement [Member]", "terseLabel": "Commercialization Agreement And Amended Commercialization Agreement" } } }, "localname": "CommercializationAgreementAndAmendedCommercializationAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails" ], "xbrltype": "domainItemType" }, "asrt_CommercializationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to the commercialization agreement.", "label": "Commercialization Agreement [Member]", "terseLabel": "Commercialization agreement, net", "verboseLabel": "Receivables from Collegium" } } }, "localname": "CommercializationAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_CommercializationRightsAndFacilitationServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pertaining to commercialization rights and facilitation services.", "label": "Commercialization Rights And Facilitation Services [Member]", "terseLabel": "Commercialization agreement, net" } } }, "localname": "CommercializationRightsAndFacilitationServicesMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_ConsultingServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consulting Services [Member]", "label": "Consulting Services [Member]", "terseLabel": "Consulting Services" } } }, "localname": "ConsultingServicesMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "asrt_ContractWithCustomerAssetDeletions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, from business combination. May include payments received during the period.", "label": "Contract with Customer, Asset, Deletions", "negatedTerseLabel": "Deductions" } } }, "localname": "ContractWithCustomerAssetDeletions", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "asrt_ContractWithCustomerAssetNetCurrentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of additions, in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer Asset Net Current Additions", "terseLabel": "Additions" } } }, "localname": "ContractWithCustomerAssetNetCurrentAdditions", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "asrt_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract With Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "asrt_ContractWithCustomerManagedCareRebateLiabilityPeriodAfterQuarterInWhichPrescriptionIsFilled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Managed Care Rebate Liability, Period After Quarter In Which Prescription Is Filled", "label": "Contract With Customer, Managed Care Rebate Liability, Period After Quarter In Which Prescription Is Filled", "terseLabel": "Contract with customer, managed care rebate liability, period after quarter in which prescription is filled" } } }, "localname": "ContractWithCustomerManagedCareRebateLiabilityPeriodAfterQuarterInWhichPrescriptionIsFilled", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ContractWithCustomerMedicarePartDCoverageGapRebateLiabilityPeriodAfterQuarterInWhichPrescriptionIsFilled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Medicare Part D Coverage Gap Rebate Liability, Period After Quarter In Which Prescription Is Filled", "label": "Contract With Customer, Medicare Part D Coverage Gap Rebate Liability, Period After Quarter In Which Prescription Is Filled", "terseLabel": "Contract with customer, Medicare Part D coverage gap rebate liability, period after quarter in which prescription is filled" } } }, "localname": "ContractWithCustomerMedicarePartDCoverageGapRebateLiabilityPeriodAfterQuarterInWhichPrescriptionIsFilled", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% [Member]", "label": "Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0% [Member]", "terseLabel": "Convertible Senior Notes 2.5% And Convertible Senior Notes 5.0%" } } }, "localname": "ConvertibleSeniorNotes2.5AndConvertibleSeniorNotes5.0Member", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_ConvertibleSeniorNotes2.5Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes, 2.5% [Member]", "label": "Convertible Senior Notes, 2.5% [Member]", "terseLabel": "2.5% Convertible Notes debt 2021" } } }, "localname": "ConvertibleSeniorNotes2.5Member", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_ConvertibleSeniorNotes5.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes, 5.0% [Member]", "label": "Convertible Senior Notes, 5.0% [Member]", "terseLabel": "5.0% Convertible Notes debt 2024" } } }, "localname": "ConvertibleSeniorNotes5.0Member", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "asrt_DebtInstrumentConvertibleIncreaseDecreaseInCarryingAmountOfEquityComponent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Increase (Decrease) In Carrying Amount of Equity Component", "label": "Debt Instrument, Convertible, Increase (Decrease) In Carrying Amount Of Equity Component", "negatedTerseLabel": "Reduction in carrying amount of equity component" } } }, "localname": "DebtInstrumentConvertibleIncreaseDecreaseInCarryingAmountOfEquityComponent", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DebtInstrumentConvertibleThresholdBusinessDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Business Days", "terseLabel": "Business days, period" } } }, "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "asrt_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period", "terseLabel": "Consecutive trading-day period" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "asrt_DebtInstrumentInterestRateAfterThirdAnniversaryPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum contractual interest rate for funds borrowed, under the debt agreement after third anniversary of the purchase date", "label": "Debt Instrument, Interest Rate After Third Anniversary, Percentage", "terseLabel": "Interest rate after third anniversary of purchase date" } } }, "localname": "DebtInstrumentInterestRateAfterThirdAnniversaryPercentage", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "asrt_DebtInstrumentInterestRateThroughThirdAnniversaryPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum contractual interest rate for funds borrowed, under the debt agreement through third anniversary of the purchase date.", "label": "Debt Instrument, Interest Rate Through Third Anniversary, Percentage", "terseLabel": "Interest rate through third anniversary of purchase date" } } }, "localname": "DebtInstrumentInterestRateThroughThirdAnniversaryPercentage", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "asrt_DebtInstrumentTenderOfferToRepurchaseDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Tender Offer To Repurchase Debt", "label": "Debt Instrument, Tender Offer To Repurchase Debt", "terseLabel": "Tender offer to repurchase debt" } } }, "localname": "DebtInstrumentTenderOfferToRepurchaseDebt", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DiscountReimbursementPeriodAfterFillingOfPrescriptionSubjectToDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the discount reimbursement period after filling of prescription subject to discount.", "label": "Discount Reimbursement Period after Filling of Prescription Subject to Discount", "terseLabel": "Discount reimbursement period after filling of prescription subject to discount" } } }, "localname": "DiscountReimbursementPeriodAfterFillingOfPrescriptionSubjectToDiscount", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_DiscountTakenOffPeriodAfterQuarterInWhichProductShippedToCustomer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the discount taken off period after the quarter in which product shipped to the customer under certain wholesaler and retail pharmacy discounts.", "label": "Discount Taken Off Period after Quarter in which Product Shipped to Customer", "terseLabel": "Discount taken off period after the quarter in which product shipped to the customer" } } }, "localname": "DiscountTakenOffPeriodAfterQuarterInWhichProductShippedToCustomer", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_DisposalGroupAnnualLumpSumPaymentDueInYearsTwoAndThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Annual Lump Sum Payment Due In Years Two And Three", "label": "Disposal Group, Annual Lump Sum Payment Due In Years Two And Three", "terseLabel": "Lump sum payments obligation" } } }, "localname": "DisposalGroupAnnualLumpSumPaymentDueInYearsTwoAndThree", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupConsiderationReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Consideration Receivable, Current", "label": "Disposal Group, Consideration Receivable, Current", "terseLabel": "Consideration receivable from sale of Gralise" } } }, "localname": "DisposalGroupConsiderationReceivableCurrent", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountOfNetSalesAfterClosing": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Amount Of Net Sales After Closing", "label": "Disposal Group, Including Discontinued Operation, Consideration, Amount Of Net Sales After Closing", "terseLabel": "Net sale after closing, contingent consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationAmountOfNetSalesAfterClosing", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationConsiderationBasePurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Base Purchase Price", "label": "Disposal Group, Including Discontinued Operation, Consideration, Base Purchase Price", "terseLabel": "Consideration received, base purchase price", "verboseLabel": "Proceeds from divestiture of businesses, base purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationBasePurchasePrice", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingBasePurchasePriceAndInventoryAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Including Base Purchase Price And Inventory Adjustment", "label": "Disposal Group, Including Discontinued Operation, Consideration, Including Base Purchase Price And Inventory Adjustment", "terseLabel": "Consideration received, including base purchase price and inventory adjustment", "verboseLabel": "Consideration received, including base purchase price, inventory adjustment and royalties received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingBasePurchasePriceAndInventoryAdjustment", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationConsiderationThresholdForNetSalesAfterClosing": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Threshold For Net Sales After Closing", "label": "Disposal Group, Including Discontinued Operation, Consideration, Threshold For Net Sales After Closing", "terseLabel": "Threshold for consideration receivable on net sales after closing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationThresholdForNetSalesAfterClosing", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsAccruedThirdPartyConsentFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Accrued Third-Party Consent Fee", "label": "Disposal Group, Including Discontinued Operations, Accrued Third-Party Consent Fees", "terseLabel": "Accrued third-party consent fees" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsAccruedThirdPartyConsentFees", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsCarryingValueIntangibleDerecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Carrying Value, Intangible Derecognized", "label": "Disposal Group, Including Discontinued Operations, Carrying Value, Intangible Derecognized", "terseLabel": "Carrying value of intangible derecognized" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsCarryingValueIntangibleDerecognized", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsConsiderationPercentageOfNetSalesAfterClosing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Consideration, Percentage Of Net Sales After Closing", "label": "Disposal Group, Including Discontinued Operations, Consideration, Percentage Of Net Sales After Closing", "terseLabel": "Consideration receivable as percentage of net sales after closing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsConsiderationPercentageOfNetSalesAfterClosing", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "percentItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsContingentConsiderationDeemedProbable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Contingent Consideration Deemed Probable", "label": "Disposal Group, Including Discontinued Operations, Contingent Consideration Deemed Probable", "terseLabel": "Contingent consideration deemed to be probable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsContingentConsiderationDeemedProbable", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsInventoryAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Inventory Adjustment", "label": "Disposal Group, Including Discontinued Operations, Inventory Adjustment", "terseLabel": "Consideration received, inventory adjustment upon disposal", "verboseLabel": "Proceeds from divestiture of businesses, inventory amount" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsInventoryAdjustment", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsInventoryTransfer": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Inventory Transfer", "label": "Disposal Group, Including Discontinued Operations, Inventory Transfer", "terseLabel": "Inventory transfer" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsInventoryTransfer", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsRoyaltiesReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Royalties Received", "label": "Disposal Group, Including Discontinued Operations, Royalties Received", "terseLabel": "Royalties received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsRoyaltiesReceived", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupIncludingDiscontinuedOperationsUpfrontConsiderationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Upfront Consideration Received", "label": "Disposal Group, Including Discontinued Operations, Upfront Consideration Received", "terseLabel": "Upfront consideration received", "verboseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsUpfrontConsiderationReceived", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "asrt_DisposalGroupLumpSumPaymentObligationNumberOfPayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal Group, Lump Sum Payment Obligation, Number Of Payments", "label": "Disposal Group, Lump Sum Payment Obligation, Number Of Payments", "terseLabel": "Number of lump sum payments" } } }, "localname": "DisposalGroupLumpSumPaymentObligationNumberOfPayments", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "integerItemType" }, "asrt_DisposalOfIntangibleAssetsFinitelived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Of Intangible Assets, Finite-lived", "label": "Disposal Of Intangible Assets, Finite-lived", "negatedLabel": "Disposition", "verboseLabel": "Write-off of remaining carrying value, disposition" } } }, "localname": "DisposalOfIntangibleAssetsFinitelived", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_EquityIncentivePlan2014Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive Plan 2014 [Member]", "label": "Equity Incentive Plan 2014 [Member]", "terseLabel": "Equity Incentive Plan 2014" } } }, "localname": "EquityIncentivePlan2014Member", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "asrt_ExtinguishmentOfDebtCashPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Extinguishment Of Debt, Cash Paid", "label": "Extinguishment Of Debt, Cash Paid", "terseLabel": "Extinguishment of debt, cash paid" } } }, "localname": "ExtinguishmentOfDebtCashPaid", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_FairValueAdjustmentOfAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value Adjustment Of Assets And Liabilities", "label": "Fair Value Adjustment Of Assets And Liabilities", "negatedLabel": "Recurring fair value measurement of assets and liabilities" } } }, "localname": "FairValueAdjustmentOfAssetsAndLiabilities", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_FinancingReceivableExpectedAllowanceForCreditLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Financing Receivable, Expected Allowance For Credit Loss", "label": "Financing Receivable, Expected Allowance For Credit Loss", "terseLabel": "Expected allowance for credit loss" } } }, "localname": "FinancingReceivableExpectedAllowanceForCreditLoss", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finite-Lived Intangible Assets, Amortization Expense, After Year Three", "label": "Finite-Lived Intangible Assets, Amortization Expense, After Year Three", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_GraliseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Gralise, a product of the entity.", "label": "Gralise [Member]", "terseLabel": "Gralise" } } }, "localname": "GraliseMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingEmployeeRelatedLiabilities": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. Excludes employee related liabilities.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities Excluding Employee Related Liabilities", "terseLabel": "Accounts payable and other accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingEmployeeRelatedLiabilities", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period related to rebates, returns and discounts incurred but not paid.", "label": "Increase (Decrease) in Accrued Rebates, Returns and Discounts", "terseLabel": "Accrued rebates, returns and discounts" } } }, "localname": "IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_JanssenNucyntaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents activity related to NUCYNTA and related inventory.", "label": "Janssen Nucynta [Member]", "terseLabel": "NUCYNTA", "verboseLabel": "NUCYNTA and Lazanda product sales adjustments" } } }, "localname": "JanssenNucyntaMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_LazandaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Lazanda, a product of the entity.", "label": "Lazanda [Member]", "terseLabel": "Lazanda" } } }, "localname": "LazandaMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "domainItemType" }, "asrt_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Operating lease, number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "asrt_LesseeOperatingLeaseNumberOfSubleases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number Of Subleases", "label": "Lessee, Operating Lease, Number Of Subleases", "terseLabel": "Number of subleases" } } }, "localname": "LesseeOperatingLeaseNumberOfSubleases", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "asrt_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pertaining to the license agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "domainItemType" }, "asrt_LicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the license fee incurred during the period.", "label": "License Fee", "terseLabel": "License fee received in cash" } } }, "localname": "LicenseFee", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_LossOnDebtPrepayment": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Loss On Debt Prepayment", "label": "Loss On Debt Prepayment", "negatedTerseLabel": "Loss on prepayment of Senior Notes", "verboseLabel": "Loss on prepayment of Senior Notes" } } }, "localname": "LossOnDebtPrepayment", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_ManufacturingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing [Member]", "label": "Manufacturing [Member]", "terseLabel": "Manufacturing" } } }, "localname": "ManufacturingMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "asrt_MultidistrictOpioidLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Multidistrict Opioid Litigation.", "label": "Multidistrict Opioid Litigation [Member]", "terseLabel": "Multidistrict Opioid Litigation" } } }, "localname": "MultidistrictOpioidLitigationMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "domainItemType" }, "asrt_NUCYNTAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NUCYNTA [Member]", "label": "NUCYNTA [Member]", "terseLabel": "NUCYNTA" } } }, "localname": "NUCYNTAMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "domainItemType" }, "asrt_NeurologyProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Neurology product.", "label": "Neurology Product [Member]", "terseLabel": "Total neurology product sales, net" } } }, "localname": "NeurologyProductMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_NucyntaErAndNucyntaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pertaining to NUCYNTA ER and NUCYNTA.", "label": "Nucynta Er And Nucynta [Member]", "terseLabel": "NUCYNTA ER and NUCYNTA" } } }, "localname": "NucyntaErAndNucyntaMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "domainItemType" }, "asrt_NumberOfShareholderDerivativeActionsFiled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of shareholder derivative actions that were filed.", "label": "Number of Shareholder Derivative Actions Filed", "terseLabel": "Number of shareholder derivative actions filed" } } }, "localname": "NumberOfShareholderDerivativeActionsFiled", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "integerItemType" }, "asrt_NuvoPharmaceuticalsAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nuvo Pharmaceuticals Agreement [Member]", "label": "Nuvo Pharmaceuticals Agreement [Member]", "terseLabel": "Nuvo Pharmaceuticals Agreement" } } }, "localname": "NuvoPharmaceuticalsAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "domainItemType" }, "asrt_OtherExpenseIncomeNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Expense (Income), Net [Member]", "label": "Other Expense (Income), Net [Member]", "terseLabel": "Other" } } }, "localname": "OtherExpenseIncomeNetMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "domainItemType" }, "asrt_PaymentForDebtExitFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment For Debt Exit Fee", "label": "Payment For Debt Exit Fee", "terseLabel": "Payment accrued exit fees" } } }, "localname": "PaymentForDebtExitFee", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_PaymentOfDebtPrepaymentCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment Of Debt Prepayment Cost", "label": "Payment Of Debt Prepayment Cost", "terseLabel": "Debt prepayment fee" } } }, "localname": "PaymentOfDebtPrepaymentCost", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "asrt_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance based restricted stock units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance-based Restricted Stock Units", "verboseLabel": "PSUs" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_PeriodAfterQuarterInWhichPrescriptionIsFilledForPayingRebate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the period after the quarter in which prescription is filled for paying rebate to each participating state under the Medicaid rebate programs.", "label": "Period After Quarter in which Prescription is Filled for Paying Rebate", "terseLabel": "Period after the quarter in which prescription is filled for paying rebate" } } }, "localname": "PeriodAfterQuarterInWhichPrescriptionIsFilledForPayingRebate", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ProductReturnPeriodAfterExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the period after expiration of a product within which the entity accepts return of unsalable product from customers.", "label": "Product Return Period after Expiration Date", "terseLabel": "Period after expiration for accepting unsalable product (up to)" } } }, "localname": "ProductReturnPeriodAfterExpirationDate", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ProductReturnPeriodPriorToExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the period prior to expiration of a product within which the entity accepts return of unsalable product from customers.", "label": "Product Return Period Prior to Expiration Date", "terseLabel": "Product return period prior to expiration" } } }, "localname": "ProductReturnPeriodPriorToExpirationDate", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ProductRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal rights held to use a product.", "label": "Product Rights [Member]", "terseLabel": "Product rights" } } }, "localname": "ProductRightsMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "asrt_ProductSalesReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Sales Receivable [Member]", "label": "Product Sales Receivable [Member]", "terseLabel": "Receivables related to product sales, net" } } }, "localname": "ProductSalesReceivableMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "domainItemType" }, "asrt_ProductShelfLifeFromDateOfManufacturing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the product shelf-life from the manufacturing date.", "label": "Product Shelf Life from Date of Manufacturing", "terseLabel": "Product shelf-life" } } }, "localname": "ProductShelfLifeFromDateOfManufacturing", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ProvisionForInventoryAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Provision For Inventory And Other Assets", "label": "Provision For Inventory And Other Assets", "terseLabel": "Provision for inventory and other assets" } } }, "localname": "ProvisionForInventoryAndOtherAssets", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "asrt_ReceivablesCollectionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the typical collection period for receivables after product delivery, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Receivables, Collection Period", "terseLabel": "Collection period after delivery" } } }, "localname": "ReceivablesCollectionPeriod", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "durationItemType" }, "asrt_ReimbursableDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reimbursable Development Expenses", "label": "Reimbursable Development Expenses", "terseLabel": "Reimbursable development expenses" } } }, "localname": "ReimbursableDevelopmentExpenses", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "asrt_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Units And Performance Based Restricted Stock Units [Member]", "label": "Restricted Stock Units And Performance Based Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Units and Performance-based Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "asrt_RevenueRecognitionThirdPartyRoyaltyNetExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Third-Party Royalty Net Expense", "label": "Revenue Recognition, Third-Party Royalty Net Expense", "terseLabel": "Expense related to third-party royalties" } } }, "localname": "RevenueRecognitionThirdPartyRoyaltyNetExpense", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails" ], "xbrltype": "monetaryItemType" }, "asrt_RoyaltiesAndMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalties And Milestones [Member]", "label": "Royalties And Milestones [Member]", "terseLabel": "Royalties and milestones", "verboseLabel": "Royalties and milestone revenue" } } }, "localname": "RoyaltiesAndMilestonesMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]", "terseLabel": "Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesLineItems", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "asrt_ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash and cash equivalent balances and investments in marketable securities.", "label": "Schedule of Cash and Cash Equivalents and Marketable Securities [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents and Marketable Securities [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesTable", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "asrt_ScheduleOfInterestExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of interest expense.", "label": "Schedule of Interest Expense [Table Text Block]", "terseLabel": "Summary of interest expense for the Notes" } } }, "localname": "ScheduleOfInterestExpenseTableTextBlock", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "asrt_ScheduleOfLiabilityComponentsOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of the liability components of debt instruments.", "label": "Schedule of Liability Components of Debt Instruments [Table Text Block]", "terseLabel": "Summary of the liability component of the Convertible Notes" } } }, "localname": "ScheduleOfLiabilityComponentsOfDebtInstrumentsTableTextBlock", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "asrt_SecuritiesClassActionLawsuitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information related to the securities calss action lawsuits.", "label": "Securities Class Action Lawsuit [Member]", "terseLabel": "Securities Class Action Lawsuit and Related Matters" } } }, "localname": "SecuritiesClassActionLawsuitMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "domainItemType" }, "asrt_SlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for the information related to Slan and cosyntropin.", "label": "Slan [Member]", "terseLabel": "Slan" } } }, "localname": "SlanMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails" ], "xbrltype": "domainItemType" }, "asrt_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Summary of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "stringItemType" }, "asrt_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to various accounting policies of the entity.", "label": "Summary of Significant Accounting Policies [Table]", "terseLabel": "Summary of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "stringItemType" }, "asrt_ThirdPartyConsentAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third-Party Consent Agreement [Member]", "label": "Third-Party Consent Agreement [Member]", "terseLabel": "Third-Party Consent Agreement" } } }, "localname": "ThirdPartyConsentAgreementMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "domainItemType" }, "asrt_ZipsorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Zipsor, a product of the entity.", "label": "Zipsor [Member]", "terseLabel": "Zipsor" } } }, "localname": "ZipsorMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "asrt_ZylaLifeSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zyla Life Sciences [Member]", "label": "Zyla Life Sciences [Member]", "terseLabel": "Zyla Life Sciences" } } }, "localname": "ZylaLifeSciencesMember", "nsuri": "http://www.assertiotx.com/20200331", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r62", "r108" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails", "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r143", "r213", "r216", "r320", "r321" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails", "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r185", "r287" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "ASU 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "ACCOUNTS RECEIVABLES, NET" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r14", "r30", "r144", "r145", "r214" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails", "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r64", "r65", "r253" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Shares withheld for payment of employee's withholding tax liability" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "negatedNetLabel": "Reacquisition in additional paid-in capital, equity component", "negatedTerseLabel": "Reacquisition of equity component", "terseLabel": "Reacquisition of equity component of 2021 Notes and 2024 Notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r223", "r225", "r238", "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r225", "r234", "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r97", "r273" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Accretion of debt discount and debt issuance costs", "verboseLabel": "Amortization of debt discount and debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r155", "r161" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive common shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r142", "r299", "r310" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r15", "r16", "r61" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r257" ], "calculation": { "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r226", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r248", "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Equity Interests Issued or Issuable [Line Items]", "terseLabel": "Business Acquisition, Equity Interests Issued or Issuable [Line Items]" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditures incurred but not yet paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "terseLabel": "Contract asset, amortization" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r294", "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by project.", "label": "Project [Axis]", "terseLabel": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r12", "r41", "r99" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r269" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant, exercise price per share (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrant, number of shares (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r184", "r303", "r315" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r183", "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Par value of common stock (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r105", "r252", "r254", "r255" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of contract assets and liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r208", "r210", "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract asset, End of Period", "periodStartLabel": "Contract asset, Beginning of Period" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r208", "r209", "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "netLabel": "Convertible senior notes", "terseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r73", "r74" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of sales (excluding amortization of intangible assets)" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r77" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Accrued rebates, returns and discounts" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Senior Notes, current portion" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r24", "r25", "r26", "r300", "r301", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r26", "r192", "r301", "r309" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails": { "order": 1.0, "parentTag": "us-gaap_SeniorLongTermNotes", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal amount of the Notes", "verboseLabel": "Principal amount of the Senior Notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Carrying amount of equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r51", "r202", "r203", "r205" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "verboseLabel": "Stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r272", "r274" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Par value of debt", "verboseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value of debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r50", "r196", "r272" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Repurchased aggregate principal amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r109", "r202", "r204", "r205", "r206", "r271", "r272", "r274", "r308" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r271", "r274" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails": { "order": 2.0, "parentTag": "us-gaap_SeniorLongTermNotes", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount balance", "negatedTerseLabel": "Unamortized discount of the liability component" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r193", "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Unamortized balances of debt discount and debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r140" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Adjustments" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Potentially dilutive common shares:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r166", "r170" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Sale of disposal group, total value" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r97", "r166", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Gain (loss) on disposal" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r117", "r122", "r123", "r124", "r125", "r129", "r306", "r318" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) per share (in dollars per share)", "verboseLabel": "Basic net (loss) income per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic net income (loss) per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r117", "r122", "r123", "r124", "r125", "r129", "r306", "r318" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income (loss) per share (in dollars per share)", "verboseLabel": "Diluted net (loss) income per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income (loss) per share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r105", "r126", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r110", "r242", "r243" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r242", "r243", "r245" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Average vesting period for recognition of unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense, non-options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee compensation costs", "verboseLabel": "Employee Severance and Benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "netLabel": "Stock Options", "terseLabel": "Stock options, awards and equivalents" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Debt extinguishment, amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r257", "r258", "r259", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r220", "r221", "r222", "r258", "r289" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r257", "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r257", "r258", "r260", "r261", "r266" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r220", "r221", "r222", "r258", "r290" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r220", "r221", "r222", "r258", "r291" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "netLabel": "Level 2", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r220", "r221", "r222", "r258", "r292" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "negatedLabel": "Fair value adjustment, recorded loss" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r263", "r266" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Remaining Useful Life (In years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r160" ], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2020 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r162" ], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r162" ], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r156", "r157", "r160", "r163", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r160", "r293" ], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible assets", "verboseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r156", "r159" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r160" ], "calculation": { "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfFutureAmortizationExpenseOfIntangibleAssetsDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain Contingencies [Line Items]", "terseLabel": "Legal matters" } } }, "localname": "GainContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingenciesTable": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.", "label": "Gain Contingencies [Table]", "terseLabel": "Gain Contingencies [Table]" } } }, "localname": "GainContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesLegalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r97" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Recognized gain", "terseLabel": "Gain (loss) on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r97" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedTerseLabel": "Gain (Loss) on sale of assets" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r97", "r198", "r199" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of convertible notes", "terseLabel": "Loss on extinguishment of convertible notes" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r97", "r164" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "negatedTerseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r117", "r298", "r304", "r319" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails", "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails", "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r141", "r246" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Expense from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "verboseLabel": "Net cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r96" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "verboseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r154", "r158" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r139", "r270", "r273", "r307" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r80", "r197" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense Senior Notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r82" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "verboseLabel": "Stated coupon interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r91", "r94", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r19", "r20", "r48" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES, NET" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r13", "r60", "r150" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r59" ], "calculation": { "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r60", "r114", "r150", "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r58" ], "calculation": { "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetScheduleOfInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r316" ], "calculation": { "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments, net" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r282", "r283" ], "calculation": { "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease cost components, Cash Flow information, and term and discount rate information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r302", "r313" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "ACCOUNTS RECEIVABLES, NET" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Three month LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r26", "r194", "r301", "r311" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Senior Notes", "verboseLabel": "Notes remaining" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Unclassified [Abstract]" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments, net" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r188" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfConvertibleNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r66", "r68", "r75", "r98", "r127", "r305", "r317" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r116", "r118" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Investment, long-term loan receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRecentlyAdoptedAndIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r280", "r283" ], "calculation": { "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r275", "r276", "r285" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r115", "r119", "r138", "r256" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18", "r19", "r20", "r48" ], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r17", "r18", "r48" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other", "verboseLabel": "Co-promotion service income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfGraliseDetails", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r92", "r173" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r90" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedLabel": "Payments in connection with debt payment", "terseLabel": "Payment of debt extinguishment" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Shares withheld for payment of employee's withholding tax liability" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r226", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r15", "r39", "r40" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Sale of disposal group, cash received" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r87" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from the issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r85" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]", "terseLabel": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r22", "r23", "r167", "r314" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Non-cancelable purchase obligations" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CommitmentsAndContingenciesPurchaseAndOtherCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r241" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r97", "r172", "r177", "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r174", "r177", "r182" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "RESTRUCTURING CHARGES" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r173", "r178" ], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Accrued restructuring costs" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r172", "r180" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "verboseLabel": "Accrued restructuring liability" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Accrued restructuring and severance costs rollforward" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r207", "r312" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Earnings (Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Product Sales and Royalties" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesProductSalesAndRoyaltiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r212", "r213" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueScheduleOfDisaggregatedRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r106", "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.assertiotx.com/role/RevenueSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivables, net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of anti-dilutive securities excluded from computation of diluted net (loss) income per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Schedule of the equity interest (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire an entity in a business combination.", "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails", "http://www.assertiotx.com/role/RevenueRoyaltiesMilestonesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r109", "r202", "r204", "r205", "r206", "r271", "r272", "r274", "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Summary of the carrying value of the Senior Notes" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of calculation of basic and diluted earnings per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r225", "r233", "r237" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r225", "r233", "r237" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense recognized for stock options, stock awards, restricted stock units and the Company's employee stock purchase program (ESPP)" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of revenue from contracts with customers" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r257", "r258" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r156", "r159" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsNarrativeDetails", "http://www.assertiotx.com/role/IntangibleAssetsSummaryOfGrossCarryingAmountsAndNetBookValuesOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r156", "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of the gross carrying amounts and net book values of our intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r21", "r36", "r37", "r38" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories, net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/InventoriesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r175", "r176", "r179" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r173", "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of accrued restructuring and severance costs" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r226", "r236" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of the future amortization expenses of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78", "r149" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expense", "verboseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails", "http://www.assertiotx.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorLongTermNotes": { "auth_ref": [ "r52" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes, Noncurrent", "totalLabel": "Total" } } }, "localname": "SeniorLongTermNotes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails", "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfInterestExpenseOfSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Award granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r224", "r228" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails", "http://www.assertiotx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r105", "r226", "r229" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Awards vesting by the end of the first year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r28", "r29", "r201" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r55", "r201" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r201", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Extinguishment of debt, shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r201", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock in conjunction with vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r201", "r207", "r230" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Issuance of common stock upon exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r55", "r201", "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r33", "r34", "r146" ], "calculation": { "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r281", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/LeasesLeaseCostComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesMergerAgreementDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails", "http://www.assertiotx.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/AccountsReceivablesNetScheduleOfAccountsReceivablesNetDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsSaleOfNucyntaDetails", "http://www.assertiotx.com/role/AcquisitionsAndDispositionsTerminationOfSlanAgreementsDetails", "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails", "http://www.assertiotx.com/role/RevenueCommercializationAgreementWithCollegiumDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/RestructuringChargesNarrativeDetails", "http://www.assertiotx.com/role/RestructuringChargesScheduleOfAccruedRestructuringAndSeveranceCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r43" ], "calculation": { "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails": { "order": 3.0, "parentTag": "us-gaap_SeniorLongTermNotes", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Unamortized debt issuance costs", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtSummaryOfCarryingValueOfSeniorNotesDetails", "http://www.assertiotx.com/role/DebtSummaryOfLiabilityComponentOfConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties associated with unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r133", "r134", "r135", "r136", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Collegium warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/FairValueNarrativeDetails", "http://www.assertiotx.com/role/FairValueScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesCommercializationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r125" ], "calculation": { "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "verboseLabel": "Add: effect of dilutive stock options, awards, and equivalents (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r121", "r125" ], "calculation": { "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Shares used in computing diluted net income (loss) per share (in shares)", "totalLabel": "Denominator for diluted income (loss) per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r125" ], "calculation": { "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Shares used in computing basic net income (loss) per share (in shares)", "verboseLabel": "Weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.assertiotx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.assertiotx.com/role/NetIncomeLossPerShareScheduleOfEarningsLossPerShareAndDilutiveSharesInformationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 1", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 3", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888252" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r322": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r323": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r324": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r325": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r326": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r327": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" } }, "version": "2.1" } XML 64 R36.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Information (Details)
 3 Months Ended
Mar. 31, 2020
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 1
XML 65 R32.htm IDEA: XBRL DOCUMENT v3.20.1
NET INCOME (LOSS) PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Schedule of calculation of basic and diluted earnings per common share Basic and diluted earnings per common share are calculated as follows (in thousands, except for per share amounts):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Basic net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Basic net income (loss) per share
 
$
0.58

 
$
(0.22
)
 
 
 
 
 
Diluted net income (loss) per share
 
 
 
 
Net income (loss)
 
$
41,230

 
$
(14,301
)
Weighted average common shares outstanding
 
70,940

 
64,239

Add: effect of dilutive stock options, awards, and equivalents
 
111

 
—

Denominator for diluted income (loss) per share
 
71,051

 
64,239

Diluted net income (loss) per share
 
$
0.58

 
$
(0.22
)
Schedule of anti-dilutive securities excluded from computation of diluted net (loss) income per share
The following table sets forth outstanding potentially dilutive common shares that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):
 
 
Three Months Ended March 31,
 
 
2020
 
2019
2.5% Convertible Notes debt 2021
 
5,111

 
17,931

5.0% Convertible Notes debt 2024
 
26,248

 
—

Stock options, awards and equivalents
 
7,144

 
6,103

Total potentially dilutive common shares
 
38,503

 
24,034
XML 66 R23.htm IDEA: XBRL DOCUMENT v3.20.1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of revenue from contracts with customers
The following table summarizes revenue from contracts with customers for the three months ended March 31, 2020 and 2019 (in thousands):
 
 
 
Three Months Ended March 31,
 
 
2020
 
2019
Product sales, net
 
 
 
 
CAMBIA
 
$
6,274

 
$
8,808

Zipsor
 
2,331

 
4,231

Gralise
 
547

 
13,278

Total neurology product sales, net
 
9,152

 
26,317

NUCYNTA and Lazanda product sales adjustments
 
100

 
133

Total product sales, net
 
9,252

 
26,450

Commercialization agreement, net
 
11,258

 
30,856

Royalties and milestone revenue
 
407

 
623

Total revenues
 
$
20,917

 
$
57,929
Summary of contract assets and liabilities
The following table presents changes in the Company’s contract assets as of March 31, 2020 (in thousands):
 
Balance as of
 
 
 
 
 
Balance as of
 
December 31, 2019
 
Additions
 
Deductions
 
March 31,
2020
Contract asset - Collegium, net
1,896

 
—

 
(1,896
)
 
—
ZIP 67 0001005201-20-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001005201-20-000035-xbrl.zip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